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ABSTRACT 
Oswal, Pravin Dhawal Ph.D., Biomedical Sciences Ph.D. program, Department of 
Biochemistry and Molecular Biology, Wright State University, 2014. Peroxisome 
proliferator-activated receptor alpha: Insight into the structure, function and energy 
homeostasis
Peroxisome proliferator-activated receptor alpha (PPARα) belongs to the family 
of ligand-activated nuclear transcription factors and serves as a lipid sensor to regulate 
nutrient metabolism and energy homeostasis. The transcriptional activity of PPARα is 
thought to be regulated by the binding of exogenous ligands (example, fenofibrate, 
TriCor
®
), as well as endogenous ligands including fatty acids and their derivatives. 
Although long-chain fatty acids (LCFA) and their thioesters (long-chain fatty acyl-CoA; 
LCFA-CoA) have been shown to activate PPARα of several species, the true identity of 
high-affinity endogenous ligands for human PPARα (hPPARα) has been more elusive. 
This two part dissertation is a structural and functional evaluation of human and mouse 
PPARα binding to LCFA and LCFA-CoA using biophysical and biochemical approaches 
of spectrofluorometry, circular dichroism spectroscopy, mutagenesis, molecular 
modelling and transactivation assays. 
The first goal of this dissertation was to determine whether LCFA and LCFA-
CoA constitute high-affinity endogenous ligands for full-length hPPARα. Data from 
spectrofluorometry suggests that LCFA and LCFA-CoA serve as physiologically relevant 
endogenous ligands of hPPAR. These ligands bind hPPARα and induce strong 
secondary structural changes in the circular dichroic spectra, consistent with the binding 
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of ligand to nuclear receptors. Ligand binding is also associated with activation of 
hPPARα, as observed in transactivation assays. The second goal of this dissertation was 
to determine whether there exist species differences for ligand specificity and affinity 
between hPPARα and mouse PPARα (mPPARα). This is important because despite high 
amino acid sequence identity (>90%), marked differences in PPARα ligand binding, 
activation and gene regulation have been noted across species.  
Similar to previous observations with synthetic agonists, we reported differences 
in ligand affinities and extent of activation between hPPARα and mPPARα in response to 
saturated long chain fatty acids. In order to determine if structural alterations between the 
two proteins could account for these differences, we performed in silico molecular 
modeling and docking simulations. Modeling suggested that polymorphisms at amino 
acid position 272 and 279 are likely to be responsible for differences in saturated LCFA 
binding to hPPARα and mPPARα. To confirm these results experimentally, 
spectrofluorometry based-binding assays, circular dichroism, and transactivation studies 
were performed using a F272I mutant form of mPPARα. Experimental data correlated 
with in silico docking simulations, further confirming the importance of amino acid 272 
in LCFA binding. Although the driving force for evolution of species differences at this 
position are yet unidentified, this study enhances our understanding of ligand-induced 
regulation by PPARα. 
Apart from demonstrating significant structure activity relationships explaining 
species differences in ligand binding, data in this dissertation identifies endogenous 
ligands for hPPAR which will further help delineate the role of PPAR as a nutrient 
sensor in regulating energy homeostasis. 
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INTRODUCTION 
The relationship between obesity and metabolic disturbances, including increased 
lipids and glucose, cardiovascular disease (CVD), hypertension and diabetes, has been 
known and described for decades. A syndrome linking obesity to metabolic 
abnormalities, CVD and diabetes was described in 1988 by Dr. Reaven in his Banting 
lecture as ‘syndrome X’ (1). Today, this syndrome is referred to as the metabolic 
syndrome (named by the World Health Organization; WHO) and has a WHO diagnostic 
code of ICD9. The metabolic syndrome includes a group of risk factors that increase the 
risk for cardiovascular morbidities and diabetes (2, 3). Obesity, which tops the list in the 
metabolic syndrome, affects more than one-third of adults (35.7%) and approximately 
17% (or 12.5 million) of children in the US alone (4, 5). It is a major risk factor for 
coronary heart disease, hypertension, atherosclerosis, dyslipidemia and diabetes and the 
estimated 2012 annual direct medical cost of obesity in the United States (for data from 
2000-2005) is $190.2 billion (6). The exact molecular mechanisms underlying these 
associations are still not clear.  
Obesity is a medical condition defined as an increased mass of adipose tissue and 
has often been related to dysregulated lipid homeostasis. It is an illeness where the health 
of an individual (and hence life expectancy) is adversely affected by excess body fat. 
Under normal energy homeostasis, dietary long chain fatty acids (LCFA) not only serve 
as major metabolic fuels and important components of biological membranes, but they 
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also play a significant role as gene regulators and signaling molecules that regulate 
metabolic pathways governing fuel utilization, storage, transport and mobilization. 
Dysregulated LCFA alter this energy homeostasis and thus have been implicated in 
various metabolic, endocrine and cardiovascular complications. One of the plausible 
explanations of such regulation and mis-regulation includes their interactions with the 
nutrient sensing family of transcription factors called the peroxisome proliferator-
activated receptors (PPAR). 
 
Peroxisome proliferator-activated receptors (PPAR) 
PPARs belong to the nuclear hormone receptor superfamily of ligand-activated 
transcription factors which play important regulatory roles in numerous cellular processes 
related to fatty acid metabolism, glucose metabolism, inflammation, differentiation and 
proliferation (7-10). PPARs form the group C of subfamily 1 of the superfamily of 
nuclear hormone receptors (NR1). There are three members of this subfamily of nuclear 
receptors: PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3) (9). The founding 
member of the family (PPARα) was identified because a structurally diverse group of 
chemicals including fibric acid derivatives, phthalate plasticizers and certain herbicides 
resulted in massive proliferation of peroxisomes in rodents (11-13). Reddy et. al. (1987) 
used these chemicals as affinity ligands to identify and purify the receptor/protein 
responsible for such effects from the cytosolic fraction of rat livers (14). This 
protein/receptor was indicative of being isolated as a dimer and was termed as 
peroxisome proliferator-binding protein (PPbP) (14). The exact identity of the true 
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peroxisome proliferator binding protein (in the dimeric complex) remained elusive until 
1990.  
Isseman and Green (1990) were the first to clone the receptor activated by 
peroxisome proliferators which became named as peroxisome proliferator-activated 
receptor alpha (15). Since the discovery of PPARα, two other PPAR subtypes, PPARβ/δ 
and PPARγ were identified (16, 17). They are encoded by distinct single copy genes 
located on human chromosomes 22 (PPARα), 6 (PPARβ/δ) and 3 (PPARγ) (18-20). 
While the splice variants of PPARγ (γ1 and γ2) are generated as a result of alternate 
promoter usage and splicing (21), the PPARα splice variant transcript lacks 200 bp 
around exon 6 (9.7kb compared to 9.9kb) and gives rise to a premature stop codon 
resulting in truncated protein that lacks a large part of the ligand binding region (174 
amino acids as compared to 468 in wild-type; Fig. 1) (22). This truncated protein is 
present widely in human tissues and when compared to the wild-type PPARα its ratio 
varies among individuals (from 1:1 to 1:4 - based on the two subjects tested in a previous 
study) (22). The truncated PPARα protein is believed to have a repressive activity on the 
wild-type form of the protein (by competing with cofactors that bind the N-terminal 
portion of the protein) (22). 
The three PPAR subtypes display distinct patterns of tissue distribution (16). 
PPARα is expressed in tissues mainly with high metabolism rates such as liver, heart, 
muscle, kidney and brown fat where it serves as a potent activator of genes involved in 
lipid catabolism. In fact, synthetic agonists of PPARα (example, fenofibrate, TriCor
®
; 
fenofibric acid, TriLipix
®
; gemfibrozil, Lopid
®
) have been used as therapeutic agents in 
the treatment of hyperlipidemia (7-10). PPARβ/δ is broadly expressed with highest levels 
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found in intestines and keratinocytes. Apart from exerting metabolic effects similar to 
PPARα in gut, skin and brain, it is also involved in neuronal development, inflammation, 
keratinocyte differentiation and wound healing (7-10). PPARβ/δ agonists (example, 
GW501516 and MBX-2085) have been under clinical investigations (in clinical trials) 
(23, 24) but are yet to be seen on the market. PPARγ on the other hand is predominantly 
expressed in adipocytes and macrophages where it activates genes involved in 
lipogenesis and adipocyte differentiation (7-10). While thiazolidinediones such as 
pioglitazone (Actos
®
) are potent PPARγ agonist used in management of diabetes, others 
such as rosiglitazone (Avandia
®
) have either been taken off the market in some countries 
(mainly Europe) or prescribed with caution (U.S.A.), owing to side effects such as weight 
gain and increased risks of heart attacks.  
PPARα: Structure  
The human PPARα gene spans ~93.2 kb on chromosome 22 and gives rise to a 
9.9 kb transcript in humans (8.5 kb in mouse). This transcript encodes a 468 amino acid 
and 52 kDa protein (18). Like other members of the nuclear hormone receptors, the 
PPARα protein structure also consists of distinct functional domains – the N terminal 
A/B domain, the DNA binding domain (DBD) or C domain, hinge region or D domain 
and the ligand binding domain (LBD) or E/F domain (Fig. 1). The PPAR transcript 
reveals common structural organization with the translated region composed of 8-9 
coding exons depending on the transcript variant in question (18, 25).  
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Fig. 1. Pre-messenger RNA and domain structure of PPARα. Top panel: The pre-
messenger RNA for human PPARα demonstrating splicing events, Swt and Str, that 
generate wild-type PPARα (9.9 kb) and truncated PPARα transcripts (9.7 kb; with 
premature stop codon in exon 7). Bottom panel: Domain structure of PPARα protein 
(wild-type), left to right: the N-terminus A /B domain, the C domain or DNA binding 
domain containing two zinc-finger motifs that bind the DNA in the regulatory region of 
target genes, the D domain or hinge region that allows for conformational changes upon 
ligand binding and the - the E/F domain or the ligand-binding domain (LBD) containing 
the ligand-dependent transactivation function (AF-2). The hPPARα ribbon structure is 
adopted from PDB code 1K7L (26) 
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The A/B region: The N-terminal A/B domain amongst most nuclear hormone 
receptors displays the weakest evolutionary conservation and is highly variable, both in 
sequence and length. These domains are also poorly structured, and this has been 
confirmed using deuterium exchange mass spectrometry, circular dichroism spectroscopy 
and NMR spectroscopy (27-29). For this reason, the X-ray crystal structure of the A/B 
domain has not been resolved till date. The length of the N-terminal A/B domain in 
PPARα is 100 amino acids (Fig. 1), and it harbors a ligand-independent transactivation 
function (AF-1) that is responsible for low-level transactivation activity of the receptor 
(tested in GAL4-fusion proteins) (30). Although the A/B domain in PPARα has poor 
structural organization, it has been suggested that secondary structure formation in this 
domain is an important step towards AF1 mediated transactivation (30). This was 
demonstrated by two observations 1) AF-1 domain adopts α-helical characteristic in the 
presence of a strong α-helix stabilization agent such as trifluoroethanol and 2) mutation 
of hydrophobic amino acids in the AF-1 domain (possibly involved in α-helix formation) 
impacted the transcriptional activity of the protein (30). 
The importance of the A/B domain in PPARα is highlighted by the fact that 
deletion of the A/B domain results in a gene-dependent alteration in PPARα 
transcriptional activity. For example, deletion of the A/B domain disrupts the PPARα-
mediated transactivation of the acyl-CoA oxidase promoter, but it does not affect the 
transactivation of cytochrome P450 4A6 promoter (30, 31). In addition, the A/B domain 
of PPAR is suggested to contribute towards maintaining subtype specificity amongst the 
PPAR subtypes. For example, addition of the PPARα A/B domain to PPARγΔAB (A/B 
domain truncated) enhances its ability to activate PPARα specific target genes (32) and 
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the addition of PPARγ A/B domain to non-adipogenic PPARβ/δΔAB (A/B domain 
truncated) imparts adipogenic potential to the resulting PPARβ/δ protein (33). As far as 
its relation/association with other domains in the protein is concerned, a recent research 
article demonstrates that mutation of residues in the A/B domain (S112) altered ligand 
binding and activity (function of E/F domain) of PPARγ (34). These findings suggest that 
studies carried out using individual nuclear receptor domains or truncated forms of 
nuclear receptors must be interpreted with caution.  
DNA binding domain (DBD) or C domain: The DNA binding domain is the most 
conserved domain within the nuclear hormone receptor superfamily (9). The DBD of 
nuclear hormone receptors recognizes a 6 nulceotide core motif in the DNA and binds to 
two copies of such a motif (constituting a hormone responsive element) as a dimer. 
Factors such as the 5’ flanking extension of the core motifs, spacing of the two core 
motifs and their relative orientation (direct repeats, inverted repeats or everted repeats) 
determine which nuclear receptor dimer binds the hormone response element (35). 
Amongst the PPAR subtypes, the DBD bears about 78-86 % amino acid identity and it 
encompasses amino acids 101-166 in PPARα (Fig. 1) (8, 36). The PPAR-DBD consists 
of two zinc finger motifs and in each motif four cysteine residues coordinate and chelate 
one Zn
2+
 ion. The alpha helical components of the two zinc finger motifs lie 
perpendicular to each other. The amino acids that are responsible for registering contacts 
with specific nucleotides in the DNA are present towards the C terminus of the first zinc 
finger in a region termed as the “P box.” Hydrogen bonding contacts are made between 
amino acid residues in this region and the major groove of the DNA. Similarly, the region 
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towards the N terminus of the second zinc finger is referred to as the “D box” and amino 
acids present in this region are involved in heterodimerization. (25, 29, 37, 38) 
PPARα binds DNA as obligate heterodimers with other nuclear receptors, mainly 
the retinoid X receptors (RXR). The PPAR-RXR heterodimer recognizes and binds to a 
consensus sequence on the DNA, termed the peroxisome proliferator response element 
(PPRE). While these PPRE were first characterized using synthetic oligonucleotides (39), 
the first natural PPRE was found in the regulatory region (promoter) of the acyl-CoA 
oxidase (ACOX) gene (17, 40). In addition, recent genome-wide profiling of PPARα 
binding sites has revealed about 46% of PPAR-RXR binding sites within the intronic 
regions (41). The PPRE belongs to the direct repeat 1 (DR1) category and consists of two 
AGG(A/T)CA half sites separated by one nucleotide (Fig. 2). The binding to the PPRE 
occurs in a manner such that PPAR is oriented towards the 5’ end and RXR is oriented to 
the 3’end. This is in contrast to other nuclear receptor heterodimers such as the vitamin D 
receptor-retinoid X receptor heterodimer (VDR-RXR) or thyroid receptor-retinoid X 
receptor heterodimer (TR-RXR) where RXR is oriented towards the 5’end (38, 42).  
Detailed analysis of PPRE sequences from PPAR target genes has helped to 
define additional PPRE determinants (43). These PPRE determinants impart subtype 
specificity as well as DNA binding polarity to the PPAR-RXR heterodimer and include 
the spacing nucleotide as well as the COOH-terminal extension (CTE) of the DBD (31, 
42-44). The amino acid residues present in the CTE of the PPARs play a significant role 
in the recognition of the PPRE and form significant interactions with the 5’ flanking 
sequence of the PPRE (Fig. 2) (29, 43). While PPAR binds DNA only as a heterodimer 
(and not as a monomer), deletion of its N-terminal A/B domain allows the truncated 
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protein to non-specifically bind DNA as a monomer in in vitro assays (31). While the 
physiological significance of such binding is unclear, it serves as evidence of interdomain 
communication and the importance of full-length nuclear receptors. The DBD of a 
nuclear receptor such as PPAR, forms an interface with its own LBD as well as the LBD 
of its heterodimeric partner – thereby influencing ligand binding (29). These data point to 
two important conclusions; 1) since PPARs bind to DNA only as a heterodimer it reflects 
the evolution and divergence of PPARs from its monomeric nuclear receptor cousins and 
2) since the DBD can influence ligand binding, it emphasizes on the importance of 
conducting ligand-binding studies with full-length forms of nuclear receptors. 
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Fig. 2. Illustration of PPAR-RXR heterodimer binding to DNA. X-ray crystallized 
complex of PPARγ (magenta) and RXRα (green) bound to a PPRE containing AGGTCA 
direct repeat separated by one nucleotide (DR1) (Source PBD code 3DZY (29)). 
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Hinge region or D domain: Adjacent to the DNA binding domain is the D domain 
or the hinge region. As the name suggests the D domain serves as a ‘hinge’ between the 
highly structured C and E/F domains (Fig. 1). The hinge region is not well conserved 
amongst PPAR subtypes or amongst nuclear receptors in general (45). It allows for 
conformational changes in protein structure upon ligand binding. The D domain also 
contains the CTE of the DBD which renders polarity and subtype specificity for binding 
to the PPRE (31, 42-44). For example, the CTE of the DBD (contained in the hinge 
region) interacts with nucleotides in the 5’ flank of the PPRE (29) and conservation of 
this 5’ flanking sequence of the PPRE is essential for PPARα binding - thus imparts 
subtype specificity (43)  This region is also thought to harbor the nuclear localization 
signals and contain sites for protein-protein interaction (45).  
Ligand binding domain or E/F domain: The C-terminal ligand binding domain 
(LBD) or E/F domain for the PPARs is highly structured and contains ligand-dependent 
activation function (AF-2). Compared to the DNA binding domain, the LBD bears less 
amino acid identity (63-71 %) amongst the PPAR isotypes (9, 36). The X-ray crystal 
structures of all the PPAR-LBD isotypes have been resolved and studied in great detail. 
Before going in depths of the PPARα structure, it is necessary to clarify some 
terminology issues, particularly with the E and F domains. In addition to the A/B, C and 
D domains, researchers in the nuclear receptor field often classify receptors as having 
only an E domain (46), both E and F domains (46, 47) or an E/F domain (8, 10). It is thus 
important to clarify these differences in terminology. Classically, the nuclear receptor 
LBD is defined as the domain between the beginning of helix 1 through the end of helix 
12 (AF-2) (46). Any region beyond helix 12 (seen in the progesterone, estrogen and 
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retinoic acid receptors) is referred to as the ‘F domain’ (46). Since the PPARα-LBD is 
composed of 12 α-helices, with only four amino acids at the C-terminus, for the sake of 
simplicity herein the LBD is referred to as the E/F domain.  
The human PPARα-LBD extends from amino acids 280-468 (Fig. 1) and contains 
a ligand-dependent transactivation function (AF-2), a major dimerization interface and 
sites for interaction with coactivator and corepressor proteins (8-10). Recently, it has also 
been demonstrated that the PPAR-LBD may have additional interfaces for interaction 
with its own DBD as well as the DBD of its heterodimeric partner (29). Structurally the 
PPARα-LBD is folded in a three-layered helical sandwich formed by 12 α-helices 
(designated H1-H12) and a four stranded β-sheet (26). The central core of this helical 
sandwich is packed in way to create a 1400 Å
3
 cavity, the ligand binding pocket (26). The 
volume of the PPARα-LBD pocket is quite comparable to other PPAR isotypes but is 
substantially larger than some other nuclear receptors such as thyroid receptor (600 Å
3
) 
and retinoid X receptor (RXR; ~500 Å
3
)
 
(9, 26, 48-50).  
X-ray crystal structures of the PPARs in complex with agonist-bound ligands and 
the understanding of nuclear receptor activation has helped in the design of specific 
agonists, partial agonists as well as antagonists. The crystal structure of the PPARα-LBD 
in complex with GW409544 agonist reveals that the carboxylic acid group of the agonist 
forms hydrogen bonds with Y464 on helix 12 and Y314 on helix 5 (Fig. 3) (26). The rest 
of the GW409544 ligand is largely lipophilic and is stabilized by hydrophobic 
interactions with the amino acids lining the pocket of the PPARα-LBD. These 
interactions stabilize the receptor in an “active” conformation. Based on this information, 
Xu et al.  elegantly designed a potent PPARα antagonist in which the carboxylic acid 
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group of the GW409544 agonist was substituted by an ethyl amide such that it would 
disrupt the hydrogen bonding with Y464 (51). As a result of this substitution, the 
antagonist blocks the helix 12 from adopting the “active” conformation.  
The ligand binding pocket of human PPARα assumes a Y-shape and spans 
between the C-terminal helix 12 and the 4 stranded β-sheet, splitting into roughly two 
arms along helix 3. Compared to the PPARα-LBD structure, the ligand binding pocket of 
agonist bound PPARγ-LBD and PPARβ/δ-LBD are ‘T’ and ‘Y’ shaped respectively (49, 
50). The amino acids lining their ligand binding pocket bear several conserved and 
nonconserved amino acid changes that dictate the shape and volume of the pocket and 
thereby impart ligand specificity to the isotypes. For example, H323 in the human 
PPARγ-LBD corresponds to Y314 in the human PPARα-LBD and imparts ~1000-fold 
greater selectivity for the binding of farglitazar (thiazolidinediones) to PPARγ (26). Also, 
a single methionine to valine substitution at 417 (M417V) in human and/or chick 
PPARβ/δ imparts fibrate (PPARα specific agonist) binding characteristic to the protein 
(52).  
Several hydrophilic residues lining the PPARγ or PPARβ/δ pocket are converted 
to hydrophobic residues in PPARα – rendering the PPARα pocket much more 
hydrophobic as compared to either PPARγ or PPARβ/δ (26). In the ligand bound 
(agonist) conformation the human PPARα pocket is lined by a mix of largely 
hydrophobic residues (I241, L247, L254, I272, F273, I317, F318, L321, M330, V332, 
I339, L344, L347, F351, I354, M355, V444, L456, L460), a few polar residues (S280, 
T279, E251, C275, C276, Y314, H440) and is capped by Y464 from the AF-2 helix (26). 
However, irrespective of the amino acid changes or the distinct ligand binding 
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specificities amongst all PPAR isotypes, they all contain a similar network of hydrogen 
bond forming amino acid residues (near the AF-2) that are involved in receptor activation 
upon ligand binding (26). PPARα binds to the PPRE in its target genes only as an 
obligate heterodimer with RXR (38, 39, 47). The heterodimerization interface is mainly 
formed by helices 9 and 10. This was confirmed in studies involving deletion of helix 10-
12 as well as a L433R mutation in PPARα which caused impaired heterodimerization 
with RXR (53, 54). 
PPARα: Mode of Action 
Conformational changes: Ligand binding induced conformational changes are 
hallmarks of nuclear receptor action (53). The human genome contains 48 nuclear 
receptors and notably many of their LBD have been crystallized in the holo or liganded 
state. This is because the binding of a ligand stabilizes the conformation of a nuclear 
receptor, making it convenient to crystallize (26, 49, 50, 55, 56). Nonetheless, a few 
nuclear receptors have been crystallized in the unliganded state; including, apo-RXRα-
LBD and apo-PPARγ-LBD (49, 57). Based on comparison of the apo and holo state of 
nuclear receptors, a “mousetrap” model/mechanism of nuclear receptor activation has 
been proposed (58).  
The “mousetrap” model was first proposed on the basis of x-ray crystal structures 
of the apo-RXR-LBD (57) and the holo-retinoic acid receptor LBD (RAR-LBD) (59) and 
later extended to other nuclear receptors using apo/holo-state structures of the RXRα-
LBD and PPARγ-LBD (49, 57). According to this model, in the unliganded nuclear 
receptor, the helix 12 (AF-2) is angled away from the body of the LBD. The binding of a 
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ligand causes conformational changes and concomitant swinging of helix 12 (AF-2; 
moves closer to the LBD) such that it “traps” the ligand and prevents its exit (Fig. 3) (58). 
Hydrophobic and electrostatic interactions between the ligand and amino acids lining the 
pocket and helix 12 (Y464 in PPARα; (26)) stabilize and reposition helix 12. In some 
nuclear receptors, including the PPARs, the AF-2 is stabilized by specific interactions 
between the ligand and the amino acids of helix 12 (58), but in others the helix 12 is 
stabilized indirectly by other intervening residues (55, 56, 58) (Fig. 3).  
While the “mousetrap” model is widely accepted for nuclear receptor activation 
(including that for PPARα), recently a “dynamic stabilization” model has also been 
proposed to account for the plasticity of the nuclear receptor ligand binding pocket and to 
explain the appearance of helix 12 proximal to the LBD, even in absence of ligands (56, 
60, 61). According to this model, the AF-2 along with other regions of the LBD are rather 
mobile in an unliganded nuclear receptor. The binding of ligand stabilizes overall 
conformational dynamics of the receptor along with repositioning of helix 12 via specific 
interactions with the ligand (Y464 in PPARα) (60). However, if the helix 12 is stabilized 
proximal to the LBD in an unliganded state, then according to this model that nuclear 
receptor is likely to show constitutive activity (55, 56, 61). For example, the constitutive 
activity of nuclear receptor related protein 1 (NURR1) (62) is explained by this model. 
This model helps explain the dynamic/plastic nature of most nuclear receptors including 
the PPARs (56) and has been well supported by various solution based biophysical 
studies. For example, NMR studies (63), proteolytic sensitivity studies (64, 65), 
fluorescence studies (66) as well as secondary structure melting studies (67) have all 
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demonstrated that the relatively unstable apo-state nuclear receptor LBD switches to a 
more rigid and stable conformation upon ligand binding (60, 61).       
Regardless of the “mousetrap” mechanism or the “dynamic stabilization” model, 
the helix 12 (AF-2) switches from a rather mobile conformation to a more stable position 
proximal to the ligand binding pocket. This results in exposure of a new surface on the 
receptor that recruits transcriptional activators and other components of the transcription 
machinery, resulting in enhanced/repressed transcription of a specific set of target genes 
(68, 69). This phenomenon, mediated by ligand binding, is crucial for receptor activation.  
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Fig. 3. Illustration of “mousetrap” model for PPARα activation. In the unliganded state 
the helix 12 (AF-2; red) is away from the LBD of PPARα (position 1). Upon ligand 
binding the AF-2 is stabilized proximal to the ligand binding pocket (position 2) by 
specific interactions between the ligand and amino acids residing in helix 12 (example 
Tyr-464). (PDB  file (1K7L) adapted from (26)) 
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Coactivators and Corepressors: Nuclear receptor mediated transcriptional regulation of 
genes is a complex process and also involves two classes of transcriptional 
cofactors/coregulators (corepressors and coactivators) (68, 69). The development of 
squelching experiments and yeast two hybrid have marked the discovery and 
identification of a large number of coactivators and corepressors that transmit the nuclear 
receptor signals to the transcriptional machinery (70, 71). In the simplest form, 
corepressors bind to the PPAR-RXR heterodimer in an unliganded state and render it 
inactive. Ligand binding induces specific conformational changes that result in the 
release of corepressors and the recruitment of coactivator proteins. Coactivators or 
corepressors respectively bring about transcriptional activation or repression of the target 
genes by mechanisms including chromatin modification (via intrinsic histone 
acetyltransferase activity (HAT) or histone deacetylase activity (HDAC)) and physical 
interactions with the transcriptional initiation machinery (68, 69).  
The first class of nuclear receptor coregulators includes the coactivators. Binding 
of an agonist ligand results in repositioning of helix 12 together with other structural 
changes that lead to the creation of a distinct surface on the protein. These novel surfaces 
allow for recruitment of coactivator proteins with a conserved LXXLL motifs or (L, 
leucine and X, any amino acid; also called ‘NR box’) such as the steroid receptor 
coactivator (SRC-1) (68, 69, 72). SRC-1 was the first nuclear receptor coactivator to be 
discovered (72), and its interaction with LXXLL motifs were first seen in the crystal 
structure of the PPARγ-LBD (49). In addition to interacting with LXXLL motifs in the 
LBD of nuclear receptors, coactivator proteins may also interact with the A/B domain of 
nuclear receptors. For example, SRC-1 and coactivators belonging to the transcriptional 
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mediators/intermediary factor 2 (TIF-2) family also interact with the A/B domain of 
nuclear receptors such as the estrogen and androgen receptors (73, 74) . It is thus possible 
that the N-terminal A/B domain (AF-1) and the LBD (AF-2) may not always function 
independently but may rather serve as a single common recruiting surface for such 
coactivators. The molecular mechanism of action of coactivators results from their ability 
to reorganize/remodel chromatin. While coactivators such as SRC-1 possess intrinsic 
HAT activity that aid in chromatin remodeling, others such as TIF-2 function by 
physically recruiting histone acetyltransferases (70, 73, 74). Decondensation of chromatin 
is then followed by recruitment of basal transcriptional machinery to the target gene 
promoters including TATA binding protein (TBP) and RNA polymerase II (75).   
The observation that certain nuclear receptors such as the thyroid receptor (TR) 
and retinoic acid receptor (RAR) repress transcription even in the liganded state led to the 
discovery of a second class of nuclear receptor coregulators called the corepressors (76). 
Examples of corepressor proteins that bind the PPAR-RXR heterodimer in an unliganded 
state include nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and 
thyroid hormone receptors (SMRT) (76, 77).  These corepressors bind to a LXXXIXXXL 
motif (also termed as the ‘CoRNR box’) on the surface of the protein that does not 
involve helix 12 (78). Although the CoRNR box is similar to the LXXXL coactivator 
motif, the three extra amino acids in the CoRNR box cannot be accommodated in the 
ligand bound nuclear receptor conformation (with the repositioned helix 12) (78, 79). In 
contrast to the mechanism of action for coactivators, corepressors bring about 
transcriptional repression through intrinsic or recruited histone deacytylase activity (70, 
75, 76), and the phenomenon of coactivator recruitment is accompanied by corepressor 
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release. For example, release of NCoR upon binding of Wy-14,643 (agonist) to PPARα 
(77). 
Since the discovery and cloning of SRC-1 (72) and NCoR (76, 77), more than 300 
transcriptional cofactors have been identified that associate with nuclear receptors such as 
the PPAR (8, 80). These cofactors allow for the interaction of the PPAR-RXR complex 
with other proteins/complexes associated with the basal transcription machinery, 
resulting in enhanced/repressed transcription of a specific set of target genes (Fig. 4) (68, 
69). However such diversity of 300 or more cofactors not only enhances the multiplicity 
of nuclear receptor activation, but also adds complexity in our understanding of nuclear 
receptor mediated transcriptional regulation. For example: why are there multiple 
coregulators with the same HAT/HDAC activity? Do they bind nuclear receptors in a 
sequential or combinatorial manner? Does there exist competition for these coregulators? 
How do tissue-restricted distribution and/or regulation of cofactors affect nuclear receptor 
action? While many of these questions are still under extensive investigations, some of 
the outcomes are presented below.   
 Tissue restricted distribution and physiological regulation of these cofactors 
could be a means of finer regulation of nuclear receptor action. For example, 1) PPARγ 
can activate the transcription of uncoupling protein 1 (UCP1) in brown fat but not 
fibroblasts. This was because PPARγ coactivator-1 (PGC-1), which serves as a 
coactivator for PPARγ, is expressed primarily in brown fat and skeletal muscles (81). 
Further PGC-1 expression is also regulated physiologically by body temperature. Thus 
exposure of mice to cold temperatures increases the activity of PGC-1 and thereby 
increases the transcriptional activity of PPARγ (81). Similarly tissue restricted 
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distribution of other cofactors such as SRC-1 may further modulate the transcriptional 
activity of nuclear receptors (82).    
Irrespective of the vast scope of research in understanding the downstream 
molecular mechanism of cofactors, the phenomenon of coactivator-recruitment upon 
ligand binding has resulted in the development of coactivator-dependent receptor ligand 
binding assays (CARLA) (83, 84). Although these assays have provided valuable 
information on the identity of ligands for orphan receptors, many of these assays were 
conducted with truncated forms of nuclear receptors (only the LBD). Since coactivators 
such as SRC-1 has been demonstrated to interact with the A/B domain of nuclear 
receptors (in addition to LXXLL motifs in the LBD) (74), the significance of these 
findings are not clear. These data further emphasize the need to conduct such ligand 
binding studies with full-length forms of nuclear receptors.  
Cellular localization and chain of events: The cellular localization of nuclear hormone 
receptors is a result of equilibrium between the nucleus and the cytoplasm (85).  
According to the widely accepted dogma, nuclear receptors are predominantly localized 
in the nucleus at equilibrium (even in absence of ligand) (46). However, in contrast to 
this, unliganded steroid hormone receptors are primarily localized in the cytoplasm where 
they are bound/chaperoned to heat-shock protein 90 (HSP90) (86, 87). They translocate 
to the nucleus to perform their transcription regulatory function upon ligand binding (86, 
87). As far as PPARα is concerned, it is generally agreed that it is predominantly 
localized in the nucleus (88-92). However, recent studies demonstrate some evidence for 
dynamic shuttling of PPARα between the cytosol and the nucleus (89, 93-95). Umemoto 
et al. further demonstrated that the nuclear transport of PPARα is accelerated by the 
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addition of ligands (93). These findings suggest that extracellular signals (ligands) could 
dissect the PPARα dynamics into discrete nuclear-cytoplasmic shuttling steps. 
In addition to this, there is also controversy regarding the chain of events – 
particularly heterodimerization and DNA binding. Based on the definition of a “domain” 
and information from individual crystal structures of nuclear receptor LBD or DBD, it 
was thought that each functions independently (55). However, the intact structure of the 
PPAR-RXR heterodimer bound to a PPRE revealed three heterodimerization interfaces 
(29). Two of these were already known and included the LBD-LBD interface and the 
DNA dependent DBD-DBD interface. What was not known was this third interface (also 
DNA dependent) formed between the PPAR-LBD and the RXR-DBD (29). This interface 
suggests that PPAR ligands could influence DNA binding through the PPAR-LBD. This 
led to the idea that ligands could themselves target a specific subset of genes (55). In 
contrast, the fact that the PPAR-RXR complex had two DNA dependent interfaces, 
suggests that DNA motifs could allosterically regulate heterodimerization and receptor 
activation (29, 55).  
Although these finding do not give a clear picture on the chain of events, they do 
add to our understanding of the dynamic nature of nuclear receptor activation. The static 
model for transcription factor action assumes that upon activation the transcription factor 
is either: 1) bound (for a fairly long length of time), or 2) not bound to the DNA (96-98). 
However recent studies with chromatin immunoprecipitation and sequencing (ChIP-seq), 
fluorescence recovery after photobleaching (FRAP) and fluorescence correlation 
spectroscopy (FCS) have given light to the dynamic properties of nuclear receptors (96, 
98). These studies gave rise to a dynamic or “hit and run” model of transcription factor 
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action where there is a rapid cycling of DNA binding-unbinding with ligand-dependent 
cycle/binding time and receptor mobility (96, 98). For example, RXR agonist treatment 
largely affected the occupancy time of genomic regions to which RXR bound (96-98). It 
is anticipated that other nuclear receptors such as PPARα also follow a similar trend 
where they rapidly bind and unbind DNA in the absence of ligands. However, addition of 
ligands results in slowing down of such shuttling such that the residence time on the 
DNA is significantly increased. 
To summarize, PPARα binds to a PPRE in its target genes as a permissive 
heterodimer with RXR (PPARα-RXR) (Fig. 4). Ligand binding and recruitment of 
cofactors (coactivators or corepressors) mediates the ability of PPARα to regulate 
transcription of its target genes. Like mentioned earlier, irrespective of high structural 
homology, identical PPRE sequences and shared cofactors, a number of factors determine 
isotype specificity among the PPARs. These include: amino acids lining the ligand 
binding pocket (26), the 5’ flanking extension (to the DR1), spacing nucleotide (in PPRE) 
(31, 42-44), tissue restricted expression of each isoform (7-10, 16), availability of 
ligands, competition for mutual dimerization partners (such as RXR), availability and 
recruitment of cofactors (8, 9, 81, 82).  
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Fig. 4. PPAR mechanism of action. PPARs form heterodimers with retinoid X receptors 
(RXR) and bind to DNA sequences called peroxisome proliferator response element 
(PPRE) in the promoter region of target genes. Recruitment of cofactors (coactivators or 
corepressors) mediates the ability of PPAR’s to stimulate or repress the transcription of 
target genes involved in difference cellular functions (modified from (99)). 
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PPARα: Ligands, physiological role and knockout mice phenotype 
Ligands: Even before the discovery and cloning of the PPARα gene, a vast array of 
structurally diverse chemicals were known to lower serum lipids and cause massive 
peroxisomal proliferation in mice.  These chemicals included fibric acid and its 
derivatives, nafenopin, methyl clofenapate, industrial phthalate-monoester plasticizers 
such as, di-(2-ethylhexyl)-phthalate (DEHP; used as a solvent/softner in manufacture of 
PVC plastics), certain herbicides, pesticides and industrial solvents (7-13). A mechanistic 
search on how these chemicals act lead to the discovery of a protein dimer which was 
aptly named peroxisome proliferator-binding protein (PPbP) (14). However, since the 
cloning of the receptor responsible for binding to peroxisome proliferators it was 
designated as Peroxisome Proliferator-Activated Receptor alpha (PPARα) (15). Today 
the ligands of PPARα have been classified into two main categories: endogenous ligands 
and exogenous (synthetic) ligands.  
Synthetic ligands of PPARα include agonists such as clofibrate, fenofibrate 
(TriCor
®
), fenofibric acid (TriLipix
®
), gemfibrozil (Lopid
®
), ciprofibrate, Wy-14,643 and 
chemicals such as certain industrial plasticizers (DEHP, di-(2-ethylhexyl)-adipate 
(DEHA)), herbicides (phenoxyacetic acid) and pesticides (diclofop-methyl and pyrethrin 
family) (7-13). While, short-term administration of synthetic PPARα ligands in mice or 
rats leads to transactivation of genes involved in lipid catabolism, chronic administration 
leads to peroxisomal proliferation and hepatic carcinomas (7-13). The chronic effects of 
PPARα agonists are not seen in non-rodent species like guinea pig, dog, rhesus monkeys, 
nonhuman primates or humans (100-104) where they serve as potent hypolipidemic 
agents to lower plasma VLDL and triglyceride levels and increase high density 
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lipoprotein (HDL) levels. For this reason PPARα agonists have continued to be an 
attractive drug target for the pharmaceutical industry and are used in the treatment of 
dyslipidemia. In conjunction with statins, they are also prescribed in the treatment of 
hypercholesterolemia (high cholesterol) (8-10, 105-107). Other chemicals, particularly 
plasticizers (example DEHP - used in the manufacturing of plastics) and herbicides that 
activate PPARα are potential environmental toxins that contaminate ground water. While 
their acute impact in human health is unclear, they do raise long-term or lifetime health 
concerns.   
 A quest for natural endogenous ligands revealed that PPARα was not an orphan 
receptor. Pioneering studies using different reporter assays (GAL4, chloramphenicol 
acetyltransferase or CAT assay, luciferase), CARLA assays and competition assays 
(radioactive) demonstrated that a variety of fatty acids and their derivatives are able to 
interact with, and transactivate PPARα (83, 84, 108-113). These include fatty acid 
derivatives obtained via lipoxygenase (leukotriene B4 or LTB4, hydroxyeicosatetraenoic 
acid or HETE) or cycloxygenase (prostaglandins) pathways (111, 112), branched chain 
fatty acids (phytanic acid) (114) and long chain dietary fatty acids (115-117). As such, 
fatty acids and their metabolites that interact with PPARα can be derived from the diet or 
obtained via de novo synthesis. Alternatively, it has been proposed that fatty acids and 
their derivatives are presented to PPARα in the nucleus by specific intracellular proteins 
such as fatty acid binding protein (FABP) or acyl-CoA binding protein (ACBP) (118, 
119). This hypothesis is supported by data demonstrating interaction of FABP with fatty 
acids and their ability to translocate across to the nucleus to interact with PPARα (88, 89, 
95, 120).   
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 Evidence suggests that PPARα has evolved to primarily sense endogenous lipids 
and/or lipid metabolites as ligands and regulate the expression of target genes involved in 
their metabolism (111, 114, 121). The first set of evidence for this came from studies 
involved the use of fatty acyl CoA oxidase 1 (ACOX1) knockout mice (121). ACOX is 
the first and rate limiting enzyme involved in the fatty acid β-oxidation pathway and is 
regulated by PPARα. Disruption of ACOX1 caused accumulation of long chain fatty 
acyl-CoA and profound activation of PPARα (owing to accumulation of PPARα ligands) 
(121). Another study that highlighted the role of PPARα as a lipid sensor was done 
utilizing PPARα knockout mice (PPARα-/-). LBT4 is an inflammatory eicosanoid 
derived from arachidonic acid that activates PPARα and induces genes that would 
neutralize or degrade LBT4 itself (111). Exposure of PPARα-/- mice to LBT4 (or its 
precursors) leads to a prolonged inflammatory response (compared to wild-type mice) 
because genes involved in neutralizing the inflammatory response are not induced (111). 
Today it is established that PPARα plays a crucial role not only in the transport 
and β-oxidation (break-down) of fatty acids but also in the inhibition of de novo fatty acid 
synthesis (8-10). Since altered levels of fatty acids are associated with the development of 
diabetes, obesity, hypertension, cardiovascular diseases and atherosclerosis, mis-
regulation of PPARα activity and/or metabolic pathways may contribute to the pathology 
of these disease states. Alternately PPARα activation by pharmacological or dietary 
intervention may help combat obesity and its co-morbities. 
Physiological role of PPARα in lipid metabolism: Lipid metabolism orchestrated 
in the liver primarily involves fatty acid oxidation and lipogenesis. Fatty acid oxidation 
primarily occurs in three main subcellular organelles: mitochondria, peroxisomes (β-
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oxidation) and microsomes (ω-oxidation). Some of the key enzymes involved in these 
processes possess PPRE motifs in their promoters and are under direct control of PPARα. 
These include 1) proteins involved in the transport of fatty acids into the cell such as fatty 
acid transport protein (FATP), fatty acid translocase (FAT/CD36) (122, 123), fatty acid 
binding protein (FABP) (124) and carnitine palmitoyl transferase I (CPT I) (125) (Fig. 5), 
2) the enzyme that esterifies free fatty acids into fatty acyl coenzyme A – acyl CoA 
synthase (126), 3) enzymes involved in the process of peroxisomal, mitochondrial and 
microsomal fatty acid oxidation such as ACOX (17, 40, 127), medium chain acyl CoA 
dehydrogenase (MCAD) (128) and cytochrome P450 (129, 130) amongst others (Fig. 5) 
(25).  
As far as lipogenesis is concerned, PPARα downregulates enzymes involved in de 
novo lipid synthesis such as acetyl CoA carboxylase (ACC) and fatty acid synthase 
(FAS) (Fig. 5) (25). While this effect appears paradoxical to its well established function 
in fat catabolism, it is believed to be an indirect effect brought about by regulation of 
other transcription factors such as sterol regulatory element-binding protein (SREBP-1c) 
and liver X receptor α (LXRα) (8, 9, 131, 132). SREBP-1c is a transcription factor that 
plays crucial role in the regulation of lipogenic genes such as FAS and stearoyl CoA 
desaturase (133). In humans, its role in lipogenesis is under direct regulation of PPARα 
and LXRα - brought via two LXR response elements (LXRE) and one PPRE in the 
SREBP-1c gene (132). Interestingly, LXRα is an ‘oxysterol sensor,’ whose role in 
cholesterol homeostasis and lipogenesis (via SREBP-1c) is under direct regulation of 
PPARα via an active PPRE found in its regulatory region (134). Thus PPARα regulates 
lipogenesis in a dual manner – directly via SREBP-1c and indirectly via LXRα.  
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Fig. 5. Example of some genes regulated by PPARα and their role in lipid metabolism. 
Upregulated genes are shown in green and include FATP – fatty acid transport protein, 
FABP – fatty acid binding protein, MCAD – medium chain acyl CoA dehydrogenase, 
P450 – cytochrome P450 fatty acid ω-hydroxylase, ACOX – acyl CoA oxidase, CPTI – 
carnitine palmitoyl transferase I and ACC – acetyl CoA carboxylase. Downregulated 
genes are shown in red and include FAS – fatty acid synthase and ACS – acyl CoA 
synthetase. FFA – free fatty acids. 
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Physiological role of PPARα in lipoprotein metabolism: Owing to enhanced β-oxidation 
caused by PPARα agonists, triglyceride-rich lipoprotein particles are subjected to 
catabolism - resulting in decreased secretion of very low density lipoproteins (VLDL) by 
the liver (8).  PPARα agonists also induce lipoprotein lipase (LPL) activity resulting in 
increased triglyceride hydrolysis. This effect is brought about in a dual manner: 1) they 
induce the LPL promoter (containing a PPRE) (135) and 2) they reduce the activity/levels 
of apolipoprotein (Apo) C-III (ApoC-III) which is an inhibitor of LPL (136, 137). The 
expression of human ApoA-I and ApoA-II is also under direct control of PPARα and 
such regulation is not seen in rodents (138, 139). ApoA-I and ApoA-II are major 
component of HDL that help clear cholesterol (138, 139). Therefore in humans, PPARα 
agonists increase the formation and secretion of HDL, and aid in transport (reverse 
cholesterol transport) and excretion of cholesterol (anti-atherosclerotic) (8, 138, 139). In 
addition to these effects, PPARα agonists also bring about cholesterol homeostasis 
indirectly  through LXRα-mediated regulation/induction of ATP-cassette transporter A1 
(ABCA1) and cholesterol 7α-hydroxylase (CYP7A) – resulting in an efflux and excretion 
of cholesterol into bile (140, 141).   
Physiological role of PPARα in inflammation: PPARα brings about anti-inflammatory 
actions by two means. First, PPARα directly binds inflammatory fatty acid derivatives 
like LBT4 and promotes their breakdown/metabolism by inducing genes involved in such 
pathways (111). Second, PPARα agonists decrease/inhibit inflammatory cytokines (IL-1, 
IL-6), tumor necrosis factor α (TNFα), inducible nitric acid synthase (iNOS) and 
cyclooxygenase-2 (COX-2) indirectly via negative crosstalk with the nuclear factor-
kappa beta (NfκB) (142, 143). In chronic hyperlipidemia and/or early atherosclerosis 
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macrophages engulf oxidized LDL (generated via free oxygen radicals), giving rise to 
macrophage foam cells. When these foam cells accumulate at particular foci within the 
intima of a blood vessel, it begins the formation of a necrotic, inflammatory 
atherosclerotic lesion (144).  Owing to the beneficial role played by PPARα in reducing 
inflammation (preventing formation of oxidized LDL) and promoting reverse cholesterol 
transport (described above), PPARα agonists prevent the formation of macrophage foam 
cells and also have anti atherosclerotic effects (8, 138-141).  
PPARα knockout mice model: Gonzalez et al. generated the first PPARα knockout mouse 
by targeted disruption of the PPARα ligand binding domain coding region (145). These 
mice are viable, fertile and display no detectable gross phenotype. However, under 
condition of fasting these mice exhibit severe hypoglycemia and hypothermia (145). 
While such fasting would normally result in PPARα activation and induction of fatty acid 
oxidation, in PPARα knockout mice, fatty acid oxidation is largely impaired, resulting in 
enhanced accumulation of fat droplets in the liver (145). The role of PPARα in lipid 
homeostatis is further highlighted by the fact that PPARα knockout mice exhibit reduced 
capacity to metabolize long chain fatty acids and develop dyslipidemia and steatosis 
(146-148). These findings therefore augment the role of PPARα as a lipid sensor in the 
regulation of lipid metabolism.    
Although PPARα knockout mice display normal basal levels of peroxisomal β-
oxidation enzymes in the liver, administration of synthetic PPARα agonists fails to 
induce PPARα responsive genes such as ACOX (145). In contrast to the normal basal 
levels of peroxisomal β-oxidation enzymes in the liver, PPARα knockout mice display 
lower levels of mitochondrial fatty acid oxidation enzymes (146). PPARα knockout mice 
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also do not display the ‘classical’ peroxisome proliferator response and fail to develop 
hepatic cancers when chronically treated with PPARα agonists such as clofibrate or 
WY14,643 (145). Further, transgenic PPARα knockout mice that express human PPARα 
in the liver also do not exhibit any liver tumors when chronically exposed to PPARα 
agonists such as WY14,643 (149, 150) - suggesting that there exist some species 
variation in the structure/function of PPARα. All these findings with PPARα knockout 
mice have during the past 18 years have further highlighted the role of PPARα in energy 
homeostasis and inflammation. 
Development of hypothesis 
Although a plethora of exogenous ligands have been shown to activate PPARα, 
the identity of high-affinity endogenous ligands has been more elusive. In the last two 
decades, an overwhelming amount of data indicate that PPARα is not an orphan receptor, 
and that fatty acids and its derivatives are able to regulate PPARα transcriptional activity. 
The first endogenous ligands (fatty acids) able to activate PPARα were identified in 
transactivation assays that used the glucocorticoid response element or estrogen response 
element containing reporters and chimeric receptor constructs of glucocorticoid receptor 
DBD and PPARα-LBD or estrogen receptor DBD and PPARα-LBD (109, 110). 
However, since such transactivation could result from multiple indirect pathways, the 
direct interaction of fatty acids with PPARα had to be tested.  
 Owing to its important role in regulating metabolism and energy homeostasis, a 
number of assays have been developed to study the interaction of fatty acids and their 
derivatives with recombinant forms of mouse and xenopous PPARα. These include: 1) 
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Radioligand binding assays – these are competition assays based on displacement of 
bound radioligand by the ligand of interest (108, 111), 2) Scintillation proximity assays – 
uses scintillation to measure the binding of a receptor-bound radioligand to another 
molecule localized to a microsphere (151), 3) Limited proteolysis assays – based on the 
protease sensitivity of the receptor in presence and absence of ligand (53), 4) Ligand 
induced complex (LIC) assays – based on the ligand dependent binding of PPAR-RXR 
heterodimer to a PPRE (113), and 5) Co-activator recruitment assays – based on the 
ligand dependent recruitment of co-activators (83). A combination of all of these studies 
have indicated that fatty acids and their metabolites (fatty acyl-coenzyme A) interact with 
this class of nuclear receptors (83, 84, 108-113). These studies utilized the recombinant 
LBD of mouse, rat, or xenopous PPARα protein and reported binding affinities (Kd) in 
the micromolar ranges (83, 84, 108-113). Although these studies provide a wealth of 
information, particularly on the possible endogenous ligands for PPARα, they have 
certain limitations. These include limitations in the techniques used, the use of truncated 
and tagged form of PPARα-LBD and the lack of consideration of the possible species 
differences in the activity and function of the PPARα protein. 
In order to be classified as a ligand for a nuclear receptor, mere in vitro physical 
interaction is not sufficient. The ligand must also be present within the cell/nucleus in 
sufficient amounts (46, 118). The nuclear concentration of fatty acids and their 
metabolites have been determined to be in the nanomolar ranges (88, 95, 117, 118, 120, 
152) – making these micromolar binding affinities (for FA and FA-CoA) physiologically 
irrelevant. Many of the assays described above involve the physical separation of bound 
vs. unbound fraction which often disturbs the equilibrium. Therefore dissociation 
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constants (Kd) derived by such means often underestimate the binding affinity (115, 117, 
118). The binding affinities reported for FA and their derivatives from these studies are in 
the micromolar ranges (88, 95, 117, 118, 120, 152) and it is doubtful that local FA 
concentrations will ever reach such high levels in vivo (118). Thus the significance of 
such findings are not clear. 
Pioneering studies by Ellinghaus et al., Lin et al. and Hostetler et al. using 
fluorescence based binding assays circumvented this problem  and reported binding 
affinities for FA and their derivatives in the physiological ranges (114, 115, 117). 
However, these studies were again carried out with truncated forms of the mouse protein 
which may give rise to anomalous results that may not be representative of the human 
PPARα (153, 154). While such studies with truncated/tagged forms of mouse or 
xenopous PPARα have led to accumulation of valuable information particularly on ligand 
discovery, they also did not account for the A/B domain effects or the likelihood of 
interdomain communication.  
Classically it was believed that nuclear receptor domains are like individual beads 
on a string, such that each domain could function independently. However, an increasing 
number of solution based biophysical studies, some of which are listed below, have 
suggested that nuclear receptor domains are integrated together such that information or 
changes in one part of a domain are transmitted to another (55). For example, 1) Deletion 
or mutation in the N-terminal A/B domain of PPARs affects DNA binding (31), ligand 
binding (34) and ligand-mediated transcriptional activation, depending on the target gene 
(30, 31) and 2) The DBD of nuclear receptors such as androgen receptor, glucocorticoid 
receptor and PPARs has been demonstrated to communicate with their respective LBD 
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such that the DBD impacts the receptor structure and activity at the LBD (155-157). 
These findings emphasize the need to carry out binding studies using putative 
endogenous ligands for PPARα and full-length forms of the protein.  
While FA and FA-CoA have been demonstrated to serve as ligands for mouse, rat 
and xenopous forms of PPARα (16, 108, 110, 113, 115-117) no such studies have been 
conducted using the full-length human PPARα (hPPARα). This is an important gap in 
research that needs to be addressed, because, based on the type of assays used, these same 
studies also demonstrate species differences for ligand specificity and affinity (16, 84, 
108, 110, 113, 115-117). For example the xenopus PPARα seems to have a weaker 
affinity for fatty acids than hPPARα (84, 108), but higher affinity than rat PPARα (83, 
110). Similar differences in the binding and activation of PPARα has also been seen in 
response to synthetic agonists (158-160). While a strong divergence in the pattern of 
PPARα regulated genes has been seen in humans vs. rodents, differences in the extent of 
transcriptional activation of human and mouse PPARα proteins have also been observed 
in response to certain hypolipidemic agents and pthalate monoesters (161-163). Since a 
single amino acid change in the mouse PPARα-LBD (E282) resulted in altered activity of 
the protein (164) and alteration of a single amino acid in human PPARα (V444M) 
produced PPARδ ligand binding characteristics (52), it is possible that amino acid 
differences affect ligand binding.  
Considering the crucial role of PPARα in lipid homeostasis, it is essential to 
elucidate its endogenous ligands of full length forms of the protein using an assay whose 
functional read-out is not just physiologically relevant, but also sensitive enough to 
determine species differences in such binding between the human and mouse forms of the 
36 
 
protein. Therefore, we hypothesize that long chain fatty acids (LCFA) and/or their 
thioesters (LCFA-CoA) constitute high affinity endogenous ligands for full-length 
hPPARα and there exist significant differences in such affinity between hPPARα and 
mPPARα. Studies that would ascertain the identity of true endogenous ligands of human 
PPARα would aid in a deeper understanding of energy metabolism and possible 
therapeutic dietary interventions. 
The goals of this dissertation are 1) to investigate whether LCFA and LCFA-CoA 
constitute high-affinity endogenous ligands for full-length hPPARα. These data will be 
important to understand the molecular role of dietary nutrients in hPPARα mediated 
regulation of energy homeostasis. 2) To determine if there exist differences in affinity for 
ligands between hPPARα and mPPARα and further explore the possible mechanisms for 
such differences. This is important because the rodent model has been used as a classical 
model to study PPARα. Such differences in ligand binding specificity and affinity 
between mouse and human PPARα will call for careful interpretation of data using mouse 
as a model for studying this protein. Further, knowledge about the mechanisms of species 
differences may help develop better drugs and dietary regimens with greater specificity 
for human versus rodent PPARα for combating obesity and its related disorders.   
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CHAPTER I 
DIVERGENCE BETWEEN HUMAN AND MURINE PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTOR ALPHA LIGAND SPECIFICITIES 
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1. Abstract 
Peroxisome proliferator-activated receptor alpha (PPARα) belongs to the family of 
ligand-dependent nuclear transcription factors which regulate energy metabolism.  
Although there exists remarkable overlap in the activities of PPARα across species, 
studies utilizing exogenous PPARα ligands suggest species differences in binding, 
activation, and physiological effects.  While unsaturated long-chain fatty acids (LCFA) 
and their thioesters (long-chain fatty acyl-CoA; LCFA-CoA) function as ligands for 
recombinant mouse PPARα (mPPARα), no such studies have been conducted with full-
length human PPARα (hPPARα).  The objective of the current study was to determine 
whether LCFA and LCFA-CoA constitute high-affinity endogenous ligands for hPPARα 
or whether there exist species differences for ligand specificity and affinity.  Both 
hPPARα and mPPARα bound with high affinity to LCFA-CoA; however, differences 
were noted in LCFA affinities.  A fluorescent LCFA analogue was bound strongly only 
by mPPARα and naturally-occurring saturated LCFA were bound stronger by 
hPPARα than mPPARα.  Similarly, unsaturated LCFA induced transactivation of both 
hPPARα and mPPARα, while saturated LCFA induced transactivation only in 
hPPARα expressing cells. These data identified LCFA and LCFA-CoA as endogenous 
ligands of hPPARα, demonstrated species differences in binding specificity and activity, 
and may help delineate the role of PPARα as a nutrient sensor in metabolic regulation 
(165). 
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2. Introduction 
Whole body energy homeostasis is regulated in part by nutrient-sensing 
members of the nuclear hormone receptor superfamily of ligand-dependent 
transcription factors, such as the peroxisome proliferator-activated receptor alpha 
(PPARα).  Like other nuclear hormone receptors, the PPARα protein is comprised of 
several distinct domains, including a highly conserved DNA binding domain (DBD) 
and a less conserved C-terminal ligand binding domain (LBD).  In highly metabolic 
tissues such as liver and heart, PPARα heterodimerizes with the retinoid X receptor 
alpha (RXRα, and this heterodimer potently activates genes involved in fatty acid 
oxidation (39, 110, 166).  At a cellular level PPARα regulates fatty acid metabolism, 
glucose metabolism, inflammation, differentiation, and proliferation (167-169). 
Although a multitude of exogenous ligands have been shown to activate both 
human and mouse PPARα (17, 39, 162, 170), the identity of high-affinity endogenous 
ligands has been more elusive. Studies utilizing recombinant PPARα proteins have 
largely focused on the ligand binding domain of mouse PPARα (mPPARα).  These 
studies suggest that long-chain fatty acids (LCFA) and their activated metabolites 
(long-chain acyl-CoAs, LCFA-CoA) may function as endogenous PPARα ligands 
(114-117).  Such ligand binding has been shown to induce PPARα conformational 
changes and increase transactivation, consistent with expectations for an endogenous 
ligand of a nuclear receptor. 
While LCFA and LCFA-CoA have been studied as putative ligands for mouse 
PPARα (mPPARα), no such studies have been conducted with the full-length mPPARα 
or human PPARα (hPPARα).  Although there exists remarkable overlap in the activities 
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of PPARα across species, human and mouse PPARα proteins promote transcription to a 
different extent in response to certain hypolipidemic agents and pthalate monoesters 
(161-163), suggesting species difference may exist. Administration of PPARα agonists 
(e.g. Wy-14,643) to rodents results in peroxisome proliferation and hepatic cancer – 
effects not observed in humans (102).  Even though human and mouse PPARα proteins 
share 91% identity (18), the observed physiological responses to exogenous activators 
suggest that minor sequence differences may be important to PPARα function. 
The objective of the current study was to elucidate whether LCFA and/or 
LCFA-CoA constitute high-affinity endogenous ligands for full-length hPPARα and to 
determine if species differences affect ligand specificity.  Since elevated LCFA are 
associated with metabolic, endocrine, and cardiovascular complications, these data are 
important for understanding the molecular role of dietary nutrients in PPARα mediated 
energy homeostasis.  As putative ligands of PPARα, LCFA and/or LCFA-CoA may 
control their own metabolism by binding PPARα and inducing PPARα regulated genes 
important for fatty acid uptake, transport, and oxidation.  Thus, dysregulated LCFA 
could alter the transcriptional activity of PPARα leading to hyper- or hypo- activation 
of these genes and further contributing to the metabolic imbalance. 
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3. Materials and Methods 
Chemicals: Fluorescent fatty acid (BODIPY-C12, BODIPY-C16, NBD stearate) 
were purchased from Molecular Probes, Inc. (Eugene, OR).  Eicosapentaenoyl-CoA, 
docosapentaenoyl-CoA, docosahexaenoyl-CoA, BODIPY C12-CoA BODIPY C16-
CoA were synthesized by Ms. Alagammai Kaliappan (Hostetler lab) and purified by 
HPLC as previously described ( 1 1 7 ,  1 7 1 ) , and found to be >99% unhydrolyzed.  
All other fatty acid ligands and clofibrate were from Sigma-Aldrich (St. Louis, MO). 
Rosiglitazone (LKT labs) was a kind gift from Dr Khalid Elased and bovine serum 
albumin (lipid-free) was obtained from Gemini Bioproducts (Sacramento, CA).  
Purification of Recombinant PPARα protein: Full-length hPPARα (amino 
acids 1-468) and full-length mPPARα (amino acids 1-468) were used for all 
experiments presented herein. Bacterial expression plasmids for full-length hPPARα 
(6xhis-GST-hPPARα) and full-length mPPARα (6xhis-GST-mPPARα) were produced 
by Dr. S. Dean Rider, Jr. (Wright State University). Protein expression, purification, 
and optimization of hPPARα protein was conducted by Ms. Madhumitha 
Balanarasimha (172).  Mouse PPARα was purified using the protocol designed by Ms. 
Balanarasimha (172). Briefly, 6xhis-GST-PPARα fusions were expressed in Rosetta
™
2 
cells (Novagen, Gibbstown, NJ) and purified by GST affinity chromatography. Eluted 
proteins were concentrated, dialyzed, and tested for purity by SDS-PAGE with 
Coomassie blue staining and immunoblotting as previously described (116, 117).  
Protein concentrations were estimated by Bradford Assay (Bio-Rad Laboratories, 
Hercules, CA) and by absorbance spectroscopy using the molar extinction coefficient 
for the protein.  
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Direct Fluorescent Ligand Binding Assays: Fluorescent ligand (BODIPY C16 
or BODIPY C16-CoA) binding measurements were performed as described earlier 
(117, 173). Briefly, 0.1 µM hPPARα or mPPARα was titrated with increasing 
concentrations of fluorescent ligand.  This concentration of PPARα protein was chosen, 
because it gave the maximal signal to noise ratio, while allowing saturable binding of 
most of the examined ligands to be reached at concentrations below their critical 
micellular concentrations. The CMC for fatty acids and fatty acyl-CoA tested herein 
ranges from 1-200 µM (174). It decreases with chain length and is highly dependent on 
temperature, pressure and presence of electrolytes (175, 176).  
Fluorescence emission spectra (excitation, 465 nm; emission, 490-550 nm) were 
obtained at 24°C with a PC1 photon counting spectrofluorometer (ISS Inc., 
Champaign, IL) and corrected for background (protein only and fluorescent ligand 
only). The dissociation constant (Kd) was calculated from a single site saturation plot of 
fluorescence intensity (Fi) versus concentration (C) according to equation 1 as 
previously described (117, 177, 178). 
  
       
     
                                                      (Eq. 1) 
where Bmax represents the maximal fluorescence (Fmax) and y is the fluorescence intensity 
at a given concentration of ligand, x. The saturation curves were also fitted to a Hill plot 
according to equation 2 as described previously (116, 117) to determine the number of 
binding sites (n) (117).  
  
   
      
                                              (Eq. 2) 
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where, a is the maximal fluorescence (Fmax), b is the number of binding sites (n), and c is 
the Kd. A double reciprocal plot of 1/(1-Fi/Fmax) and C/(Fi/Fmax) was also used to confirm 
the dissociation constant (Kd) equal to the number of binding sites (n). The slope of the 
line resulting from such a plot was equal to 1/Kd and the number of linear lines is equal 
to the number of binding sites (n) (116, 117). 
Displacement of Bound  Fluorescent BODIPY C16-CoA by Non-fluorescent 
Ligands: Based on the binding affinities obtained with the direct fluorescent ligand 
binding assays for BODIPY C16-CoA, 0.1 µM PPARα was mixed with BODIPY C16-
CoA at the concentration where maximal fluorescence intensity first occurred (75nM 
for hPPARα and 130nM for mPPARα).  The maximal fluorescence intensity was 
measured, and the effect of increasing concentrations of naturally-occurring ligands 
was measured as a decrease in fluorescence (115-117, 173).  Emission spectra were 
obtained and corrected for background as described above for BODIPY. The inhibition 
constant (Ki) value for each ligand was estimated according to equation 3 (115-117, 
173). 
          
                     
   
         
                
                              
where, EC50ligand represents the concentration of naturally-occurring ligands required for 
displacing half of the fluorescent BODIPY-C16-CoA from the protein, Ki,ligand is the 
efficiency of the ligand to displace BODIPY C16-CoA, and Kd,BODIPY C16-CoA is the 
binding affinity of BODIPY C16-CoA obtained as described above.  
Quenching of PPARα Aromatic Amino Acid Residues by Non-fluorescent 
Ligands: The direct binding of hPPARα or mPPARα to non-fluorescent ligands was 
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determined by quenching of intrinsic PPARα aromatic amino acid fluorescence as 
described (116, 117).  Briefly, hPPARα or mPPARα (0.1 µM) was titrated with 
increasing concentrations of ligand.  Emission spectra from 300-400 nm were obtained 
at 24°C upon excitation at 280 nm with a PC1 photon counting spectrofluorometer (ISS 
Inc., Champaign, IL).  Data were corrected for background and inner filter effects, and 
a single site saturation plot of the change in fluorescence intensity (Fo-Fi) versus 
concentration (C) was used to determine the inhibition constant (Kd) as per equation 1 
(117). In this case, Bmax represents the maximal change in fluorescence (Fo-Fmin) and y 
is the change in fluorescence intensity (Fo-F) at a given concentration of ligand, x (116, 
117). The number of binding sites (n) was determined using a hill plot generated as per 
equation 2 where, a is the maximal change in fluorescence (Fmax), b is the number of 
binding sites (n), and c is the Kd (116, 117, 173). A double reciprocal plot of 1/(1-
Fi/Fmax) and C/(Fi/Fmax) was further used to confirm the number of binding sites (n) as 
described above. However, in this case Fi represents the change in fluorescence (Fo-F) 
and Fmax represents the maximal change in fluorescence.  
Secondary Structure Determination Effect of ligand binding on PPARα Circular 
Dichroism:  Circular dichroic spectra of hPPARα or mPPARα (0.6 µM in 600 µM 
HEPES pH 8.0, 24 µM dithiothreitol, 6 µM EDTA, 6 mM KCl and 0.6 % glycerol) 
were taken in the presence and absence of LCFA and LCFA-CoA (0.6 µM) with a J-
815 spectropolarimeter (Jasco Inc., Easton, MD) as previously described (116, 117).  
Spectra was recorded from 260 to 187 nm with a bandwidth of 2.0 nm, sensitivity of 10 
millidegrees, scan rate of 50 nm/min and a time constant of 1 s.  Ten scans were 
averaged for percent compositions of α-helices, β-strands, turns and unordered 
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structures with the CONTIN/LL program of the software package CDpro (116, 117, 
179). 
Mammalian Expression Plasmids: Mammalian expression plasmids pSG5-
hPPARα, pSG5-mPPARα, pSG5-hRXRα, and pSG5-mRXRα were produced by Dr. S. 
Dean Rider, Jr. (Wright State University). The reporter construct, PPRE×3 TK LUC 
was a kind gift of Dr. Bruce Spiegelman (Addgene plasmid # 1015) and contained 
three copies of the acyl-CoA oxidase (ACOX) peroxisome proliferator response 
element (PPRE) (180). 
Cell culture and Transactivation assays: COS-7 cells (ATCC, Manassas, VA) 
were grown in DMEM supplemented with 10 % fetal bovine serum (Invitrogen, Grand 
Island, NY) at 37°C with 5% CO2 in a humidified chamber.  Cells were seeded onto 
24-well culture plates and transfected with Lipofectamine™ 2000 (Invitrogen, Grand 
Island, NY) and 0.4 µg of each full-length mammalian expression vector (pSG5-
hPPARα, pSG5-hRXRα, pSG5-mPPARα, pSG5-mRXRα) or empty plasmid (pSG5), 
0.4 µg of the PPRE×3 TK LUC reporter construct, and 0.04 µg of the internal 
transfection control plasmid pRL-CMV (Promega Corp., Dinosaur, WI) as previously 
described (117, 173).  Following transfection incubation, medium was replaced with 
serum-free medium for 2 h, ligands (1µM) were added, and the cells were grown for an 
additional 20 h.  Fatty acids were added as a complex with bovine serum albumin 
(BSA) as described (181).  Firefly luciferase activity, normalized to Renilla luciferase 
(for transfection efficiency), was determined with the dual luciferase reporter assays 
system (Promega, Madison, WI) and measured with a SAFIRE
2
 microtiter plate reader 
(Tecan Systems, Inc. San Jose, CA).  Clofibrate treated samples overexpressing both 
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PPARα and RXRα were arbitrarily set to 1. 
Statistical Analysis: Data were analyzed by SigmaPlot™ (Systat Software, San 
Jose, CA) and a one-way ANOVA was used to evaluate overall significance.  A Fisher 
Least Significant difference (LSD) post-hoc test was used to identify individual group 
differences.  The results are presented as mean ± SEM.  The confidence limit of p < 0.05 
was considered statistically significant. 
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4. Results 
Full-length hPPARα and mPPARα protein purification: Based on recent 
demonstrations that truncation of a nuclear transcription factor can significantly affect 
ligand binding affinity, specificity, and consequently receptor activity (153, 154), full-
length hPPARα and mPPARα were used for all experiments.  SDS-PAGE and 
Coomassie blue staining indicated predominant bands of 52 kDa corresponding to the 
expected size of full-length hPPARα and mPPARα, for which densitometry indicated 
greater than 85% purity (Fig. 6A).  Western blotting confirmed that the predominant 
protein bands were PPARα (Fig. 6B). 
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Fig. 6. (A) SDS-PAGE and Coomassie blue staining of 3 µg and 6 µg purified 
recombinant hPPARα (left) and mPPARα (right) showing relative purity of the protein. 
The prominent band at 52 kDa is full-length, untagged recombinant PPARα. (B) 
Western blot of 1 µg purified recombinant hPPARα (left) and mPPARα (right) 
confirming the 52 kDa band is untagged, full-length PPARα. 
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Binding of fluorescent fatty acid and fatty acyl-CoA to PPARα:  The sensitivity 
of the BODIPY fluorophore to environmental hydrophobicity is useful for determining 
if binding represents a direct molecular interaction within the hydrophobic ligand 
binding pocket of PPARα.  In aqueous buffer without protein, BODIPY fluorescence 
was low for each of the examined fluorophores.  Titration of hPPARα with BODIPY 
C16-CoA resulted in increased fluorescence with an emission maximum near 515 nm 
(Fig. 7A).  This increased fluorescence was saturable near 100 nM (Fig. 7B, circles), 
indicating high affinity binding (Kd = 25 ± 4 nM).  These data transformed into a linear 
double reciprocal plot (Fig. 7B, inset), consistent with a single binding site (R
2
 > 0.95).  
In contrast, a smaller, non-saturable increase in fluorescence was seen upon titration of 
hPPARα with BODIPY C16 fatty acid (Fig. 7C), indicating only weak or non-specific 
binding.  Binding of hPPAR to BODIPY C12 fatty acid (Fig. 7D, triangles), BODIPY 
C12-CoA (Fig. 7D, filled circles) or NBD stearate (Fig. 7E) resulted in non-saturable 
changes in fluorescence (Kd > 450 nM).  
Titration of mPPARα with BODIPY C16-CoA resulted in a similar increase in 
BODIPY C16-CoA fluorescence (Fig. 8A) as noted for hPPARα, with the exception 
that slightly higher BODIPY C16-CoA concentrations were required to reach saturation 
(Fig. 8B).  This resulted in a lower binding affinity (Kd = 65 ± 9 nM), but was still 
consistent with a single binding site (Fig. 8B, and inset).  While hPPARα binding to 
BODIPY C16 fatty acid was non-saturable, mPPARα binding to BODIPY C16 fatty 
acid resulted in strong fluorescence changes with saturation near 50 nM (Fig. 8C), 
suggesting high affinity binding (Kd = 19 ± 4 nM).  Although these data were consistent 
with previous data suggesting that a truncated mPPARα protein can bind to both 
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BODIPY C16 fatty acid derivative and BODIPY C16-CoA with high affinity (173), 
these data also suggested that species differences exist in ligand binding specificity. 
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Fig. 7.  (A) Corrected fluorescence emission spectra of 0.1 M hPPAR titrated with 0 
(filled circles), 10 (open circles), 20 (filled triangles), 50 (open triangles), 75 (filled 
squares) and 100 nM (open squares) of BODIPY C16-CoA upon excitation at 465 nm, 
demonstrating increased fluorescence intensity upon binding to hPPAR.  Plot of 
hPPAR maximal fluorescence emission as a function of BODIPY C16:0-CoA (B) and 
BODIPY C16:0 FA (C).  Plot of the maximal hPPARα fluorescence emission as a 
function of BODIPY C12:0 FA (D, triangles), BODIPY C12:0-CoA (D, filled circles) 
and NBD stearate (E, filled circles) concentration. Insets reperesent linear plots of the 
binding curves for BODIPY C16-CoA (B), BODIPY C16 FA (C) BODIPY C12-CoA 
(D) and NBD stearate (E).  All values represent the mean ± S.E., n ≥ 3.  
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Fig. 8. (A) Corrected fluorescence emission spectra of 0.1 M mPPAR titrated with 0 
(filled circles), 20 (open circles), 50 (filled triangles), 75 (open triangles), 100 (filled 
squares) and 200 nM (open squares) of BODIPY C16-CoA upon excitation at 465 nm, 
demonstrating increased fluorescence intensity upon binding to mPPAR.  Plot of 
mPPAR maximal fluorescence emission as a function of BODIPY C16:0-CoA (B) and 
BODIPY C16:0 FA (C).  Insets represent linear plots of the binding curve from each 
panel. All values represent the mean ± S.E., n ≥ 3.  
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bound BODIPY C16-CoA:  To determine the ligand specificity of hPPARα for 
naturally-occurring, endogenous fatty acids, LCFA and LCFA-CoA were examined for 
their ability to displace BODIPY C16-CoA from the hPPARα ligand binding pocket, 
which was observed as decreased BODIPY fluorescence.  With the exception of lauric 
acid and lauryl-CoA (Fig. 9U, Fig. 9V), titration with fatty acids and fatty acyl-CoAs 
resulted in significantly decreased BODIPY fluorescence (Fig. 9A-R).  Quantitative 
analyses of these data suggested strong affinity binding (Ki = 10-40 nM, Table I).  By 
comparison, the synthetic PPARα agonist clofibrate showed slightly weaker affinity 
(Fig. 9S; Ki = 48 nM), while the synthetic PPARγ agonist rosiglitazone showed no 
displacement (Fig. 9T; Table I).  These data revealed that both LCFA and LCFA-CoA 
are capable of displacing a fluorescent fatty acyl-CoA, suggesting that both LCFA and 
LCFA-CoA could be endogenous ligands of hPPARα.  These data are in contrast with 
displacement studies conducted with a truncated form of mPPARα, which showed that 
only unsaturated LCFA, but not saturated LCFA, could displace a bound fluorescent 
fatty acid (115), and suggest that important differences may exist between hPPARα and 
mPPARα. 
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Fig. 9. Interaction of naturally occurring fatty acids and fatty acyl-CoA with hPPARα 
based on displacement of hPPARα-bound BODIPY C16-CoA. hPPARα complexed with 
BODIPY C16-CoA at mole ratio corresponding to the number of binding sites was 
titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA, (C) palmitoleic 
acid, (D) palmitoleoyl-CoA (E) stearic acid (F) stearoyl-CoA, (G) oleic acid, (H) oleoyl-
CoA, (I) linoleic acid, (J) linoleoyl-CoA (K) arachidonic acid, (L) arachidonoyl-CoA (M) 
eicosapentaenoic acid, (N) eicosapentaenoyl-CoA, (O) docosapentanoic acid, (P) 
docosapentanoyl-CoA, (Q) docosahexanoic acid, (R) docosahexanoyl-CoA, (S) 
clofibrate, (T) rosiglitazone, (U) lauric acid and (V) lauryl-CoA. The maximal 
fluorescence emission of BODIPY C16-CoA was measured at 515 nm (excitation at 465 
nm). Data are presented as percent change of initial fluorescence plotted as a function of 
ligand concentration. All values represent mean ± S.E., n ≥ 3. 
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Binding of endogenous LCFA and LCFA-CoA to mPPARα – Displacement of 
bound BODIPY C16-CoA:  To compare the ability of naturally-occurring LCFA and 
LCFA-CoA to displace BODIPY C16-CoA from the binding pocket of mPPARα 
(versus hPPARα), we first mixed mPPARα with a saturating concentration of BODIPY 
C16-CoA. Since the BODIPY C16-CoA binding affinity for mPPARα is much weaker 
than for hPPARα, a higher concentration of BODIPY C16-CoA is needed to reach 
saturation and ensure BODIPY C16-CoA-bound mPPARα (130 nM). This was 
followed by titration with naturally occurring LCFA and LCFA-CoA. Displacement of 
bound BODIPY C16-CoA was observed as a decrease in BODIPY fluorescence.  With 
the exception of lauric acid and lauryl-CoA (Fig 10O, 10P), titration with fatty acids 
and fatty acyl-CoA resulted in significantly decreased BODIPY fluorescence (Fig. 
10A-L).  Quantitative analyses of these data suggested that, with the exception of the 
saturated LCFA (palmitic acid, Ki = 135 nM and stearic acid, Ki = 134 nM), most 
LCFA and LCFA-CoA demonstrated strong affinity binding (Ki = 13-38 nM, Table II) 
for mPPARα.  The mPPARα showed similar displacement and affinity for the synthetic 
PPARα agonist clofibrate (Fig 10M; Ki = 46 nM, Table II) as compared hPPARα 
(Table I), and the synthetic PPARγ agonist rosiglitazone showed no displacement (Fig. 
10N; Table II).  These data show that LCFA and LCFA-CoA are both capable of 
displacing a fluorescent fatty acyl-CoA, suggesting that both LCFA and LCFA-CoA 
could be endogenous ligands of mPPARα.  When compared to binding data from 
hPPARα (Table I), these data also suggest differences in the ligand binding specificity 
between hPPARα and mPPARα, particularly for saturated LCFA. 
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Fig. 10. Interaction of naturally occurring fatty acids and fatty acyl-CoA with mPPARα 
based on displacement of mPPARα-bound BODIPY-C16 CoA. mPPARα complexed 
with BODIPY C16-CoA at mole ratio corresponding to the number of binding sites was 
titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA, (C) palmitoleic 
acid, (D) palmitoleoyl-CoA (E) stearic acid (F) stearoyl-CoA, (G) oleic acid, (H) oleoyl-
CoA, (I) eicosapentaenoic acid, (J) eicosapentaenoyl-CoA, (K) docosahexanoic acid (L) 
docosahexanoyl-CoA, (M) clofibrate, (N) rosiglitazone (O) lauric acid and (P) lauryl-
CoA.  The maximal fluorescence emission of BODIPY C16-CoA was measured at 515 
nm (excitation at 465 nm). Data are presented as percent change of initial fluorescence 
plotted as a function of ligand concentration. All values represent mean ± S.E., n ≥ 3. 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
Binding of endogenous LCFA and LCFA-CoA to hPPARα – Quenching of 
intrinsic aromatic amino acid fluorescence:  Since previous data has suggested that 
fluorescent fatty acid analogues are not always bound the same as endogenous fatty 
acids due to bulky side chains altering the energy minimized state of the molecule (117, 
173), the binding of LCFA and LCFA-CoA to hPPARα was also measured directly by 
spectroscopically monitoring the quenching of hPPARα aromatic amino acid emission.  
Titration of hPPARα with the saturated LCFA palmitic acid (Fig. 11A) and stearic acid 
(Fig. 11E) yielded sharp saturation curves with maximal fluorescence changes at 100 
nM, and both transformed into linear reciprocal plots (insets), indicating high affinity 
binding at a single binding site (R
2
 > 0.9).  Similar results were obtained for all 
examined LCFA and LCFA-CoA (Fig. 11A-R), with single site binding affinities in the 
10-30 nM range (Table I), similar to affinities determined by displacement assays.  
Titration with lauric acid (Fig. 11U) and lauryl-CoA (Fig. 11V) did not significantly 
alter hPPARα fluorescence, and no binding was detected (Table I).  The PPARα 
agonist clofibrate strongly quenched hPPARα fluorescence (Fig. 11S), but displayed 
weaker affinity than the LCFA (Table I), while the PPARα agonist rosiglitazone 
showed no binding (Fig. 11T), further confirming that hPPARα bound saturated, 
monounsaturated, and polyunsaturated LCFA and LCFA-CoA with high affinity. 
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Fig. 11.  Interaction of naturally-occurring fatty acids and fatty acyl-CoA with hPPAR.  
Direct binding assay based on quenching of hPPAR aromatic amino acid fluorescence 
emission when titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA, 
(C) palmitoleic acid, (D) palmitoleoyl-CoA (E) stearic acid (F) stearoyl-CoA, (G) oleic 
acid, (H) oleoyl-CoA, (I) linoleic acid, (J) linoleoyl-CoA (K) arachidonic acid, (L) 
arachidonoyl-CoA (M) eicosapentaenoic acid, (N) eicosapentaenoyl-CoA, (O) 
docosapentanoic acid, (P) docosapentanoyl-CoA, (Q) docosahexanoic acid, (R) 
docosahexanoyl-CoA, (S) clofibrate, (T) rosiglitazone, (U) lauric acid and (V) lauryl-
CoA.  Data are presented as the change in fluorescence intensity (F0- Fi) plotted as a 
function of ligand concentration.  Insets represent linear plots of the binding curve from 
each panel.  All values represent mean ± S.E., n ≥ 3. 
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Table I. Affinity of hPPAR for non-fluorescent ligands determined by quenching of 
hPPAR aromatic amino acid fluorescence and by displacement of hPPAR-bound 
BODIPY C16-CoA.  
Ligand Chain length: 
double bonds 
(position) 
Kd (nM) 
Fatty 
acid 
Kd (nM) 
Fatty 
acyl-CoA 
Ki (nM) 
Fatty 
acid 
Ki (nM) 
Fatty acyl-
CoA 
Lauric acid/CoA C12:0 ND ND ND ND 
Palmitic acid/CoA  C16:0 22±3 11±1 16±2 10±2 
Palmitoleic acid/CoA C16:1 (n-7) 16±2 29±4 26±6 46±8 
Stearic acid/CoA C18:0 14±2 16±2 13±3 15±2 
Oleic acid/CoA C18:1 (n-9) 19±3 13±1 13±2 16±3 
Linoleic acid/CoA C18:2 (n-6) 12±1 12±2 26±6 40±8 
Arachidonic 
acid/CoA 
C20:4 (n-6) 24±5 23±3 24±3 17±2 
Eicosapentanoic 
acid/CoA 
C20:5 (n-3) 34±4 16±2 38±5 26±5 
Docosapentanoic 
acid/CoA 
C22:5 (n-3) 13±2 18±4 10±2 30±6 
Docosahexanoic 
acid/CoA 
C22:6 (n-3) 30±5 14±1 18±3 28±5 
Clofibrate  58±6  48±6  
Rosiglitazone  ND  ND  
Values represent the mean ± S.E. (n ≥ 3). ND, not determined. 
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Binding of endogenous LCFA and LCFA-CoA to mPPARα – Quenching of 
intrinsic aromatic amino acid fluorescence:  Binding of full-length mPPARα to LCFA 
and LCFA-CoA was also measured by spectroscopically monitoring the quenching of 
mPPARα aromatic amino acid emission.  Although titration with the saturated LCFA 
palmitic acid (Fig. 12A) and stearic acid (Fig. 12E) resulted in decreased mPPARα 
fluorescence, the slopes of these curves were much shallower than that of hPPARα with 
palmitic acid (Fig. 11A) or stearic acid (Fig. 11E), with the change in fluorescence 
intensity plateauing off at approximately 300 nM.  Transformation of these data into 
double reciprocal plots yielded single lines (Fig. 12A, Fig. 12E, insets), indicating 
single binding sites for both.  However, multiple replicates yielded much weaker 
binding affinities for mPPARα (Kd = 92 nM for palmitic acid and 81 nM for stearic 
acid, Table II) than hPPARα (Table I).  Titration of mPPARα with the other examined 
LCFA and LCFA-CoA yielded sharp saturation curves with the maximal change in 
fluorescence intensity noted at approximately 100 nM (Fig. 12A-L) indicating high 
affinity binding (Kd = 14-37 nM, Table II).  These data transformed into linear 
reciprocal plots (insets), indicating binding at a single binding site (R
2
 > 0.9).  Similar 
to hPPARα, no significant mPPARα binding was noted for lauric acid (Fig. 7O), lauryl-
CoA (Fig. 12P), or rosiglitazone (Fig. 12N), while clofibrate binding resulted in the 
strongest fluorescence changes (Fig. 12M).  Although the weak binding of palmitic 
acid and stearic acid to full-length mPPARα was consistent with previous data using 
mPPARΔAB (115-117), it was significantly different from the binding of hPPARα 
with the same ligand (Table I).  On the other hand, while mPPARΔAB demonstrated 
weak binding towards polyunsaturated fatty acids (PUFA), such as eicosapentanoic 
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acid and docosahexaenoic acid, our data employing full-length mPPARα and hPPARα 
demonstrated high-affinity binding for both these PUFA (Table I and Table II).  These 
findings suggest two important conclusions.  There exist species dependent differences 
in the ligand binding specificity and affinity between human and mouse PPARα, and 
the N-terminal domain of PPARα plays an unexpected, but important, role in the ligand 
binding function of the protein. 
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Fig. 12.  Interaction of naturally-occurring fatty acids and fatty acyl-CoA with mPPAR.  
Direct binding assay based on quenching of mPPAR aromatic amino acid fluorescence 
emission when titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA, 
(C) palmitoleic acid, (D) palmitoleoyl-CoA (E) stearic acid (F) stearoyl-CoA, (G) oleic 
acid, (H) oleoyl-CoA, (I) eicosapentaenoic acid, (J) eicosapentaenoyl-CoA, (K) 
docosahexanoic acid (L) docosahexanoyl-CoA, (M) clofibrate, (N) rosiglitazone (O) 
lauric acid and (P) lauryl-CoA.  Data are presented as the change in fluorescence 
intensity (F0- Fi) plotted as a function of ligand concentration.  Insets represent linear 
plots of the binding curve from each panel.  All values represent mean ± S.E., n ≥ 3. 
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Table II. Affinity of mPPAR for non-fluorescent ligands determined by quenching of 
mPPAR aromatic amino acid fluorescence and by displacement of mPPAR-bound 
BODIPY C16-CoA.  
Ligand Chain length: 
double bonds 
(position) 
Kd (nM) 
Fatty 
acid 
Kd (nM) 
Fatty acyl-
CoA 
Ki (nM) 
Fatty 
acid 
Ki (nM) 
Fatty acyl-
CoA 
Lauric acid/CoA C12:0 ND ND ND ND 
Palmitic acid/CoA  C16:0 92±13 14±2 135±13 23±4 
Palmitoleic acid/CoA C16:1 (n-7) 32±3 24±5 35±3 31±4 
Stearic acid/CoA C18:0 81±15 28±5 134±30 37±5 
Oleic acid/CoA C18:1 (n-9) 22±5 37±5 37±4 38±6 
Eicosapentanoic 
acid/CoA 
C20:5 (n-3) 24±6 17±3 33±5 21±3 
Docosahexanoic 
acid/CoA 
C22:6 (n-3) 31±2 24±2 34±3 13±3 
Clofibrate  39±6  46±3  
Rosiglitazone  ND  ND  
Values represent the mean ± S.E. (n ≥ 3). ND, not determined. 
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Effect of endogenous fatty acids and fatty acyl-CoAs on hPPARα secondary 
structure: Ligand-activated receptors, such as PPARα, undergo conformational changes 
upon ligand binding, which allows for altered co-factor interactions (10, 117, 182).  
Circular dichroism was used to examine whether the binding of LCFA or LCFA-CoA 
altered the hPPARα secondary structure.  The far UV circular dichroic spectrum of 
hPPARα suggested the presence of substantial α-helical content, exhibiting a large 
positive peak at 192 nm and two negative peaks at 207 and 222 nm (Fig. 13A-K, filled 
circles).  Quantitative analyses of the circular dichroic spectra confirmed that hPPARα 
was composed of approximately 32 % α-helix, 18 % β-sheets, 21 % β-turns and 29 % 
unordered structures (Table III).   
Since most of the examined ligands were shown to bind at a single binding site, 
ligand effects were measured at a molar concentration equivalent to that of hPPARα.  
The addition of high-affinity LCFA and LCFA-CoA ligands resulted in alterations in 
molar ellipticity at 192, 207, and 222 nm (Fig. 13B-J), demonstrating hPPARα 
conformational changes.  Although both increases and decreases of the 192 nm peak 
were noted, most of the examined LCFA and LCFA-CoA resulted in less negative 
peaks at 207 and 222 nm (Fig. 13B-J), suggestive of decreased α-helical content.  
Quantitative analyses confirmed that most high-affinity LCFA and LCFA-CoA ligands 
significantly decreased the estimated fraction of α-helical content and concomitantly 
increased the estimated fraction of β-sheets (Table III).  However, lauric acid and its 
CoA thioester, which showed no binding, resulted in only minor, non-significant 
changes to the hPPARα secondary structure (Fig. 13A, Table III).  Contrary to 
previously published mPPARα data (116, 117), the strongest conformational changes 
76 
 
were noted with palmitic acid, stearic acid, eicosapentaenoic acid, and docosahexaenoic 
acid (Fig. 13, Table III).  These changes in spectra and percent composition were 
stronger than those observed with the addition of clofibrate (Fig. 13K, open circles, 
Table III), and no changes were observed with the addition of rosiglitazone (Fig. 13K, 
filled triangles, Table III), consistent with the decreased affinity of hPPARα for these 
compounds. 
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Fig. 13.  Far UV circular dichroic (CD) spectra of hPPAR in the absence (filled circles) 
and presence of added ligand: (A) lauric acid (open circles) or lauryl-CoA (filled 
triangles); (B) palmitic acid (open circles) or palmitoyl-CoA (filled triangles); (C) 
palmitoleic acid (open circles) or palmitoleoyl-CoA (filled triangles); (D) stearic acid 
(open circles) or stearoyl-CoA (filled triangles); (E) oleic acid (open circles) or oleoyl-
CoA (filled triangles); (F) linoleic acid (open circles) or linoleoyl-CoA (filled triangles); 
(G) arachidonic acid (open circles) or arachidonoyl-CoA (filled triangles); (H) 
eicosapentaenoic acid (open circles) or eicosapentaenoyl-CoA (filled triangles); (I) 
docosapentanoic acid (open circles) or docosapentanoyl-CoA (filled triangles); (J) 
docosahexanoic acid (open circles) or docosahexanoyl-CoA (filled triangles); and (K), 
clofibrate (open circles) or rosiglitzone (filled triangles).  Each spectrum represents an 
average of 5 scans for a given representative spectrum from at least three replicates. 
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Table III. Effect of ligands on the relative proportion of hPPAR secondary structure 
determined by CD.  These structures were as follows: total helices (H; a sum of regular α-
helices and distorted α-helices), total sheets (S; a sum of regular β-sheets and distorted β-
sheets), turns (Trn; β-turns), and unordered (Unrd) structures. 
Average Total H ± 
S.E. 
Total S ± 
S.E. 
Trn ± S.E. Unrd ± 
S.E. 
hPPAR  32±1 19±1 21.3±0.3 29.3±0.5 
hPPAR + lauric acid 30±1 20±2 21.8±0.4 28.7±0.3 
hPPAR + lauryl-CoA 31±3 18.2±0.2 20±1 29±1 
hPPAR + palmitic acid 16±3
**
 32±2
**
 21.7±0.4 30±1 
hPPAR + palmitoyl-CoA 13±3
**
 34±2
**
 22.5±0.2 30±1 
hPPAR + palmitoleic acid 22±4
*
 28±3
*
 21±1 28±1 
hPPAR + palmitoleoyl-CoA 24±5
#
 27±3
*
 21±1 29±1 
hPPAR + stearic acid 14±3
**
 33±2
**
 22.0±0.2 31±2 
hPPAR + stearyl-CoA 24±4
#
 27±2
*
 21±1 29±1 
hPPAR + oleic acid 18±2
**
 31±2
**
 22±1 29±1 
hPPAR + oleoyl-CoA 26±3 25±2
#
 21±1 28.3±0.3 
hPPAR + linoleic acid 27±6 28±2
*
 19±2
*
 26±3 
hPPAR + linoleoyl-CoA 24±3
#
 26±2
*
 21±1 28.8±0.1 
hPPAR + arachidonic acid 19±1
*
 30±1
**
 21.8±0.3 28.9±0.1 
hPPAR + arachidonoyl-CoA 30±1 23.4±0.4 19.4±0.5
#
 26.9±0.4 
hPPAR + EPA 14±7
**
 24±6 23±2 33±5 
hPPAR + EPA-CoA
 21±1
*
 29±1
*
 21.6±0.3 29±1 
hPPAR + DPA 17±4
**
 32±3
**
 21.9±0.1 30±1 
hPPAR + DPA-CoA
 20±1
*
 30±1
**
 21±1 29.6±0.2 
hPPAR + DHA 12±3
**
 38±4
**
 21±1 30±1 
hPPAR + DHA-CoA 20±2
*
 29±2
*
 22±1 28.9±0.2 
hPPAR + Clofibrate 33±1 15±1
*
 22±1 30±1 
hPPAR + Rosiglitazone 29±1 22±2 20±1 28±1 
Asterisks represent significant differences between hPPAR only and hPPAR in the 
presence of added ligand (* P < 0.05, ** P < 0.001 and 
# 
P = 0.07).  
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Effect of endogenous fatty acids and fatty acyl-CoAs on mPPARα secondary 
structure:  Consistent with hPPARα the far UV circular dichroic spectrum of mPPARα 
suggested the presence of substantial α-helical content, exhibiting a large positive peak 
at 192 nm and two negative peaks at 207 and 222 nm (Fig. 14A-K, filled circles).  
Quantitative analyses of the circular dichroic spectra confirmed that mPPARα was 
composed of approximately 30 % α-helix, 19 % β-sheets, 22 % β-turns, and 29 % 
unordered structures (Table IV), similar to hPPARα (Table III).  With the exception of 
lauric acid and lauryl-CoA (Fig. 14A), the addition of fatty acids (Fig. 14B-J, open 
circles) and fatty acyl-CoA (Fig. 14B-J, filled triangles) resulted in mPPARα 
conformational changes consistent with decreased molar ellipticity at 192 nm and 
increased molar ellipticity at 207 and 222 nm.  Addition of clofibrate resulted in the 
strongest changes to the mPPARα spectrum, but consistent with binding data, no 
changes were seen with the addition of rosiglitazone (Fig. 14K).  Quantitative analyses 
of multiple replicates indicated that LCFA and LCFA-CoA significantly decreased the 
mPPARα estimated α-helical content and concomitantly increased the estimated 
percentage of α-sheets (Table IV), a trend similar to that seen with hPPARα.  However, 
for several ligands the magnitude of the change was different between the two proteins.  
While palmitic acid and stearic acid resulted in some of the strongest changes to the 
hPPARα structure, addition of these same ligands resulted in some of the weakest 
changes seen to the mPPARα structure.  Moreover, clofibrate had the strongest effect 
on mPPARα secondary structure and a very small effect on hPPARα secondary 
structure.  The changes in circular dichroic spectra and estimated percentage 
composition were consistent with the affinity of mPPARα for each ligand.  These data 
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further suggest that species differences in ligand specificity and affinity exist between 
mouse and human PPARα. 
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Fig. 14.  Far UV circular dichroic (CD) spectra of mPPAR in the absence (filled circles) 
and presence of added ligand: (A) lauric acid (open circles) or lauryl-CoA (filled 
triangles); (B) palmitic acid (open circles) or palmitoyl-CoA (filled triangles); (C) 
palmitoleic acid (open circles) or palmitoleoyl-CoA (filled triangles); (D) stearic acid 
(open circles) or stearoyl-CoA (filled triangles); (E) oleic acid (open circles) or oleoyl-
CoA (filled triangles); (F) linoleic acid (open circles) or linoleoyl-CoA (filled triangles); 
(G) arachidonic acid (open circles) or arachidonoyl-CoA (filled triangles); (H) 
eicosapentaenoic acid (open circles) or eicosapentaenoyl-CoA (filled triangles); (I) 
docosapentanoic acid (open circles) or docosapentanoyl-CoA (filled triangles); (J) 
docosahexanoic acid (open circles) or docosahexanoyl-CoA (filled triangles); and (K), 
clofibrate (open circles) or rosiglitzone (filled triangles).  Each spectrum represents an 
average of 10 scans for a given representative spectrum from at least three replicates. 
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Table IV. Effect of ligands on the relative proportion of mPPAR secondary structure 
determined by CD.  These structures were as follows: total helices (H; a sum of regular α-
helices and distorted α-helices), total sheets (S; a sum of regular β-sheets and distorted β-
sheets), turns (Trn; β-turns), and unordered (Unrd) structures. 
Average Total H ± 
S.E. 
Total S ± 
S.E. 
Trn ± S.E. Unrd ± S.E. 
mPPAR  30±1 19±2 22±1 29±1 
mPPAR + lauric acid 29±1 20±1 22±1 28.8±0.1 
mPPAR + lauryl-CoA 27±3 23±3 22.1±0.1 28.9±0.1 
mPPAR + palmitic acid 23±3
*
 23±2 21±2 30±2 
mPPAR + palmitoyl-CoA 16±1
**
 32±1
**
 23±1 29.2±0.2 
mPPAR + palmitoleic acid 14±1
**
 29±1
*
 23±1 34±5 
mPPAR + palmitoleoyl-CoA 19±1
*
 34±5
**
 21±1 28±1 
mPPAR + stearic acid 21.8±0.5
*
 28±0.5
*
 21.2±0.1 28.6±0.2 
mPPAR + stearyl-CoA 21±2
*
 30±4
*
 21±1 29.7±0.3 
mPPAR + oleic acid 10±4
**
 36±3
**
 23±2 31±1 
mPPAR + oleoyl-CoA 22±4
*
 28±2
*
 20±1 29±1 
mPPAR + linoleic acid 21±1
*
 30±1
*
 22±1 28.5±0.3 
mPPAR+ linoleoyl-CoA 17±2
**
 33±2
**
 22.0±0.5 28.7±0.1 
mPPAR + arachidonic acid 18±1
**
 31±1
*
 22.5±0.5 28.7±0.2 
mPPAR + arachidonoyl-CoA 22±3
*
 28±3
*
 21.7±0.1 28±1 
mPPAR + EPA 15±2
**
 31±3
*
 21±1 30±1 
mPPAR + EPA-CoA
 
22.5±1.5
*
 28±2
*
 20.1±0.3 30±1 
mPPAR + DPA 20±1
*
 29±1
*
 22±1 29.1±0.3 
mPPAR + DPA-CoA
 
16±3
**
 34±3
**
 22.1±0.2 27.9±0.5 
mPPAR + DHA 16±5
**
 30±4
*
 21±1 30±2 
mPPAR + DHA-CoA 9.5±0.5
**
 37±1
**
 21.9±0.2 31.8±0.2 
mPPAR + Clofibrate 13±3
**
 34±3
**
 22.4±0.1 31±1 
mPPAR + Rosiglitazone 27±2 24±3 25.5±3.5 23±2 
Asterisks represent significant differences between mPPAR only and mPPAR in the 
presence of added ligand (* P < 0.05, ** P < 0.001).  
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Effect of fatty acids and fatty acyl-CoA on transactivation of PPARα-RXRα 
heterodimers: Since PPARα heterodimerizes with RXRα to induce transactivation (7), 
COS-7 cells were cotransfected with pSG5 empty vector, PPARα alone, RXRα alone, 
or PPARα with RXRα and analyzed for transactivation of an acyl-CoA oxidase PPRE-
luciferase reporter construct in the absence or presence of ligands (Fig. 15).  
Transactivation was measured as percent firefly luciferase activity normalized to 
Renilla luciferase (internal control). In comparison to cells overexpressing RXRα alone 
(extremely low transactivation; Fig. 15A, 15B), cells overexpressing PPARα alone (Fig 
15A, 15B) had significant transactivation even in the absence of ligands. While these 
findings could be a result of some basal endogenous levels of RXRα, they also suggest 
that transactivation is indeed mediated by PPARα. In cells overexpressing only 
hPPARα (Fig. 15A) or mPPARα (Fig. 15B), docosahexaenoic acid and clofibrate 
significantly increased transactivation.  Although normalized activity was extremely 
low in hRXRα (Fig. 14A) and mRXRα (Fig. 15B) over-expressing cells, 
docosahexaenoic acid significantly increased transactivation in both, suggesting that 
this ligand (or its metabolite) is a strong activator of endogenous PPARα.  While cells 
over-expressing hPPARα and hRXRα (Fig. 15A) or mPPARα and mRXRα (Fig. 15B) 
both showed increased activity, even in the absence of ligand, differences were noted in 
their ligand-induced effects.  For cells over-expressing hPPARα and hRXRα, addition 
of palmitic acid, palmitoleic acid, stearic acid, oleic acid, eicosapentaenoic acid, and 
docosahexaenoic acid resulted in similar effects on transactivation as the PPARα 
agonist, clofibrate (Fig. 15A).  These data further validated LCFA or their metabolites 
as endogenous ligands of hPPARα needed to induce PPARα activity.  However, 
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addition of only the examined unsaturated LCFA and clofibrate significantly increased 
activity levels in COS-7 cells overexpressing mPPARα and mRXRα (Fig. 15B).  The 
addition of the palmitic acid and stearic acid resulted in no significant changes in 
activity (Fig. 15B), consistent with the weak binding affinity of mPPARα for these 
ligands.  In addition to suggesting that LCFA and LCFA-CoA represent high-affinity 
ligands for mPPARα, these data also suggested that differences in binding affinity for 
saturated LCFA could significantly affect the activity of PPARα.  
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Fig. 15.  PPARα ligands alter PPARα transactivation.  COS-7 cells transfected with 
pSG5 empty vector, PPARα, RXRα, and both PPARα and RXRα were analyzed for 
transactivation of the acyl-CoA oxidase-PPRE-luciferase reporter construct in the 
presence of vehicle (open bars), 1 µM palmitic acid (diagonally upward bars), 1 µM 
palmitoleic acid (diagonally downward bars), 1  µM  stearic  acid  (cross-hatched  
bars),  1  µM  oleic  acid  (horizontal  lined  bars),  1  µM eicosapentaenoic acid 
(vertically lined bars), 1 µM docosahexanoic acid (hatched bars), and 1 µM 
clofibrate (open bars). For comparison between human and mouse effects, COS-7 cells 
were transfected with human versions of these proteins (A) or mouse versions of these 
proteins (B). The y-axis represents values for firefly luciferase activity that have been 
normalized to Renilla luciferase (internal control), where PPARα and RXRα 
overexpressing cells in the presence of 1 µM clofibrate were arbitrarily set to 1.   
The bar graph represents the mean values (n ≥ 3) ± standard error. * P < 0.05, ** P 
< 0.01. 
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5. Discussion 
Although lipids have been shown to be endogenous ligands of PPARα from 
several species, including mouse, studies with hPPARα have focused on exogenous 
ligands.  Since an increasing number of studies suggest species differences exist for 
ligand specificity and affinity (102, 161-163), this study focused on LCFA and/or 
LCFA-CoA as putative endogenous ligands of hPPARα.  These data are the first to 
demonstrate full-length hPPARα binding to LCFA and LCFA-CoA at physiologically 
relevant concentrations.  Human PPARα displayed high affinity binding for saturated, 
monounsaturated, and polyunsaturated LCFA and LCFA-CoA (Kd
 
= 11-40 nM), 
consistent with previously reported nuclear concentrations (3-68 nM) of LCFA and 
LCFA-CoA (88, 120).  These high affinity ligands significantly altered the secondary 
structure of hPPARα, while ligands that did not bind hPPARα (lauric acid, lauryl-CoA, 
and rosiglitazone) did not demonstrate any significant change in the structure of the 
protein.  LCFA that bound to hPPARα in vitro transactivated the ACOX PPRE-
luciferase reporter in a PPARα dependent manner in COS-7 cells, further suggesting 
that LCFA and LCFA-CoA are endogenous ligands of hPPARα.  These data are 
consistent with experiments using peroxisomal ACOX and/or PPARα knockout mice 
which also suggest that LCFA and their thioester derivatives serve as natural ligands 
for PPARα in vivo (145, 146, 183).   
Apart from identifying LCFA and LCFA-CoA as physiologically relevant 
endogenous ligands for hPPARα, these data highlight important species differences 
with respect to ligand specificity and affinity.  While affinities for LCFA-CoA and 
unsaturated LCFA were similar between full-length human and murine PPARα, 
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mPPARα only weakly bound the saturated palmitic acid and stearic acid, yet hPPARα 
strongly bound both.  Similarly, some of the strongest changes in hPPARα secondary 
structure occurred with the addition of saturated and polyunsaturated LCFA, whereas 
saturated LCFA had only minor effects on mPPARα secondary structure.  Consistent 
with these data, COS-7 cells overexpressing mPPARα and mRXRα treated with these 
saturated LCFA did not transactivate the ACOX-PPRE-luciferase reporter at the 
examined concentrations, while unsaturated LCFA did.  Taken together, these data 
suggested that the human and mouse PPARα proteins bind and respond differently to 
specific ligands.   
Given the high evolutionary rate exhibited by PPARα (184), it is not surprising 
to see such differences between hPPARα and mPPARα.  In addition, strong 
physiological differences exist between human and rodent PPARα activation.  Long-
term administration of PPARα agonists are associated with hepatic carcinomas in 
rodents, but “humanized” PPARα mice are resistant to PPARα agonist induced 
hepatocellular adenomas and carcinomas (102, 150).  The potency and efficacy of 
many hypolipidemic agents and phthalate monoesters on the activation of human and 
mouse PPARα are also different (161-163).  As previous microarray experiments have 
demonstrated a strong divergence between PPARα regulated genes in mouse and 
human hepatocytes (163), it is likely that a combination of ligand binding differences 
and target gene differences are responsible for the overall physiological variations.  
Other factors, including differences in ligand uptake and ligand metabolism between 
cell types, may account for some of these differences as well.  However, this same 
study showed a high conservation in PPARα regulation of genes involved in lipid 
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metabolism (163), suggesting that differences in these processes must be due to another 
mechanism – not just variation in target genes.  Since a single mutation in the mouse 
PPARα ligand binding domain (E282G) results in altered activity but displays similar 
DNA binding capacity, protein levels, and protein localization (164), it suggests that 
individual amino acid differences in the ligand binding domain can affect activity 
through ligand binding.  Such differences in specificity of mouse and human PPARα 
for specific nutrients could reflect an adaptation to different physiological and/or 
nutritional patterns of the species.   
Additionally, these data suggest that differences exist in the binding affinity of 
full-length versus truncated PPARα.  Data presented herein indicate that both full-
length hPPARα and mPPARα bound polyunsaturated LCFA with strong affinity.  This 
data challenges previously published data indicating that mouse PPARα does not bind 
saturated LCFA in the physiological range, and only weakly interacts with PUFA (115-
117).  While such differences may exist due to variations in protein preparation, ligand 
binding techniques, or changes in the protein’s secondary structure, it should be noted 
that the previously published data was generated using a truncated mouse PPARα 
protein that lacked the N-terminus (mPPARΔAB).  Therefore, it is possible that the N-
terminal domain of PPARα influences ligand binding.  This hypothesis is supported in 
the case of PPARα, where it was shown that mutation of specific residues within the N-
terminal A/B domain affects the binding affinity of a synthetic PPARα agonist (34).   
In summary, LCFA and LCFA-CoA function as endogenous hPPARα ligands; 
binding with high affinity, altering PPARα secondary structure, and affecting 
transactivation.  Although LCFA-CoA similarly bound both hPPARα and mPPARα, 
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several ligands (including fluorescent LCFA/LCFA-CoA analogues, saturated LCFA, 
PUFA, and clofibrate) resulted in significant species differences.  These data suggest 
that even though there is overlap in the endogenous ligands for mouse and human 
PPARα, significant species differences exist, and these differences may affect 
downstream gene regulation. These findings corroborate the importance of PPARα in 
allosteric regulation of fatty acid metabolism, where PPARα acts as a sensor to monitor 
the levels of fatty acids and their metabolites, then transcriptionally activates enzymes 
involved their metabolism.   
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CHAPTER II 
A SINGLE AMINO ACID CHANGE HUMANIZES LONG-CHAIN FATTY 
ACID BINDING AND ACTIVATION OF MOUSE PEROXISOME PROLIFERATOR-
ACTIVATED RECEPTOR  
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1. Abstract 
Peroxisome proliferator-activated receptor α (PPARα) is an important regulator of 
hepatic lipid metabolism which functions through ligand binding.  Despite high amino 
acid sequence identity (>90%), marked differences in PPARα ligand binding, activation 
and gene regulation have been noted across species. Similar to previous observations 
with synthetic agonists, we have recently reported differences in ligand affinities and 
extent of activation between human PPARα (hPPARα) and mouse PPARα (mPPARα) in 
response to long chain fatty acids (LCFA). The present study was aimed to determine if 
structural alterations could account for these differences. The binding of PPARα to LCFA 
was examined through in silico molecular modeling and docking simulations. Modeling 
suggested that variances at amino acid position 272 are likely to be responsible for 
differences in saturated LCFA binding to hPPARα and mPPARα. To confirm these 
results experimentally, LCFA binding, circular dichroism, and transactivation studies 
were performed using a F272I mutant form of mPPARα. Experimental data correlated 
with in silico docking simulations, further confirming the importance of amino acid 272 
in LCFA binding. Although the driving force for evolution of species differences at this 
position are yet unidentified, this study enhances our understanding of ligand-induced 
regulation by PPARα and demonstrates the efficacy of molecular modeling and docking 
simulations (185). 
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2. Introduction 
Peroxisome proliferator-activated receptor alpha (PPARα) belongs to the nuclear 
hormone receptor superfamily of ligand-dependent transcription factors and has emerged 
as one of the central regulators of nutrient-gene interactions. Structurally similar to other 
members of the nuclear hormone receptor family, the PPARα protein structure consists of 
an N-terminal ligand-independent transactivation function (AF-1), a highly conserved 
DNA binding domain (DBD), a hinge region and the C-terminal ligand binding domain 
(LBD) containing a ligand-dependent transactivation function (AF-2).  The LBD of 
PPARα constitutes a large hydrophobic ligand-binding pocket (1300-1400 Å
3
) that 
allows interaction with a broad range of natural and synthetic ligands (25, 26). PPARα 
interacts with a variety of endogenous ligands, including fatty acids and fatty acid 
metabolites, as well as synthetic compounds such as hypolipidemic fibrate drugs, to 
regulate cellular processes related to fatty acid metabolism, glucose metabolism, 
inflammation, differentiation and proliferation (83, 108, 113, 186).  
While long-chain fatty acids (LCFA) serve as major metabolic fuels and important 
components of biological membranes, they also play a significant role as signaling 
molecules and gene regulators in response to food intake and nutritional changes. 
Recently, we have demonstrated that LCFA and their thioesters (long-chain fatty acyl-
CoA; LCFA-CoA) constitute high-affinity endogenous ligands of human PPARα 
(hPPARα) and mouse PPARα (mPPARα). Such ligand binding induces PPAR 
conformational changes and increases transactivation, consistent with expectations for an 
endogenous ligand of a ligand-activated nuclear receptor (165). Thus, PPARα in 
conjunction with LCFA and their metabolites could serve to regulate metabolic pathways 
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governing fuel utilization, storage, transport and mobilization. However, we also reported 
differences in binding affinities and the extent of ligand-induced transactivation between 
mPPARα and hPPARα in response to saturated LCFA (165). 
Species differences in PPARα-mediated downstream regulation of target genes have 
been noted previously (163, 187). Human and mouse PPAR proteins promote 
transcription to a different extent in response to certain hypolipidemic agents and pthalate 
monoesters (161, 162). Furthermore, it is well established that long-term administration 
of PPARα agonists result in hepatic cancer in rats and mice – an effect that is not seen in 
guinea pigs, canines, non-human primates, or even humans (102). While a single cause 
for the existence of such differences is highly unlikely, possible explanations include: 
differences in expression levels of PPARα or differences in PPARα target genes, 
alternatively spliced or mutant forms of PPARα protein, mutations or polymorphisms in 
target gene response elements, increased expression of oncogenes and/or inhibition of 
apoptosis (102, 103, 188, 189). However, transgenic mice that express human PPARα 
mainly in the liver do not exhibit hepatocarcinogenesis upon administration of PPARα 
agonists (149, 150). This observation suggests that structural differences in the PPARα 
protein could be the underlying cause of such species variation.  
Comparison of the PPARα amino acid sequence across species, particularly of the 
LBD, resulted in >90% homology (18). However it should be noted that a single amino 
acid change can result in marked alterations in ligand selectivity of nuclear receptors. For 
example, a single amino acid change in the mouse PPARα-LBD (E282) results in altered 
activity of the protein (164), and a valine to methionine substitution in human PPARα 
(V444M) produced PPARδ ligand binding characteristics, resulting in loss of fibrate 
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responsiveness (52). While we have reported differences in mPPARα and hPPARα in 
response to saturated LCFA (165), the goal of this study was to explore the mechanisms 
underlying such divergence. We have used methods including: molecular modeling and 
in silico docking, mutagenesis, spectrofluorometry, circular dichroism spectroscopy and 
transactivation studies to identify a single amino acid change at position 272 that is 
largely responsible for the altered saturated LCFA binding.   
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3. Material and Method 
Molecular modeling simulations: The crystal structure of the ligand binding domain 
(LBD) of hPPARα complexed with a synthetic agonist (GW409544) was retrieved from 
RCSB Protein Data Bank (PDB identifier 1K7L) (26). The apo form of hPPARα-LBD 
was generated by extracting the ligand (GW409544) from the 1K7L model (using Swiss 
PDB Viewer, http://www.expasy.org/spdbv/). This structural model was used in all 
docking simulations. Since the structure of mPPARα has not been crystallized, a 
homology modeling approach was used to generate the mPPARα-LBD structure. We 
compared the amino acid sequence of hPPARα to mPPARα and substituted all amino 
acid residues that were different in the hPPAR-LBD crystal structure. In total, 23 amino 
acid residues in the hPPARα-LBD were replaced with the corresponding mPPARα 
residues, followed by energy minimization of the resulting model. This model was used 
as an initial structure of mPPARα-LBD for all docking simulations. All energy 
computations were done in vacuo using GROMOS96 43B1 parameters without reaction 
field, implemented in Swiss PDB Viewer (190). An energy minimized model of the 
F272I mPPARα-LBD was also generated using the Swiss PDB Viewer 
(http://www.expasy.org/spdbv/).   
Molecular docking simulations: In silico docking studies were performed using both 
AutoDock Vina 1.1.2 (191) and the FlexiDock™ module available on SYBYL
®
-X 2.0 
(Tripos, St. Louis, MO). While AutoDock Vina 1.1.2 allows only the ligand to have 
flexible/rotatable bonds, the FlexiDock™ module on SYBYL
®
-X 2.0 permits both 
protein (sidechains) and ligands to carry flexible/rotatable bonds. For docking with both 
AutoDock Vina 1.1.2 and FlexiDock™, a search space or putative binding site was 
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defined in a restricted region of the protein. In the present study, the ligand binding 
pocket was defined based on the experimentally obtained structure of the GW409544 
ligand bound to hPPARα-LBD (26). Once the hPPARα and mPPARα models were 
energy minimized, docking simulations were carried out using both AutoDock Vina 1.1.2 
and FlexiDock™. Docking simulations were first validated using the GW409544 ligand 
by comparing the x-ray crystal structure 1K7L (hPPARα-LBD + GW409544) with that of 
the docking output generated using apo-hPPARα with GW409544 ligand. Both 
AutoDock Vina 1.1.2 and FlexiDock™ generated multiple docking poses (differentiated 
by RMSD’s relative to the best pose) that were subjected to careful visualization and only 
the most energetically favorable conformation was chosen for further analysis.  
Docking of LCFA was carried out using both AutoDock Vina 1.1.2 and FlexiDock™. 
For each binding conformation, the binding energies were calculated using the FlexiDock 
scoring function based on the Tripos Force Field, as implemented by FlexiDock.  The 
resulting docking conformations were visualized using the PyMOL Molecular Graphics 
System (Version 1.5.0.4 Schrödinger, LLC) and the program LIGPLOT (192). Further, in 
order to determine the volumes of the ligand binding pockets of PPARα, we took 
advantage of the POVME algorithm (193). Based on the occupancy of GW409544 within 
the hPPARα ligand binding pocket we defined the ligand binding pocket using 37 
overlapping inclusion spheres. This pocket was visualized using the Visual Molecular 
Dynamics (VMD) program (194), and volume-grid points near the protein atoms were 
systematically deleted with a padding variable of 1.09 (radius of a hydrogen atom) or 0.5 
(half of a carbon-hydrogen bond length) using POVME (193). This was followed by 
volume measurement of each resultant binding pocket.     
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Chemicals: Fluorescent fatty acid (BODIPY-C16) was purchased from Molecular 
Probes, Inc. (Eugene, OR).  Docosahexaenoyl-CoA and BODIPY C16-CoA were 
synthesized and purified by HPLC as previously described (in Chapter I and  ( 1 1 7 ,  
1 7 1 ) ) , and found to be >99% unhydrolyzed.  All other fatty acid ligands and clofibrate 
were from Sigma-Aldrich (St. Louis, MO). Rosiglitazone (LKT labs) was a kind gift 
from Dr Khalid Elased and bovine serum albumin (lipid-free) was obtained from Gemini 
Bioproducts (Sacramento, CA).  
Purification of Recombinant F272I mutant mPPAR protein: The cloning and 
purification of wild-type 6xHis-GST-mPPARα has already been described in (165) and in 
chapter I of this dissertation. A mutant form of full-length mPPARα (amino acids 1-468) 
in which the phenylalanine residue at 272 in helix 3 was replaced by isoleucine (F272I; to 
mimic hPPARα) was used for all experiments presented herein. The bacterial expression 
plasmid for full-length F272I mutant mPPARα (6xhis-GST-F272I mPPARα) was 
produced by Dr. S. Dean Rider, Jr. (Wright State University). The full-length 
recombinant mutant F272I mPPARα protein was expressed in Rosetta
TM
2 cells 
(Novagen, Gibbstown, NJ) and purified as described previously in chapter I and (165) for 
the wild-type. The protein purity was verified using SDS-PAGE with Coomassie blue 
staining and immunoblotting.  Protein concentrations were estimated by Bradford Assay 
(Bio-Rad Laboratories, Hercules, CA) and by absorbance spectroscopy using the molar 
extinction coefficient for the protein.   
Fluorescence based Ligand Binding Assays: The binding affinity of F272I mPPARα 
to a fluorescent 16 carbon fatty acid analogue (BODIPY C16) or its CoA thioester 
(BODIPY C16-CoA) was determined as described previously for wild-type mPPARα and 
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hPPARα in chapter I and (165). Based on the binding affinities obtained herein, 
displacement assays were performed in the presence of BODIPY C16-CoA (110 nM) 
using non-fluorescent LCFA and LCFA-CoA as described in chapter I and (165).  The 
maximal fluorescence intensity was measured, and the effect of increasing concentrations 
of naturally-occurring non-fluorescent ligands was measured as a decrease in 
fluorescence. The direct binding of F272I mPPAR to non-fluorescent ligands was also 
determined by quenching of intrinsic PPARα aromatic amino acid fluorescence as 
described in chapter I of this dissertation for wild-type mPPARα and hPPARα (165, 173). 
For all measurements, emission spectra were corrected for background and inner-filter 
effects were avoided.  Changes in fluorescence intensity were used to calculate the 
dissociation constant (Kd), inhibition constant (Ki) and the number of binding sites (n) as 
described in chapter 1 of this dissertation. 
Circular Dichroism: Circular dichroic spectra of F272I mPPAR (0.6 M in 600 µM 
HEPES pH 8.0, 24 M dithiothreitol, 6 M EDTA, 6mM KCl and 0.6 % glycerol) were 
recorded in the presence and absence of LCFA and LCFA-CoA (0.6 M) with a J-815 
spectropolarimeter (Jasco Inc., Easton, MD) as previously described in chapter I for the 
wild-type mPPARα and hPPARα (165).  Spectra were recorded from 260 to 187 nm with 
a bandwidth of 2.0 nm, sensitivity of 10 millidegrees, scan rate of 50 nm/min and a time 
constant of 1 s.  Ten scans per replicate were averaged, and the average spectrum was 
used to determine the percent composition of -helices, β-strands, turns and unordered 
structures with the CONTIN/LL program of the software package CDpro (117, 179). 
Mammalian Expression Plasmids: The pSG5-hPPAR pSG5mPPARpSG5-
hRXRα and pSG5-mRXRα plasmids have been described in chapter I of this dissertation 
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(165). The F272I mutant mPPAR was amplified from 6xhis-GST-F272I mPPAR 
using the following primers: 5’-cggatccaccATGGTGGACACAGAGAGCCC-3’ and 
ctcctcgagTCAGTACATGTCTCTGTAGA-3’. In these primers, lowercase represents 
nucleotides outside of the PPAR open reading frame and restriction sites are underlined.  
The PCR product was cloned into the pGEM
®
-T easy vector (Promega Corp., Madison, 
WI).  A Bam HI / end-filled Xho I F272I mutant mPPAR fragment was subcloned into 
the Bam HI / end-filled Bgl II multiple cloning site of pSG5 (Stratagene, La Jolla, CA) to 
produce pSG5-F272I mPPAR The reporter construct, PPRE×3 TK LUC was a kind 
gift of Dr. Bruce Spiegelman (Addgene plasmid # 1015) and contained three copies of 
the acyl-CoA oxidase (ACOX) peroxisome proliferator response element (PPRE) (180).  
Cell culture and Transactivation assay: COS-7 cells (ATCC, Manassas, VA) were 
grown in DMEM supplemented with 10 % fetal bovine serum (Invitrogen, Grand Island, 
NY), at 37°C with 5% CO2 in a humidified chamber.  Cells were seeded onto 24-well 
culture plates and transfected with Lipofectamine™ 2000 (Invitrogen, Grand Island, NY) 
and 0.4 g of each full-length mammalian expression vector (pSG5-hPPAR and pSG5-
hRXR, pSG5-mPPAR and pSG5-mRXRpSG5- F272I mPPAR and pSG5-
mRXR) or empty plasmid (pSG5), 0.4 g of the PPRE×3 TK LUC reporter construct, 
and 0.04 g of the internal transfection control plasmid pRL-CMV (Promega Corp., 
Madison, WI) as previously described in chapter 1.  Following transfection incubation, 
medium was replaced with serum-free medium for 2 h, ligands (1M) were added, and 
the cells were grown for an additional 20 h.  Fatty acids were added as a complex with 
bovine serum albumin (BSA) as described (117, 195).  Firefly luciferase activity, 
normalized to Renilla luciferase (for transfection efficiency), was determined with the 
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dual luciferase reporter assays system (Promega Corp., Madison, WI) and measured with 
a SAFIRE
2
 microtiter plate reader (Tecan Systems, Inc. San Jose, CA).  The clofibrate 
treated samples in each case, overexpressing both PPAR and RXR were arbitrarily set 
to 1. 
Statistical Analysis: Data were analyzed using a one-way ANOVA to evaluate 
overall significance (SigmaPlot™, Systat Software, San Jose, CA).  A Fisher Least 
Significant Difference (LSD) post-hoc test was used to identify individual group 
differences.  The results are presented as mean ± SEM.  The confidence limit of p < 0.05 
was considered statistically significant. 
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4. Results and Discussion 
Since its discovery and cloning, PPARα has been shown to be activated by 
structurally diverse ligands, including the fibrate class of drugs, some herbicides, 
phthalate monoesters, fatty acids and fatty acid derivatives (83, 108, 113, 117, 186). 
However, a vast array of studies have highlighted species differences not just with respect 
to gene regulation (163, 187), but also in binding or activation of PPARα (102, 161, 162). 
For example, mouse and human PPARα display differences in ligand binding, activation 
and physiological responses upon administration of certain hypolipidemic agonists, 
phthalate monoesters and LCFA (161, 162, 165). The present study examines structural 
differences in the PPARα proteins, which could be an underlying cause of species 
differences in ligand binding. 
Molecular modeling simulations of hPPARα-LBD and mPPARα-LBD: The X-ray 
crystal structure of hPPARα is composed of a helical sandwich and a four-stranded β-
sheet. The Y-shaped PPARα ligand binding pocket (≈ 1400 Å
3
) spans between the C-
terminal helix 12 (containing the AF-2) and the 4 stranded β-sheet, splitting into 2 arms 
roughly parallel to helix 3 (26). In order to investigate the mechanisms underlying 
differential binding and activation of mouse and human PPARα in response to LCFA, the 
amino acid sequences of mPPARα and hPPARα were compared. While human and 
mouse PPARα proteins (468 amino acids) bear approximately 92% sequence identity, 
there are 35 amino acid differences (Fig. 16).  
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Fig. 16. Primary amino acid sequence of human and mouse PPARα. The N-terminal 
domain in depicted in black, DNA binding domain in red, hinge region in green and 
ligand binding domain in blue. The different amino acids between human and mouse 
PPARα are highlighted in yellow.  
Human PPARα 
1 MVDTESPLCP  LSPLEAGDLE SPLSEEFLQE MGNIQEISQS IGEDSSGSFG 
51 FTEYQYLGSC PGSDGSVITD TLSPASSPSS VTYPVVPGSV DESPSGALNI 
101 ECRICGDKAS  GYHYGVHACE GCKGFFRRTI RLKLVYDKCD RSCKIQKKNR 
151 NKCQYCRFHK  CLSVGMSHNA IRFGRMPRSE KAKLKAEILT CEHDIEDSET 
201 ADLKSLAKRI  YEAYLKNFNM NKVKARVILS GKASNNPPFV IHDMETLCMA 
251 EKTLVAKLVA  NGIQNKEAEV RIFHCCQCTS VETVTELTEF AKAIPGFANL 
301 DLNDQVTLLK  YGVYEAIFAM LSSVMNKDGM LVAYGNGFIT REFLKSLRKP 
351 FCDIMEPKFD FAMKFNALEL DDSDISLFVA AIICCGDRPG LLNVGHIEKM 
401 QEGIVHVLRL  HLQSNHPDDI FLFPKLLQKM ADLRQLVTEH AQLVQIIKKT 
451 ESDAALHPLL  QEIYRDMY    
Mouse PPARα 
1 MVDTESPICP  LSPLEADDLE SPLSEEFLQE MGNIQEISQS IGEESSGSFG 
51 FADYQYLGSC PGSEGSVITD  TLSPASSPSS VSCPVIPAST DESPGSALNI 
101 ECRICGDKAS  GYHYGVHACE GCKGFFRRTI RLKLVYDKCD RSCKIQKKNR 
151 NKCQYCRFHK  CLSVGMSHNA IRFGRMPRSE KAKLKAEILT CEHDLKDSET 
201 ADLKSLGKRI HEAYLKNFNM  NKVKARVILA GKTSNNPPFV IHDMETLCMA 
251 EKTLVAKMVA  NGVEDKEAEV RFFHCCQCMS VETVTELTEF AKAIPGFANL 
301 DLNDQVTLLK  YGVYEAIFTM LSSLMNKDGM LIAYGNGFIT REFLKNLRKP 
351 FCDIMEPKFD FAMKFNALEL DDSDISLFVA AIICCGDRPG LLNIGYIEKL 
401 QEGIVHVLKL  HLQSNHPDDT FLFPKLLQKM VDLRQLVTEH AQLVQVIKKT 
451 ESDAALHPLL  QEIYRDMY    
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In the X-ray crystal structure of hPPARα-LBD employed in this study (1K7L; 
267 amino acids), 23 amino acids are different between the hPPARα-LBD and the 
modeled structure of the mPPARα-LBD. Regardless of this difference in amino acids, 
when we compared the energy minimized apo forms of hPPARα-LBD and mPPARα-
LBD using Swiss PDB Viewer or the PyMOL Molecular Graphics System, there was no 
significant 3 dimensional structural difference between the two proteins (Cα atoms 
RMSD < 0.05 Å
3
; Fig. 17). Similarly, no differences were noted in the Ramachandran 
plots of the two proteins (data not shown). This was consistent with circular dichroism 
spectroscopy data from chapter I that demonstrated no significant differences in the 
secondary structural content of hPPARα and mPPARα (165). 
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Fig. 17. An overlay of the energy minimized structures of hPPARα-LBD (red; adopted 
from PDB code: 1K7L) and mPPARα-LBD (blue; modeled using 1K7L). No significant 
structural difference was observed between the two proteins (Cα atoms RMSD < 0.05 
Å
3
). 
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Molecular docking simulations with hPPARα-LBD and mPPARα-LBD: For all 
docking simulations we utilized both AutoDock Vina (191) and the FlexiDock™ module 
available on SYBYL
®
-X 2.0. In order to validate our docking simulations, we compared 
the energy minimized structure of hPPARα-LBD + GW409544 obtained using our 
docking approaches to the experimentally obtained X-ray crystal structure of the same 
(26). There was no significant difference between the two structures (Cα RMSD < 0.01 
Å
3
). Furthermore, the orientation of GW409544, as well as the amino acids participating 
in the interaction between GW409544 and the protein, were quite comparable in the two 
structures (Fig. 18A and 18B). Thus, this docking protocol was considered suitable for 
subsequent docking runs. We next simulated the docking of GW409544 to our energy 
minimized model of mPPARα-LBD. Although there was no significant difference 
between the RMSD value for the Cα atoms (RMSD < 0.05 Å), the orientation of 
GW409544 was remarkably different in the hPPARα-LBD and mPPARα-LBD (Fig. 18C 
and 18D). This was consistent with previous molecular modeling data which reported 
similar variations in the orientation and position of GW409544 within the ligand binding 
pockets of mPPARα-LBD and hPPARα-LBD (159). It was proposed that part of these 
variances could be attributed to the bulky phenylalanine residue at 272 in mPPARα-LBD 
(Isoleucine in hPPARα-LBD), and that this may cause a large shift in the phenyloxazol 
arm of GW409544 (Fig. 18D).  
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Fig. 18. (A) An overlay of the optimized structure of hPPARα-LBD in complex with 
GW409544 (magenta) along with its crystal structure (PDB code: 1K7L; GW409544 
shown in yellow). The right-hand figure is a close-up of the panel on the left, with key 
amino acids Tyr-314, Tyr-464 and Ile-272 labeled. (B) An overlay of GW409544 in the 
hPPARα-LBD generated using our docking approach (magenta) and/or obtained from 
PBD code 1K7L (yellow). (C) The binding pose for the energy minimized structure of 
mPPARα-LBD in complex with GW409544 with a close-up view around the ligand 
(magenta). (D) An overlay of GW409544 conformations from docking poses generated 
using hPPARα-LBD (yellow) and mPPARα-LBD (magenta).  
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Upon validation of the docking parameters, the docking of LCFA to hPPARα-
LBD and mPPARα-LBD were examined. Docking of saturated LCFA (palmitic and 
stearic acid) were preferentially examined, because mPPARα and hPPARα have been 
shown to bind with different affinities to such LCFA (165). Based on reported crystal 
structures and structure-activity relationships, most PPARα agonists bind to PPARα with 
the acidic head group forming hydrogen bonds with Y314 on helix 5 and Y464 on the 
AF-2 of helix 12. The hydrophobic tails of these ligands are stabilized by numerous 
hydrophobic interactions extending upward or downward in the 2 arms of the PPARα 
pocket (26). Based on these observations and the fact that LCFA serve to activate 
PPARα, we expected the carboxylic acid group of the LCFA to form a specific hydrogen 
bonding network with Y314 and Y464 to stabilize the AF-2 helix, permitting PPARα 
activation.  
The binding mode of palmitic acid to hPPARα-LBD demonstrated striking 
resemblance to that of other PPARα agonists – stabilized by a combination of hydrogen 
bonds and hydrophobic interactions. The carboxylic acid group of palmitic acid was 
oriented towards the AF-2 helix forming hydrogen bonds with Y314 and Y464, and its 
hydrophobic tail was stabilized by numerous hydrophobic interactions in the core PPARα 
pocket (Fig. 19A, Fig. 19B). Similar docking poses were generated for another saturated 
(stearic acid; C18:0; Fig. 20A), monounsaturated (palmitoleic acid; C16:1; Fig. 20B) and 
polyunsaturated (docosohexaenoic acid; C22:6; Fig. 20C) LCFA. The binding energies 
estimated by the docking software are presented in Table V. Although both AutoDock 
Vina and the SYBYL
®
-X 2.0 gave consistent and similar output for the docking modes, 
the FlexiDock™ module on SYBYL
®
-X 2.0 was used to obtain binding energies 
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associated with this docking. The FlexiDock™ module on SYBYL
®
 - X 2.0 was chosen 
because 1) it permits both protein (sidechains) and ligands to carry flexible/rotatable 
bonds, and 2) the FlexiDock™ energy evaluation function is based on the Tripos Force 
Field and estimates the binding energy of ligand, the receptor binding pocket, as well as 
the interaction between them. These results demonstrated that LCFA are bound in a 
similar manner as other PPARα ligands and further support previous observations that 
suggest LCFA are high affinity endogenous ligands of hPPARα (108, 117, 165).  
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Fig. 19. Comparison of the binding modes of C16:0 complexed with (A) hPPARα LBD, 
(C) mPPARα LBD and (E) F272I mPPARα LBD. All docking poses presented here were 
generated using the FlexiDock™ module available on SYBYL
®
 - X 2.0 and are 
comparable to those generated using AutoDock Vina. In the left-hand figures AF2 helix 
12, helix 3 and helix 5 are depicted in red, cyan and green respectively. The right-hand 
figures are close-up views of respective panels from the left. The ligand is colored in 
magenta and the amino-acids Tyr 314, Tyr 464 and Ile-272 or Phe-272 are labeled. Two-
dimensional representations of key hydrogen bonding (green dotted lines) and 
hydrophobic interactions (red dashed lines) between C16:0 and hPPARα LBD (B) or 
mPPARα LBD (D) or F272I mPPARα LBD (F) were produced using LIGPLOT (192).  
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Fig. 20. Energy minimized structures of hPPARα-LBD in complex with (A) palmitoleic 
acid, (B) stearic acid and (C) docosahexaenoic acid. The figures in the right panels are 
close-up views of respective panels on the left. All docking poses presented here were 
generated using the FlexiDock™ module available on SYBYL
®
 - X 2.0 and are 
comparable to those generated using AutoDock Vina. 
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Table V. Comparison of binding energies (kcal/mol) for mouse and human PPARα LBD 
complexed with LCFA ligands.  
Ligand Chain length: double 
bonds (position) 
hPPARα 
kcal/mol 
mPPARα 
kcal/mol 
F272I 
mPPARα 
kcal/mol 
Palmitic acid C16:0 -1150 -284 -1089 
Palmitoleic acid C16:1 (n-7) -1149 -1143 -1149 
Stearic acid C18:0 -1153 -298 -1112 
Docosahexanoic 
acid 
C22:6 (n-3) -1187 -932 -1039 
Binding energies were derived using the FlexiDock™ module available on SYBYL
®
 - X 
2.0 (Tripos, St. Louis, MO). 
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While experimental results have shown that mPPARα binds with strong affinity to 
monounsaturated and polyunsaturated LCFA, it binds only weakly to saturated LCFA 
(165). Consistent with these observations, our docking simulations demonstrated that, 
with the exception of saturated LCFA, the binding modes and energies generated for the 
mPPARα-LBD in complex with monounsaturated (C16:1; Fig. 21A) and polyunsaturated 
(C22:6; Fig. 21C) LCFA are quite comparable to that of hPPARα-LBD. However, the 
conformation and position of saturated palmitic (Fig. 19C, 19D) and stearic acid (Fig. 
21B) in the mPPARα-LBD are remarkably different, demonstrating 4-fold higher binding 
energies (weaker binding) when compared to the docking poses in hPPARα-LBD (Table 
V).  
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Fig. 21. Energy minimized structures of mPPARα-LBD in complex with (A) palmitoleic 
acid, (B) stearic acid and (C) docosahexaenoic acid. The figures in the right panels are 
close-up views of respective panels on the left. All docking poses presented here were 
generated using the FlexiDock™ module available on SYBYL
®
 - X 2.0 and are 
comparable to those generated using AutoDock Vina. 
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Two striking features were noted between the binding orientation of palmitic acid 
and stearic acid to mPPARα-LBD compared to hPPARα-LBD. Although multiple 
docking poses were generated, suggesting several possible conformations of the palmitic 
(or stearic) acid within the binding pocket, these characteristics were consistently seen in 
all poses for the mPPARα-LBD. First, the carboxylic acid group does not form hydrogen 
bonds with the C terminal amino acids - possibly raising the binding energy (less 
negative or less favorable). Second, the alkyl chain is not fully extended in the mPPARα-
LBD pocket (Fig. 19C, 19D), and the fatty acid was unable to orient along the same axis 
as seen with the hPPAR-LBD. This may raise the binding energy, resulting in weaker 
binding affinity of saturated LCFA to mPPARα-LBD. It is known that saturated alkyl 
chains normally prefer a fully extended conformation (196). These results were consistent 
with the weaker binding affinities of saturated LCFA reported for mPPARα (165). 
 While the computational and experimental binding trends are similar, it is 
noteworthy that binding energies obtained in this study do not necessarily convert into 
the same nanomolar binding affinities reported experimentally. Such differences between 
computational binding energies and experimental binding affinities could in part be 
explained by parameters that are not taken into consideration in the docking simulations, 
including the contribution of entropy, effects of solvation and the dynamic nature of 
proteins in solution. It is worth noting that in the human and mouse PPARα comparison 
of LCFA binding, solvation by itself is not likely to be of paramount importance. This is 
because the solvation energy of palmitic or stearic acid are about the same regardless of 
the protein to which they bind (197). We anticipate that the hydration of the binding 
pocket is also similar given the similar polarity of the amino acid substitutions at 272 and 
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270 (F272I and T279M). However, the overall protein flexibility and the role of water in 
this process is of particular importance. While these possibilities were not tested in this 
study, another factor that may play a crucial role in explaining such differences is the use 
of full-length PPARα protein in experimental ligand binding studies as compared to the 
use of PPARα-LBD in computational docking simulations. 
Comparison of the amino acid sequences from the human and mouse PPARα-
LBD, especially in helices 3, 5, 7 and 12 which form the central core of the ligand 
binding pocket, exhibit two major differences in helix 3, which occur at amino acid 272 
(isoleucine to phenylalanine) and 279 (threonine to methionine). While both of these 
substitutions are fairly conservative, the amino acid at 272 in hPPARα is an isoleucine 
with a small isobutyl group, whereas in mPPARα this residue is a phenylalanine with a 
bulkier benzyl side chain. We speculated that the electron rich bulkier benzyl group of 
F272 in mPPARα might cause steric hindrance and change the shape and volume of the 
mPPARα ligand binding pocket. In order to test this hypothesis, we substituted the 
phenylalanine residue at 272 in the mPPARα-LBD structure with an isoleucine (F272I 
mPPARα-LBD). The binding modes and energies generated using such an energy 
minimized model of F272I mPPARα-LBD in complex with palmitic acid (Fig. 18E, 18F), 
as well as palmitoleic, stearic and docosahexaenoic acids (Fig. 22A, 22B, 22C) were 
similar to that obtained using the hPPARα-LBD structure (Table V). These results 
suggest that the amino acid residue at position 272 of helix 3 plays a critical role in 
determining species specificity and selectivity of PPARα ligands. 
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Fig. 22. Structural determinants of endogenous LCFA selectivity for mouse and human 
PPARα. Energy minimized structures of F272I mPPARα-LBD in complex with (A) 
palmitoleic acid, (B) stearic acid and (C) docosahexaenoic acid. The figures in the right 
panels are close-up views of respective panels on the left. All docking poses presented 
here were generated using the FlexiDock™ module available on SYBYL
®
 - X 2.0 and 
are comparable to those generated using AutoDock Vina. 
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In order to confirm the importance of the amino acid residue at position 272, 
docking simulations were also performed with an energy minimized point mutant model 
of I272F hPPARα-LBD in the presence of palmitic or stearic acid (Fig. 23). Although 
such binding/docking displayed weaker binding affinity (higher binding energies; -866 
kcal/mol, C16:0 and -745 kcal/mol, C18:0) than the wild-type hPPARα (Table V), it was 
not as weak as the F272I mPPARα (-284 kcal/mol, C16:0 and -298 kcal/mol, C18:0). The 
differences in the binding energy between I272F hPPARα-LBD and F272I mPPARα-
LBD complexed with C16:0 or C18:0 may be attributed to the manner in which the 
ligands orient around the amino acid at 279 (threonine in hPPARα and methionine in 
mPPARα) (Fig. 23). For example, if the threonine 279 in I272F hPPARα-LBD is mutated 
to methionine (like in F272I mPPARα-LBD) the binding mode/energy generated with 
palmitic or stearic acid mimics that of F272I mPPARα-LBD.  
Similarly, the orientation of the ligand around the amino acid residue at 279 also 
explains the slight difference in binding energies seen between human and mouse PPARα 
for C22:6 (Table V). This T279M substitution has previously been reported to cause 
differences in the activation of human and mouse PPARα in response to synthetic PPARα 
agonists (160). A schematic explaining the significance of these amino acids in relation to 
saturated LCFA binding is presented below (Fig. 23). Depending on the chemistry of the 
ligand both amino acid residues at 272 as well as 279 could be crucial determinants of 
PPARα ligand specificity. However for LCFA binding to mPPARα-LBD, the amino acid 
residue at 272 plays an important role in imparting ligand specificity. 
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Fig. 23. Illustration of saturated LCFA binding to human and mouse PPARα – 
Importance of amino acid residues at position 272 and 279. A) Human PPARα binds 
saturated fatty acids with high affinity. B) Owing to stearic hindrance due to 
phenylalanine at 272 (F272) mPPARα binds this ligand relatively weakly. C) Reversal of 
phenylalanine at 272 to isoleucine (F272I) in mPPARα results in high affinity binding of 
saturated LCFA. D) Mutation of isoleucine at 272 to phenylalanine in hPPARα (I272F) 
results in weaker binding of the saturated fatty acids but it is not as weak as F272I 
mPPARα in C. These differences are a result of how the ligand orients around T279 (in 
hPPARα) such that mutation of both amino acids (I272F and T279M) results in binding 
mode similar to B.     
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In order to determine the contribution of these amino acids to the PPARα ligand 
binding pocket, we evaluated binding pocket volume calculations using the POVME 
algorithm. Based on the occupancy of the GW409544 ligand (in 1K7L) and a padding 
variable set to 0.5 (deduced based in a carbon-hydrogen bond length of 1.09 Å) the ligand 
binding pocket of hPPARα-LBD was 1177 Å
3
 (Fig. 24A)  In contrast, owing to I272F 
and T279M substitutions, the binding pocket of mPPARα-LBD was 1073 Å
3
(Fig. 24B). 
A single mutation of F272I or two mutations including both F272I and M279I in 
mPPARα-LBD resulted in binding pocket volumes of 1130 Å
3
 (Fig. 24C) and 1161 Å
3
 
(Fig. 24D) respectively. It is apparent from these results that the amino acid differences at 
residues 272 and 279 do alter the size of the pocket. However, as the average volume of a 
fatty acid (e.g. palmitic acid) is < 300 Å
3
, there is plenty of space within each of these 
pockets for fatty acid binding. This suggests that favorable interactions with the AF-2 
domain (which are based on the orientation of the ligand) are more important for 
determining PPAR ligand specificity, with regards to LCFA, than the total volume 
available within the pocket. 
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Fig. 24.  Ligand binding pocket volumes for (A) hPPARα-LBD, (B) mPPARα-LBD, (C) 
F272I mPPARα-LBD and (D) F272I, M279T mPPARα-LBD determined using the 
POVME algorithm (193). 
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Purification of full-length recombinant F272I mPPARα:  In order to 
experimentally determine the effect of a phenylalanine to isoleucine substitution at amino 
acid 272 of mPPARα, full-length recombinant F272I mPPARα protein was expressed and 
purified as described for full-length mPPARα and hPPARα (165). SDS-PAGE and 
Coomassie blue staining indicated a predominant band of 52kDa corresponding to the 
expected size of full-length F272I mPPAR (>85% purity; Fig. 25B), with similar purity 
as mPPARα (Fig. 25A). The low intensity band at 75 kDa represents a small fraction of 
un-cut/tagged protein (< 10%).  
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Fig. 25. SDS-PAGE and Coomassie blue staining of 1 µg, 3 µg and 6 µg of purified 
recombinant (A) mPPARα (left) and (B) F272I mPPARα showing relative purity of the 
protein. The prominent band at 52 kDa represent full-length, untagged recombinant 
mPPARα and F272I mPPARα.  
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Binding of fluorescent fatty acids and fatty acyl-CoAs to F272I mPPARα.  While 
BODIPY fluorescence was low for each examined fluorophore in the absence of protein, 
titration of F272I mPPAR with BODIPY C16-CoA resulted in increased fluorescence 
which approached saturation near 200 nM. (Fig. 26A, 26B). This data transformed into a 
linear double reciprocal plot (Fig. 26B, inset), consistent with a single binding site (R
2
 > 
0.90).  Binding of BODIPY C16 fatty acid was also strongly saturable at a single binding 
site (Fig. 26C). Multiple replicates yielded Kd values of 55 ± 4 nM and 18 ± 3 nM for 
BODIPY C16-CoA and BODIPY C16 fatty acid, respectively, indicating high-affinity 
binding. These results were consistent with previously reported binding affinities of wild-
type mPPARα (165), suggesting that this amino acid change did not disrupt or alter the 
binding of these ligands. 
  
131 
 
Wavelength, nm
495 510 525
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
(a
.u
.)
0
300
600
900
1200
0 nM
20 nM
50 nM
100 nM
200 nM
300 nM
BODIPY C16:0 CoA, nM
0 100 200 300 400
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
(a
.u
.)
0
300
600
900
1200
[(L)/(Fi/Fmax)]
150 300
[1
/(
1
-(
F
i/
F
m
a
x
))
]
0
5
10
15
BODIPY C16:0, nM
0 100 200 300
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
(a
.u
.)
0
500
1000
1500
2000
2500
[(L)/(Fi/Fmax)]
100 200[
1
/(
1
-(
F
i/
F
m
a
x
))
]
0
10
20
A B
C
 
 
Fig. 26.  (A) Corrected fluorescence emission spectra of 0.1 M F272I mPPARα titrated 
with 0 (filled circles), 20 (open circles), 50 (filled triangles), 100 (open triangles), 200 
(filled squares) and 300 nM (open squares) of BODIPY C16-CoA upon excitation at 465 
nm. These results demonstrate increased fluorescence intensity upon binding to F272I 
mPPARα.  Plot of F272I mPPARα fluorescence emission at 515 nm (excitation 465 nm) 
as a function of BODIPY C16:0-CoA (B) and BODIPY C16:0 FA (C).  Insets represent 
double reciprocal plots of the binding curve from each panel. All values represent the 
mean ± S.E., n ≥ 3.  
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Binding of endogenous LCFA and LCFA-CoA to F272I mPPARα: In order to 
experimentally test the hypothesis that the F272I substitution could explain the 
differences in binding affinity of human and mouse PPARα for saturated LCFA, the 
ligand specificity of F272I mPPAR for naturally-occurring, endogenous LCFA and 
LCFA-CoA was examined. The binding affinities for naturally-occurring LCFA and 
LCFA-CoA were estimated by monitoring their ability to compete and displace BODIPY 
C16-CoA from F272I mPPARα, which was observed as decreased BODIPY 
fluorescence. With the exception of lauric acid and lauroyl-CoA (Fig. 27K, 27L), titration 
with the fatty acids and fatty acyl-CoA examined here resulted in significantly decreased 
BODIPY fluorescence (Fig. 27A-H).  Quantitative analyses of these data suggested 
strong binding (Ki = 17-29 nM, Table VI).  By comparison, the synthetic PPAR agonist 
clofibrate showed slightly weaker binding affinity (Fig. 27I; Ki = 51 nM), and the 
synthetic PPAR agonist rosiglitazone did not displace BODIPY C16-CoA (Fig. 27J, 
Table VI).  
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Fig. 27. Interaction of naturally-occurring fatty acids and fatty acyl-CoA with F272I 
mPPARα based on displacement of BODIPY C16-CoA. F272I mPPARα complexed with 
BODIPY C16-CoA was titrated with the following ligands: (A) palmitic acid, (B) 
palmitoyl-CoA, (C) palmitoleic acid, (D) palmitoleoyl-CoA, (E) stearic acid, (F) stearoyl-
CoA, (G) docosahexaenoic acid, (H) docosahexaenoyl-CoA, (I) clofibrate, (J) 
rosiglitazone, (K) lauric acid and (L) lauroyl-CoA.  The maximal fluorescence emission 
of BODIPY C16-CoA was measured at 515 nm (excitation at 465 nm). Data are 
presented as percent change of initial fluorescence plotted as a function of ligand 
concentration. All values represent mean ± S.E., n ≥ 3. 
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To confirm the ligand binding specificity of F272I mPPARα, the binding affinity 
of LCFA and LCFA-CoA was also measured by spectroscopically monitoring the 
quenching of F272I mPPAR aromatic amino acid emission.  Titration of F272I 
mPPAR with both palmitic (Fig. 28A) and stearic (Fig. 28E) acid (saturated LCFA) 
effectively quenched F272I mPPARα fluorescence, yielding a sharp saturation curve with 
a maximal change at 100 nM. These data transformed into linear reciprocal plots (Fig. 
28A, 28E insets), indicating high affinity binding at a single binding site (Kd of 20 nM 
and 11 nM for palmitic and stearic acids, respectively).  With the exception of lauric acid 
(Fig. 28K) and lauryl-CoA (Fig. 28L), similar results were obtained for all examined fatty 
acids and fatty acyl-CoA (Fig. 28A-H), with single site binding affinities in the 11-27 nM 
range (Table VI). The PPAR agonist clofibrate strongly quenched F272I mPPAR 
fluorescence (Fig. 28I), but displayed weaker affinity than the LCFA (Table VI), while 
the PPAR agonist rosiglitazone showed no binding (Fig. 28J, Table VI).  
While the binding affinities obtained for F272I mPPARα with saturated LCFA 
were comparable to those obtained with hPPARα (Kd = 14-22 nM), they are significantly 
different (4-5 fold) from those obtained using wild-type mPPARα (Kd = 81-135 nM) 
(165).  These data further corroborate the importance of amino acid residue 272 in 
determining species selectivity for endogenous PPARα ligands. LCFA-CoA binding was 
similar to previous reports for both mPPARα and hPPARα (165), suggesting that amino 
acid 272 is not as important for the orientation of these ligands within the pocket.   
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Docosahexanoic acid, nM (C22:6)
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Fig. 28.  Interaction of naturally-occurring fatty acids and fatty acyl-CoA with F272I 
mPPAR.  Direct binding assay based on quenching of F272I mPPAR aromatic amino 
acid fluorescence emission (excitation = 280 nm and emission = 300-400 nm) when 
titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA, (C) palmitoleic 
acid, (D) palmitoleoyl-CoA, (E) stearic acid, (F) stearoyl-CoA, (G) docosahexaenoic 
acid, (H) docosahexaenoyl-CoA, (I) clofibrate, (J) rosiglitazone, (K) lauric acid and (L) 
lauroyl-CoA.  Data are presented as the change in fluorescence intensity (F0- Fi) plotted 
as a function of ligand concentration.  Insets represent linear plots of the binding curve 
from each panel.  All values represent mean ± S.E., n ≥ 3. 
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Table VI. Affinity of F272I mPPARα for non-fluorescent ligands determined by 
quenching of hPPARα aromatic amino acid fluorescence and by displacement of F272I 
mPPARα-bound BODIPY C16-CoA.  
Ligand Chain length: 
double bonds 
(position) 
Kd 
(nM) 
Fatty 
acid 
Kd (nM) 
Fatty acyl-
CoA 
Ki 
(nM) 
Fatty 
acid 
Ki (nM) 
Fatty acyl-
CoA 
Lauric acid/CoA C12:0 ND ND ND ND 
Palmitic acid/CoA  C16:0 20±3 17±2 19±2 18±2 
Palmitoleic acid/CoA C16:1 (n-7) 19±3 21±2 22±3 28±3 
Stearic acid/CoA C18:0 11±2 18±2 15±1 19±2 
Docosahexanoic 
acid/CoA 
C22:6 (n-3) 17±3 27±3 17±2 29±3 
Clofibrate  42±6  51±3  
Rosiglitazone  ND  ND  
Values represent the mean ± S.E. (n ≥ 3). ND, not determined. 
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Effect of endogenous fatty acids and fatty acyl-CoAs on F272I mPPAR 
secondary structure. Circular dichroism (CD) was used to examine whether the binding 
of LCFA or LCFA-CoA altered the F272I mPPARα secondary structure. The far UV CD 
spectrum of F272I mPPAR suggested the presence of substantial -helical content, 
exhibiting a large positive peak at 192 nm and two negative peaks at 207 and 222 nm 
(Fig. 30A-E, filled circles). Quantitative analyses confirmed that F272I mPPAR was 
composed of approximately 30 % -helix, 18 % β-sheets, 22 % β-turns and 29 % 
unordered structures (Table VII). A comparison of the CD spectra (Fig. 29) and relative 
proportions of the secondary structures for wild-type hPPARα, mPPARα and F272I 
mPPARα suggested no significant differences in the structure of these proteins - a finding 
consistent with our observations from the modeling data. This suggested that the F272I 
mutation in mPPARα does not disrupt the secondary structure or folding of the protein.  
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Fig. 29. An overlay of the far UV circular dichroic (CD) spectra of hPPARα (filled 
circles), mPPARα (open triangles) and F272I mPPARα (filled squares) in the absence of 
any ligands.  Each spectrum represents an average of 10 scans for a given representative 
spectrum from at least three replicates. 
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The addition of high-affinity ligands to F272I mPPARα resulted in 
conformational changes demonstrated by alterations in the molar ellipticity at 192, 207, 
and 222 nm (Fig. 30B-E), indicative of ligand binding. Conversely, no changes were 
observed with the addition of lauric acid (Fig. 30A), lauroyl-CoA (Fig. 30A) or 
rosiglitazone (Fig. 30F), consistent with the lack of binding of F272I mPPAR to these 
ligands. While saturated LCFA do not induce secondary structural changes to mPPARα 
(165), there was a significant decrease in the fraction of -helical content and a 
concomitant increase in the fraction of β-sheets for F272I mPPARα (Table VII), similar 
to those reported for hPPARα (Table III) (165). Similar helix-sheet transitions have been 
previously reported with other nuclear receptors and transmembrane proteins (117, 177, 
198).  Most of the examined LCFA and LCFA-CoA resulted in F272I mPPARα 
structural changes (Table VII) similar to those previously reported for hPPARα (Table 
III) (165), further indicating the importance of residue 272 in LCFA binding. However, 
palmitoyl-CoA and docosahexaenoic acid changes (Table VII) were more similar to those 
reported for mPPARα (Table IV) (165), suggesting that ligand structure may also be 
important in determining ligand orientation and binding.  
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Fig. 30.  Far UV circular dichroic (CD) spectra of F272I mPPARα in the absence (filled 
circles) and presence of added ligand: A, Lauric acid (open circles) or Lauryl CoA (filled 
triangles); B, palmitic acid (open circles) or palmitoyl CoA (filled triangles); C, 
palmitoleic acid (open circles) or palmitoleoyl-CoA (filled triangles); D, stearic acid 
(open circles) or stearoyl-CoA (filled triangles); E, docosahexanoic acid (open circles) or 
docosahexaenoyl-CoA (filled triangles); and F, clofibrate (open circles) or rosiglitzone 
(filled triangles).  Each spectrum represents an average of 10 scans for a given 
representative spectrum from at least three replicates. 
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Table VII. Effect of ligands on the relative proportion of F272I mPPARα secondary 
structure determined by CD.  These structures were as follows: total helices (H; a sum of 
regular α-helices and distorted α-helices), total sheets (S; a sum of regular β-sheets and 
distorted β-sheets), turns (Trn; β-turns), and unordered (Unrd) structures. 
Average Total H ± 
S.E. 
Total S ± 
S.E. 
Trn ± 
S.E. 
Unrd ± 
S.E. 
F272I mPPARα  30 ± 2 18.3 ± 2.3 21.8 ± 0.2 28.8 ± 0.2 
F272I mPPARα + C12:0 29 ± 1 21 ± 2 21.8 ± 0.1 28.9 ± 0.2 
F272I mPPARα + C12:0-CoA 30 ± 1 20 ± 1 21.7 ± 0.3 29.1 ± 0.1 
F272I mPPARα + C16:0 18.1 ± 0.2
**
 31.5 ± 0.5
**
 22 ± 0.1 28.6 ± 0.3 
F272I mPPARα + C16:0-CoA 21 ± 2
*
 29 ± 1
*
 22.1 ± 0.3 29.1 ± 0.2 
F272I mPPARα + C16:1 20 ± 1
#
 30 ± 1
#
 21.7 ± 0.1 28.7 ± 0.2 
F272I mPPARα + C16:1-CoA 22 ± 2
*
 28 ± 1
*
 21.4 ± 0.2 28.5 ± 0.5 
F272I mPPARα + C18:0 18.3 ± 0.1
**
 31.1 ± 0.1
**
 21.9 ± 0.1 28.5 ± 0.1 
F272I mPPARα + C18:0-CoA 20 ± 1
*
 29 ± 1
*
 21.5 ± 0.2 28.7 ± 0.3 
F272I mPPARα + C22:6 19 ± 1
**
 30.8 ± 0.3
**
 21.5 ± 0.1 28.7 ± 0.1 
F272I mPPARα + C22:6-CoA 19.1 ± 0.1
#
 30.6 ± 0.3
**
 22 ± 1 28.6 ± 0.1 
F272I mPPARα + Clofibrate 17.1 ± 0.1
**
 31.9 ± 0.3
**
 22 ± 1 29.0 ± 0.2 
F272I mPPARα + Rosiglitazone 31 ± 1 19 ± 1 21.9 ± 0.1 28.6 ± 0.1 
Asterisks represent significant differences between F272I mPPARα only and F272I 
mPPARα in the presence of added ligand (* P < 0.05, ** P < 0.001 and 
# 
P = 0.001).  
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Effect of fatty acids on transactivation of PPAR-RXR heterodimers. In order to 
determine whether residue 272 is also responsible for variances observed between 
mPPARα and hPPARα transactivation in response to saturated LCFA (165), luciferase 
reporter assays utilizing hPPARα, mPPARα and F272I mPPARα were performed. Since 
PPAR heterodimerizes with RXR to induce transactivation, COS-7 cells were 
cotransfected with either pSG5 empty vector or a combination of hPPARα and hRXRα, 
mPPARα and mRXRα or F272I mPPARα and mRXRα. The transactivation of a PPRE×3 
TK LUC reporter construct was analyzed in the absence or presence of ligands (Fig. 31).  
Transactivation was measured as percent firefly luciferase activity normalized to Renilla 
luciferase (internal control).   
Cells overexpressing hPPARα and hRXRα demonstrated significantly increased 
transactivation of the PPRE×3 TK LUC reporter in response to high-affinity ligands of 
hPPARα (Fig. 31). In contrast, for cells overexpressing mPPARα and mRXRα, only the 
examined unsaturated LCFA and clofibrate significantly increased transactivation. 
Consistent with the weak binding affinity of saturated LCFA for mPPARα, addition of 
these ligands did not affect the activity in COS-7 cells. However, in cells overexpressing 
F272I mPPARα and mRXRα the addition of saturated LCFA (palmitic and stearic acid), 
as well as unsaturated LCFA (palmitoleic, and docosahexaenoic acid) resulted in 
significantly increased transactivation similar to clofibrate treated cells (Fig. 31). This 
was consistent with the high-affinity binding of these ligands to F272I mPPARα. In all 
treatments the addition of lauric acid, which consistently did not bind to hPPARα, 
mPPARα or F272I mPPARα, had no significant effect on activity. These findings 
suggested that only high-affinity endogenous ligands increase PPARα activity and, more 
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importantly, the amino acid at 272 could be responsible for the differences in saturated 
LCFA-mediated transactivation of the PPRE×3 TK LUC reporter in cells overexpressing 
hPPARα and mPPARα. 
These results are consistent with previous transactivation studies and gene 
expression studies which demonstrate species differences in the activity of human and 
mouse PPARα in response to synthetic agonists such as 5, 8, 11, 14-eicosatetraynoic acid 
(ETYA), WY-14,643 and 2-ethylphenylpropanoic acid derivative (KCL), among others 
(158, 160-163, 187, 199). While an I272F substitution diminished the agonistic activity 
of KCL, a T279M substitution increased the agonistic activity of WY-14,643 in hPPARα 
(158). Our studies with endogenous LCFA ligands suggested that, to a large extent, only 
amino acid 272 plays an important role in determining species differences, particularly 
for saturated LCFA. We speculate that based on the structure of ligands and their 
potential orientation and interactions within the PPARα pocket, both amino acids at 272 
and 279 are crucial determinants of species differences exhibited by PPARα across 
species.  
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Fig. 31.  Fatty acids mediate species-selective transactivation of PPARα-RXRα 
heterodimers.  Cos7 cells transfected with either both hPPARα and hRXRα, both 
mPPARα and mRXRα, or both F272I mPPARα and mRXRα analyzed for transactivation 
of the acyl-CoA oxidase reporter construct in presence of vehicle (open bars), 1 µM 
lauric acid (diagonally upward bars), 1 µM palmitic acid (hatched bars), 1 µM 
palmitoleic acid (diagonally downward bars), 1 µM stearic acid (horizontally lined bars), 
1 µM docosahexanoic acid (open bars) and 1 µM clofibrate (diagonally upward bars).  
The y-axis represents values for firefly luciferase activity that have been normalized to 
Renilla luciferase (internal control) as well as controls for cells transfected with empty 
pSG5 vector.  The bar graph represents the mean values (n ≥ 3) ± standard error. * P < 
0.01, ** P < 0.001.     
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Computational and experimental data support the notion that amino acid 
substitutions could be responsible for differences in binding affinity and activation 
observed between human and mouse PPARα.  It is believed that during the course of 
evolution, emerging nuclear receptors acquired the ligand-binding capacities and further 
refined their specificities for a particular biologically signficiant ligand (184, 200, 201).  
Among 117 vertebrate PPARα protein coding sequences identified by BLAST, isoleucine 
272 is conserved from bony fish to primates, with the exception of mouse (Mus 
musculus), rat (Rattus norvegicus) and two unrelated rodents: the naked mole rat 
(Heterocephalus glaber) and the thirteen-lined ground squirrel (Ictidomys 
tridecemlineatus). The distribution of these species suggests that the substitution of 
isoleucine for phenylalanine has evolved at least three times.  A simple transversion (A to 
T) in the first position of the codon is enough to convert an isoleucine to a phenylalanine 
codon.  However, given the high evolutionary rate of PPARα (184, 200, 201), the 
conservation of isoleucine in this position implies that there are functional and 
evolutionary consequences associated with this change (e.g. it is under purifying 
selection).   
Consistent with this, our results indicated that compared to humans, the I272F 
amino acid change seen in mouse represents a partial loss of function mutation 
(hypomorphic) with respect to LCFA binding.  Whether this change is responsible for the 
increased sensitivity of mouse to peroxisome proliferation or hepatic cancer remains to be 
determined, but the single F272I substitution in mPPARα recapitulates the human-like 
LCFA binding and trans-activation functions.  Other amino acid positions examined that 
were not predicted to alter LCFA binding energies (such as position 279) displayed much 
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greater variation among species, suggesting more relaxed functional and evolutionary 
constraints at those positions. One could speculate that PPARα underwent strong 
selective pressure that was directly affected by dietary changes and that this eventually 
provided crucial structural and functional changes like I272F in mouse.  However, there 
is no clear dietary or metabolic relationship uniquely shared among the four species that 
harbor the I272F amino acid change, and compensatory mechanisms that may allow this 
mutation to persist within these species are not clearly established.  Therefore, the 
important question that still remains unsolved is why such differences in PPARα 
structure would exist. 
Nonetheless, we demonstrated for the first time that differences in amino acids in 
the LBD of PPARα contribute to species selectivity and specificity for endogenous 
PPARα ligands. The importance of PPARα in human disease is validated by the lipid 
lowering effects of synthetic PPARα agonists. The data presented herein enhances our 
understanding of dietary effects on PPARα and may aid in the development of more 
targeted therapeutics. Moreover, these data demonstrate the efficacy of molecular 
modeling and docking simulations for examining the effect of structural variations on 
ligand binding.  
 
 
 
 
 
 
152 
 
Summary and Conclusions: 
The importance of dietary fat has been acknowledged ever since Burr and Burr 
(1929) examined the effects of fat-free diets in rats (202). They noticed that, as compared 
to rats on normal diet, rats on fat-free diets (with same calories via proteins and vitamins) 
failed to thrive and developed various physiological problems including skin disorders 
and kidney problems (202). Further, these rats were reverted to good health when dietary 
fats were added to their food (202). It is known today that dietary fatty acids are 
ubiquitous molecules that serve as major metabolic fuels, important components of 
biological membranes and signaling molecules, and play significant roles as gene 
regulators. The regulation of lipid metabolism is thus crucial for whole-body energy 
homeostasis. Since the amount of available nutrients do not always match their energetic 
demands, it is important that living organisms continuously adapt their metabolism to 
their nutritional status, such that energy intake and expenditure remain adjusted. 
Unfortunately, the rate of fat oxidation is not necessarily determined by the amount of fat 
intake, but rather by the energy gap resulting post carbohydrate metabolism (203). 
Therefore the regulation of lipid metabolism in mammals is complex in nature. It consists 
of a short/rapid component involving rapid modulation of protein activity/stability (by 
allosteric means or post-translational modifications) and a long-term component 
involving transcription factors. 
 PPARα is a ligand-activated nuclear transcription factor that plays an important 
regulatory role in cellular processes such as fatty acid metabolism, glucose metabolism, 
inflammation, differentiation and proliferation (7-10). In 2015 we will be celebrating the 
25
th
 year anniversary of the PPARα discovery. Initially isolated as a receptor that serves 
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as a target for a diverse class of peroxisome proliferators in rodents, today it is regarded 
as a lipid sensor that regulates the expression of several proteins/enzymes involved in 
fatty acid metabolism. Although fatty acids and their derivatives has been shown to 
activate PPAR of several species including mouse PPARα (mPPARα) (8, 108, 110, 
113-117), the identity of high-affinity endogenous ligands for human PPARα (hPPARα) 
have been more elusive. In order to understand the molecular role of dietary LCFA in 
human PPARα mediated regulation of energy homeostasis we set out with two main 
goals for this dissertation: 1) to determine whether LCFA and LCFA-CoA constitute 
high-affinity endogenous ligands for full-length hPPARα and 2) to investigate whether 
there exist differences in such affinity between hPPARα and mPPARα. The main 
outcomes and conclusions of this dissertation are discussed below: 
LCFA and their thioesters serve as high affinity physiological ligands for PPARα 
–metacrine signaling and transcriptional control. For the first time we demonstrated that 
LCFA and LCFA-CoA represent high affinity ligands for full-length recombinant 
hPPARα. Such binding occured at physiologically relevant concentrations (Kd
 
= 11-40 
nM) and was associated with strong secondary structural changes in the protein 
(hallmarks of nuclear receptor ligand binding). Ligand binding also resulted in a PPARα-
dependent transactivation of the ACOX PPRE-luciferase reporter in COS-7 cells, 
suggesting that these ligands could in fact activate PPARα in vivo. While it is 
acknowledged that PPARα has evolved as a lipoid sensor that regulates the expression of 
target genes involved in lipid metabolism (111, 114, 121), the identification of LCFA and 
LCFA-CoA as ligands for PPARα further substantiates our knowledge on PPARα 
function. Such a link between nutrient/metabolite and transcriptional regulation has been 
154 
 
long appreciated in bacteria. For example, the lac repressor in bacteria binds a lactose 
metabolite (allolactose) and coordinates the synthesis of the enzymes required for the 
breakdown/catabolism of lactose or its metabolites (204). It is possible that such 
allosteric regulation is in place in higher organism as well. For example, LCFA or their 
metabolites bind PPARα and induce feed-forward activation or feedback inhibition in the 
expression of genes involved in their metabolism. The first evidence or proof for such 
theory came from genetically engineered mouse models. For example, in ACOX knock-
out mice (ACOX-/-; first enzyme involved in β-oxidation) there is accumulation of 
PPARα ligands (LCFA and LCFA-CoA) and hyperactivity of PPARα because these 
ligands cannot enter the β-oxidation pathway (121). Also, peroxisomal bifunctional 
enzyme (second enzyme involved in β-oxidation) knockout mice have up-regulated 
PPARα target genes because intermediates of peroxisomal β-oxidation serve as PPARα 
ligands (205). Liver-specific fatty acid synthase (FAS; first enzyme involved in fatty acid 
biosynthesis) knockout mice on a zero-fat diet exhibit severe hypoglycemia and fatty 
liver similar to the PPARα knockout mice phenotype (206). These effects were reversed 
upon administration of either dietary fat or a PPARα agonist (206). All these findings 
along with our results further confirm the role of PPARα as a lipid sensor.  
While in most studies, LCFA and LCFA-CoA activate PPARα, Murakami et al. 
suggested that LCFA-CoA interact with PPARα and have an inhibitory effect on PPARα 
activity (84). Assuming that this is the case, it is possible that metabolites such as LCFA-
CoA could increase or decrease PPARα activity depending on the target gene or the 
effect desired. For example, LCFA are rapidly converted to LCFA-CoA by an enzyme 
called long chain acyl-CoA synthase 1 (ACSL1) - a PPARα target. It is possible that 
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while LCFA induces the expression of ACSL1 (through a PPRE in its promoter), 
depending on the relative ratio of LCFA/LCFA-CoA, LCFA-CoA may repress ACSL1 
by a negative feedback mechanism. Although this possibility has not been tested in this 
dissertation, it will be interesting to test this angle of nutrient mediated PPARα regulation 
of target genes. It is necessary to mention that the inhibitory activities of LCFA-CoA 
reported by Murakami et al. were derived on the basis of their inability to recruit a 
coactivator peptide of SRC-1 to the hPPARα-LBD. Since only one coactivator peptide 
was tested for binding to hPPARα-LBD in response to LCFA-CoA binding (no full-
length coactivator or protein), the significance of these findings are not clear. It is 
possible that LCFA-CoA bound PPARα recruits SRC-1 to the coactivator binding motif 
on the A/B domain (PPARα-LBD used in these studies) as discussed in the introduction 
of this dissertation. Alternatively, LCFA-CoA bound PPARα may selectively recruit 
other coactivators other than SRC-1.  
Although our in vitro experiments using multiple fluorescence-based approaches 
and CD spectroscopy demonstrated binding of both LCFA and LCFA-CoA to hPPARα, 
data from our transactivation assays did not differentiate the effects of LCFA on hPPARα 
activity from that of LCFA-CoA. One way to do this would be to use cells that do not 
express long chain acyl-CoA synthase (ACSL) - the cellular enzyme that converts LCFA 
to LCFA-CoA. However, there are 5 isoforms of ACSL numbered as 1, 3, 4, 5 and 6 that 
belong to a much larger family of acyl-CoA synthases (26 members including ACSLs) 
(207, 208). Owing to the many isoforms of this protein, it will be challenging to knock-
down the activity of this enzyme. Another way to approach this problem is to 
pharmacologically inhibit ACSL activity in the cell by using inhibitors such as triascin C 
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(209). Such experiments involving the use of triascin C attempted in our lab as well as by 
others, resulted in significant cell death (unpublished data Ms. Jeanette Loyer, Hostetler 
lab and (210)). Another way that one might address this issue is to treat cells with non-
metabolizable forms of LCFA (e.g. bromopalmitic acid) and LCFA-CoA (e.g. S-
hexadecyl-CoA) and determine the expression of PPARα target genes such as ACSL1. 
While this approach has not been tested in this dissertation, it will be interesting to 
determine 1) whether these ligands bind with equivalent affinity as the natural ligands 
and 2) whether these ligands exhibit any difference in PPARα mediated transactivation 
(using the ACOX PPRE×3 reporter construct) or gene expression.  
It is essential to mention that all ligand binding studies in this dissertation were 
carried out using recombinant full-length forms of human and mouse PPARα. These 
proteins were expressed in bacteria and subsequently purified using affinity 
chromatography. That being said, an important consideration must be given to the fact 
that since these proteins were expressed in bacteria, they may lack post-translational 
modifications that are commonly seen in eukaryotic organisms. PPARα undergoes post-
translational modifications in the form of phosphorylation (211), ubiquitination (212) and 
SUMOylation (213). While it is not clear whether post translational modifications have 
any observable effects on ligand binding, such modifications definitely have an impact on 
the activity of PPARα. For example, phosphorylation increases the ligand-induced 
transcriptional activity of PPARα, whereas SUMOylation decreases it. However, post-
translational modifications mainly influence PPARα activity through preferential 
recruitment of cofactors (coactivators or corepressors) (211, 213). Likewise ligand 
binding also influences the occurances of post translational modifications. For example 
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ligand binding decreases PPARα ubiquination and SUMOylation (214). Recombinant 
proteins have been widely used to study various aspects of PPARα function for a long 
time. Although we cannot rule out the effect of post-translational modifications on ligand 
binding, data from transactivation assays done in COS-7 cells (where post-translational 
modifications could occur) corroborate and confirm ligand mediated activation of 
PPARα. 
We utilized the ACOX PPRE×3 reporter construct in all our transactivation 
assays. Although this reporter has been widely used to test the PPARα activity, it 
represents an artificial reporter system where three copies of the ACOX PPRE along with 
the thymidine kinase (TK) minimal promoter have been cloned upstream of a firefly 
luciferase gene (39, 180). Such reporter assays essentially determine whether a nuclear 
receptor (PPARα) can activate or repress gene transcription (in response to ligands) when 
it binds to its response element (PPRE) (215). Since sequences around the PPRE could be 
a determinant in PPARα specificity (29, 43), it will be interesting to see how LCFA 
ligands affect the transcription of the luciferase gene driven by a much larger promoter of 
a PPARα target gene. Alternatively, it would also be interesting to determine the actual 
transcript or protein levels of PPARα target genes upon administration of such ligands.  
LCFA and their thioesters serve as high affinity physiological ligands for PPARα 
– binding affinity number considerations. In addition to demonstrating the binding of 
LCFA and LCFA-CoA to hPPARα, we also report binding affinities for such ligands. 
The interaction of ligands with their binding site on the receptor is characterized in terms 
of binding affinity. Higher binding affinity means that a lower concentration of ligand is 
sufficient to maximally occupy all the binding sites. Binding affinity is represented in 
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terms of a dissociation constant or Kd – the concentration of the ligand at which 50% of 
the receptor binding sites are occupied (178). Binding affinity numbers reported here for 
LCFA and LCFA-CoA interaction with full-length PPARα are consistent with the 
physiological concentrations of these ligands in the cell (88, 95, 117, 118, 120, 152). This 
comparison of receptor-ligand binding affinity and physiological concentration of the 
ligands serves as a guideline to confirm the relevance of the ligand for receptor function. 
For example, vitamin D receptor (VDR) binds vitamin D at nanomolar concentrations 
(consistent with cellular concentrations), but it is also activated by bile acids at much 
higher concentrations (216). It is possible that bile acids either do not represent true 
ligands for VDR (or bring about VDR activation indirectly) or VDR may have some 
other functions in the gut where the concentration of bile acids could be considerably 
higher than other organs (216). In a similar manner, LCFA and LCFA-CoA may activate 
PPARα in tissues with high involvement in fat metabolism and/or nanomolar 
concentrations of these ligands (such as liver, muscle, heart, adipose) but they may not 
play a role in other tissues which are not as dependent on fat metabolism, such as the 
brain (152, 217).  
In the case of drug molecules, binding affinity numbers are indicative of drug 
specificity and efficacy, and it helps determine the effective dose of the drug. Along with 
structure-activity relationship, binding affinity numbers help design better drugs with 
selective affinity to the targeted receptor and lesser side-effects. Knowing the binding 
affinities for different fatty acids and their derivatives will help determine the kind of 
competition a synthetic agonist or a therapeutic drug may encounter. The degree of 
PPARα activation in vivo may not result from its interactions with a single high affinity 
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fatty acid ligand but may instead arise from the pool of fatty acids and/or its metabolites. 
Thus when a drug is administered (example, a PPARα agonist such as clofibrate) it has to 
compete with this pool of endogenous ligands. Since the nutritional status of each 
individual varies greatly owing to dietary parameters and physiological/disease state, the 
anticipated therapeutic response may not be achieved in each and every individual. For 
example, clinically it is observed that fibrate treatment improves the lipid profile for the 
majority of the patients but there is always a fraction of patients, who do not respond to 
such therapy (218). Similarly differences in responses are also observed with mice strain 
variations. It is possible that in addition to genotype, diet-drug interactions could also 
result in such differences in responses to therapeutic treatments. Thus, better knowledge 
of these affinity numbers along with the metabolic/nutritional status of a patient will 
allow for careful dose adjustments for effective therapeutic treatments. 
There exist differences in activation of human and mouse PPARα in response to 
saturated LCFA – species differences considerations. One of the most important 
outcomes of this dissertation is the species differences in the ligand binding specificity 
and affinity between the full-length forms of hPPARα and mPPARα. Species differences 
in the binding of endogenous ligands for other nuclear receptors such as the estrogen 
receptors have also been observed (219). Before going into depths comparing the two 
full-length proteins, it is essential to compare our LCFA binding data from full-length 
mPPARα to that of truncated mPPARαΔAB (lacking the N-terminal A/B domain). In 
contrast to our study with full-length mPPARα, previous studies with mPPARαΔAB 
indicate very weak binding to saturated and polyunsaturated LCFA (but strong binding to 
their thioester derivatives) (115-117). While these differences could arise from 
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differences in the protein preparation or techniques used, it should also be noted that one 
of the main differences lies in the fact that these data were generated using truncated 
form of PPARα (115-117). The N-terminal A/B domain of PPARα not only contributes 
to transcriptional activity of PPARα (30, 31) but also determines DNA binding (31) and 
ligand specificity (34). Mutations of residues in the A/B domain (particularly S112) 
altered ligand binding and activity (function of E/F domain) of PPARγ (34). Berbaum et 
al. also reported differences in coactivator recruitment and fibrate-induced transcriptional 
activation between the full-length and LBD forms of PPARα (153). These results provide 
evidence to the interdomain communications between the various domains structures of 
the protein.  
We have reported significant differences in the ligand binding affinities and 
activity of hPPARα and mPPARα in response to saturated LCFA. A careful examination 
of the existing literature demonstrated that: 1) species differences in the activity of human 
and mouse PPARα in response to synthetic agonists such as WY-14,643 have been 
observed by others researchers (158, 160-163, 187, 199) and 2) differences in the target 
gene profiles and activity of human and mouse PPARα have also been reported (158, 
160-163, 187, 199). Since the discovery of peroxisomal proliferators, it has been 
established that long-term administration of PPARα agonists result in hepatic cancer only 
in rodents (102). Further, transgenic mice that express human PPARα mainly in the liver 
do not exhibit liver tumors upon administration of PPARα agonists (149, 150). All these 
observations suggest that structural differences in the PPARα protein could be one 
possible underlying cause of such species variation.  Owing to the use of the rodent 
models for toxicological evaluation of therapeutics, and the importance of PPARα as a 
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pharmaceutical target, we decided to focus on the structural aspects of the human and the 
mouse protein to explain possible mechanisms of such differences. 
 Comparison of the primary sequence of PPARα from more than 100 vertebrate 
species demonstrated that they harbor the same amino acids at 314 and 464 (tyrosine) that 
participate in direct hydrogen bonding interactions with synthetic agonists as well as 
LCFA ligands. Despite these similarities, there were differences in the binding affinities 
as well as binding energies for interaction of human and mouse PPARα with saturated 
LCFA (palmitic and stearic acids). This suggested that other amino acid residues may 
also play a role in ligand specificity. Using the strategies of molecular modeling, docking, 
pocket volume estimations and mutagenesis, we were able to narrow down two amino 
acid residues at 272 and 279 as crucial determinants of such ligand specificity. The amino 
acid residue at 272 (isoleucine in human and phenylalanine in mouse) was especially 
critical for determining ligand specificity for saturated LCFA. These findings were 
consistent with other researchers who have also demonstrated similar species differences 
with PPARα (158, 160-163, 187, 199).  
 While it is still not clear is why such differences would exist, one hypothesis 
includes the nuclear receptor evolution of ligand binding capacity. It is speculated that 
nuclear receptors evolved from a common ancesteral orphan receptor (no ligand) (184, 
200, 201). During the course of evolution, emerging nuclear receptors acquired ligand-
binding capacities and underwent very subtle changes (typically due to just a few 
mutations) resulting in further refining their specificities for a given ligand (184, 200, 
201). Except for rats and mice, the isoleucine at 272 in hPPARα is highly conserved 
across more than 100 vertebrate species. Owing to the high evolutionary rate of PPARα 
162 
 
(184, 200, 201), one could speculate that the receptor underwent evolutionary adaptations 
by mutations in response to a different range of ligands in different species. While it is 
not obvious what could have been the source of such adaptation, dietary changes have 
also been proposed to be one of the strong driving forces for such adaptation (220). For 
example, the persistence of lactase expression in populations with a long history of milk 
consumption (220). It is tempting to speculate that genes that were directly affected by 
dietary changes came under strong selective pressures which eventually lead to crucial 
structural and functional changes (example I272F). 
 With that being said, the bigger question that one needs to address is whether the 
rodent model is ideal for studying proteins with such species diversity. Mice as a model 
system have several advantages. For example, 1) their genome is fairly similar to the 
human genome, 2) their small size facilitates high through-put studies in a cost effective 
manner and 3) the availability of genetically engineered mice (such as the PPARα -/- 
mice) provides a wealth of information on disease processes (and functional aspects of 
the PPARα protein). However, there are also drawbacks – they are not humans (221). In 
addition to structural and functional differences in the mouse and human forms of 
PPARα, long-term administration of PPARα agonists results in rodent specific 
hepatocarcinogenesis (102). Since amino acid residues at 272 and 279 in the PPARα 
ligand binding domain are crucial determinants of ligand specificity, quantitative 
structure activity relationship must be utilized extensively to screen potential PPARα 
drug candidates that are more specific for the human form of the protein. Further, in order 
to carry out pharmacological and toxicological evaluation of potential PPARα drug 
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candidates, other model organisms (which do not display such diversity) or humanized 
mouse models of PPARα should be employed.    
 In conclusion, fatty acids are essential dietary components that serve as metacrine 
signals transducing metabolic parameters into regulatory events. Elevated levels of 
triglycerides or fatty acids are a major component of obesity and its co-morbidities 
including the metabolic syndrome. PPARα serves to sense the total flux of fatty acids and 
regulate various metabolic pathways associated with fatty acid metabolism. The 
importance of PPARα in human disease is validated by the lipid lowering effects of 
synthetic PPARα agonists. Our data suggests that LCFA serve as high affinity ligands for 
PPARα and thus help regulate lipid homeostasis. However special consideration must be 
given to differences in ligand binding specificity and affinity between mouse and human 
PPARα. Our results, along with others, call for careful interpretation and extrapolation of 
data that use mouse as a model for studying this protein.  Further, they emphasize on the 
need to develop drugs that have greater specificity for human versus rodent PPARα.   
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Abstract 
Adiponectin is an adipocyte-secreted adipokine that has attracted much attention due to 
its salutary effects on obesity related cardiovascular complications. Adiponectin plays a 
large role in maintaining energy homeostasis by interacting with its receptors to increase 
fatty acid oxidation, glucose uptake and decrease gluconeogenesis. Recent studies have 
reported adiponectin expression from other tissues such as heart, liver and muscle, where 
it is believed to act in a local manner to regulate homeostasis. In addition, numerous 
studies have reported decreased expression of adiponectin associated with cardiovascular 
and metabolic complications. Clinical and preclinical studies have suggested regulation 
of adiponectin by PPAR α and γ agonists. While PPARγ agonists are thought to act by 
mediating adipogenesis and transactivating adiponectin, the role of PPARα and its 
underlying mechanisms in regulating the expression of adiponectin is not clear. PPARα 
binds endogenous ligands (long chain fatty acids (LCFA)) as well as exogenous ligands 
(fibrates) to regulate the transcription of genes involved in fatty acid oxidation. The goal 
of this study was to determine whether ligand-activated human PPARα regulates the 
expression of adiponectin in cultured human hepatoma cells (HepG2). Although not 
convincing, data from electrophoretic mobility shift assays (EMSA) and transactivation 
assays suggest that PPARα may bind PPRE sequences in the adiponectin promoter and 
may contribute towards regulation of the adiponectin gene (either directly or indirectly). 
Since we were not able to detect the expression of adiponectin in HepG2 cells, future 
studies investigating the role of PPARα in adiponectin regulation must be carried out in a 
cell line that constitutively expresses adiponectin.    
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Introduction 
Obesity is defined as an increased mass of adipose tissue and is a major risk factor 
for coronary heart disease, hypertension, atherosclerosis, dyslipidemia and diabetes (1). 
The prevalence of obesity is associated with a surge in the metabolic syndrome in 
industrialized or developing countries (2, 3). For this reason, there has been a great 
scientific interest in studying the physiology of the adipose tissue. The adipose tissue has 
been traditionally considered as a site of triglyceride (TG) storage and free fatty acid 
release in response to increased energy demands (1, 4). However in the past decade, 
adipose tissue has been recognized to have endocrine functions regulating energy 
homeostasis and inflammation by releasing a number of biologically active peptides. The 
term adipokine or adipocytokine was coined to describe these signaling messengers that 
are secreted by the adipose tissue, some of which include leptin (5), resistin (6), tumor 
necrosis factor α (TNFα) (7) and adiponectin (8-11).  
Adiponectin was originally reported independently by four groups using different 
approaches and is also referred to as AdipoQ (11), Acrp30 (30 kDa adipocyte 
complement related protein) (8), apM1 (adipose most abundant gene transcript) (9) and 
gelatin binding protein of 28 kDa (GBP28) (10). Today, the most widely accepted name 
is adiponectin, which will therefore be used hereafter. The human adiponectin is a 30 kDa 
and 247 amino acid protein that consists of an N-terminal signal sequence/peptide (SS), a 
hypervariable region (VR), a collagenous domain and a C-terminal globular domain (11, 
12) (Fig. 32). The collagenous domain consists of 22 Gly-X-Y repeats (where X and Y 
are any amino acid) along with prolines and lysine residues that are subjected to post-
translational modifications including glycosylation and hydroxylations (11). The 
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carboxy-terminal globular domain on the other hand is similar to complement factor C1q, 
VIII and X and also bears structural homology (but no amino acid sequence homology) 
with TNFα (12).  
The human adiponectin gene spans a length of 17 kb and is localized to 
chromosome 3q27, a region highlighted as a genetic susceptibility locus for type 2 
diabetes and metabolic syndrome (13). Its transcript is most abundantly found in 
adipocytes and consists of three exons and two introns (14). It exists abundantly in 
human blood (5-30 μg/ml) forming about 0.05 % of all plasma proteins and the molar 
concentration of 5 µg/ml adiponectin in human plasma corresponds to approximately 3 
nM (8-11). Adiponectin circulates in the blood predominantly in three different 
oligomeric forms – trimer, hexamer and high molecular weight oligomer (12-18 
protomers; Fig. 32). Three adiponectin monomers come together via hydrophobic 
interactions in the globular domain to form a trimer, which is also referred to as the low 
molecular weight adiponectin (LMW). Two trimers then associate to form hexamers 
(medium molecular weight; MMW) and high molecular weight oligomers comprised of 
12-18 protomers/monomers (high molecular weight; HMW) (8-11). The disulfide bridges 
formed by cysteine residues at position 39 are responsible for the oligomerization of 
adiponectin and mutation of this residue (C39S) abolishes the formation of such 
oligomers (15). Post-translational modifications in the collagenous domain are also 
required for the assembly of the HMW oligomers (16).  
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Fig. 32 - Primary structure of adiponectin consisting of signal sequence (SS), 
hypervariable region (VR) collagen-like domain prolines (P) and lysines (K) and C-
terminal globular domain. Multimer formation of adiponectin where monomer forms 
trimer (hydrophobic interactions) and trimers come together to form hexamers and high 
molecular weight oligomers (disulphide bonds via C39). Figure modified from (17)  
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While it is speculated that different forms of adiponectin (monomeric, trimeric, 
oligomeric) have distinct tissue specific levels biological activities, many of these results 
are controversial and not clear at this stage. For example, several studies indicate that the 
HMW form of adiponectin is the most bioactive form of adiponectin (18-20). Kadowaki 
at al. have reported that populations with rare mutations in the adiponectin gene (G90S, 
G84R) have lower levels of HMW adiponectin and are associated with insulin resistance 
and type 2 diabetes (18). While these findings suggest that HMW may be the most 
bioactive form of adiponectin, mutant recombinant adiponectin (G90S, G84R) expressed 
in NIH-3T3 fibroblasts fail form the HMW multimers (18). Thus lower levels of HMW 
oligomers in these populations could just be a result of impaired multimerization. 
Besides, other researchers have suggested that monomeric or trimeric forms of 
adiponectin may be important in mediating the pleotropic effects of adiponectin in 
skeletal muscles (19, 21-23). Since the significance of the different oligomeric forms of 
adiponectin are not clear, the total plasma adiponectin measurements are the most 
commonly reported (24).     
Irrespective of their oligomeric state, adiponectin exerts its effects by binding to 
two isoforms of adiponectin receptors (AdipoR) – AdipoR1 and AdipoR2. While the 
AdipoR1 gene encodes a 42.4 kDa and 375 amino acid protein, the AdipoR2 gene 
encodes a 311 amino acid protein of 35.4 kDa (25). These proteins bear about 67% 
sequence homology and they also share about ~95 % homology between mice and 
humans. As far as the expression of these receptors is concerned, they are ubiquitously 
expressed, with the expression of AdipoR1 highest in skeletal muscle and AdipoR2 
highest in the liver (25, 26). Structurally, both AdipoR1 and AdipoR2 contain seven 
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transmembrane domains but are distinct from G protein coupled receptors (GPCR) in 
structure and function. Unlike GPCRs, adipoR1 and adipoR2 have inverted membrane 
topologies with an extracellular C-terminal domain and an intracellular N-terminal 
domain (25). The expression of the adiponectin receptors is speculated to be regulated by 
various factors including the presence of adiponectin, insulin (27), and nuclear receptors 
such as PPARα and PPARγ (28-31). However, the cause/effect relationship of such 
regulation is largely unknown. For example, the increase in levels of adiponectin 
receptors observed with a PPARγ agonist could be result of increased expression of 
adiponectin or vice versa (31). 
 In the past decade, adiponectin has attracted much attention due to its beneficial 
effects on obesity-related cardiovascular and metabolic complications. Upon binding to 
its receptors, adiponectin mediates a cascade of intracellular signaling events, including 
the activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK) – a 
key enzyme involed in maintaining cellular energy homeostasis. AMPK is activated 
under conditions of reduced cellular ATP or increased levels of AMP (32). Activation of 
AMPK on one hand stimulates ATP generating processes such as fatty acid oxidation and 
glycolysis, it also shuts down ATP consuming processes such as lipogenesis (32). For 
example, under conditions of starvation/fasting fatty acids are mobilized from the adipose 
tissue along with activation of AMPK in the liver and skeletal muscles – resulting in ATP 
generation from fatty acid oxidation (32). These effects are very similar to the pleotrophic 
effects caused by PPARα agonists. It is tempting to speculate that PPARα, in addition to 
its role in lipid metabolism, may also upregulate adiponectin and cause additive effects 
on fatty acid oxidation and inflammation pathways (via adiponectin).  
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 Recently, it was suggested that an adaptor protein containing a pleckstrin 
homology domain, a phosphotyrosine domain and a leucine zipper motif (APPL1) 
mediates the intracellular signaling events that occur following binding of adiponectin to 
its receptors (33, 34). APPL1 binds to the intracellular N-terminal part of adiponectin 
bound AdipoR and mediates the activation of AMPK (33, 34). The net result of AMPK 
activation includes increased fatty acid oxidation (due to increased activity of carnitine 
palmitoyl transferase), glucose uptake (increased activity of insulin receptor substrate and 
GLUT4 glucose transporter), production of nitric oxide (activation of nitric oxide 
synthase) and decreased gluconeogenesis (suppression of gluconeogenic enzymes) and 
diminished activity of nuclear factor κ B (NfκB; due to activation of inhibitory κ B) (26, 
32, 33). 
Indeed adiponectin exhibits cardioprotective, antidiabetic, antiatherosclerotic and 
anti-inflammatory effects (26, 33, 35, 36) and this is further supported by decreased 
circulating levels of adiponectin observed in patients with obesity (37, 38), 
cardiovascular diseases (39-42), hypertension (26, 40, 43), type 2 diabetes (38, 44) and 
metabolic syndrome (26, 36, 45). Conversely, it has been observed that increased plasma 
adiponectin levels are associated with a lowered risk for obesity related co-morbidities 
(46, 47). Consistent with clinical observations, adiponectin deficient mice are prone to 
atherosclerosis, hypertension, hyperglycemia, insulin resistance and also show delayed 
clearance of free fatty acids from plasma (35, 43, 48, 49). The levels of adiponectin are 
also downregulated in mice models of obesity and type 2 diabetes (48, 50-52). Further, 
administration of recombinant adiponectin in these mice improves insulin sensitivity, 
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glucose tolerance, increases fatty acid oxidation, glucose uptake and decreases 
gluconeogenesis (48, 53).  
Consistent with the association of hypoadiponectinemia with obesity and its co-
morbidities, several single nucleotide polymorphisms (SNPs) in the adiponectin gene are 
also associated with aspects of metabolic disorders (54). The most commonly identified 
SNPs in the adiponectin gene locus include T → G transversions at codon 45 and 276 
(55, 56). These SNPs are associated with obesity, insulin resistance, type 2 diabetes, 
altered blood pressure, coronary artery disease and dyslipidemia (54-56). Owing to all 
these experimental and clinical investigations, adiponectin has emerged as a potential 
pharmaceutical target and/or a biomarker in the context of a spectrum of metabolic 
disorders. Administration of recombinant adiponectin in preclinical models has resulted 
in improved metabolic parameters that combat insulin resistance, obesity related 
disorders and inflammation (48, 53). However, production of recombinant adiponectin on 
a large scale, along with its short half-life (1 hour in mice and 2 hours in humans (57)) 
and high circulation levels, makes it difficult to obtain high levels of the protein at a 
reasonable price (24). Thus, strategies that would improve/increase the expression of 
adiponectin (or its signaling) or prevent its down-regulation could result in improvements 
in insulin sensitivity, decrease cardiovascular risk and reduction in many parameters of 
obesity-linked disorders.  
 
 
 
208 
 
Development of hypothesis 
Based on the clinical and preclinical evidence from above and numerous other 
epidemiological studies (58), hypoadiponectinemia is an independent risk factor for 
obesity-related disorders including cardiovascular diseases, atherosclerosis, dyslipidemia 
and type 2 diabetes – most of which are coupled with metabolic imbalances with respect  
to fatty acid metabolism. For example, elevated fatty acids are associated with metabolic 
and cardiovascular complications that also foresee decreased expression of adiponectin. 
Thus “factors” regulating fatty acid metabolism may play an important role in the 
regulation of adiponectin. The adiponectin gene contains several putative transcription 
factor binding sites and is thus speculated to be under complex regulation by various 
upstream signals (59). Amongst binding sites for other transcription factors such as 
CCAAT/enhancer binding protein (C/EBP) (59), adipocyte determination and 
differentiation-dependent factor 1/Sterol regulatory element-binding protein 1c 
(ADD/SREBP1-c) (60) and cAMP response element binding protein (61), the 
adiponectin promoter also contains binding site for the peroxisome proliferator-activated 
receptors (59).  
As discussed in the earlier portions of this dissertation, the peroxisome 
proliferator activated receptors (PPAR; α, β/δ and γ) are a class of ligand dependent 
nuclear transcription factors that play crucial roles in the transcriptional regulation of 
energy metabolism and homeostasis (62-65).   While PPARα (expressed predominantly 
in liver, heart, muscle) and PPARβ/δ (expressed predominantly in intestines and 
keratinocytes) are potent activators of genes involved in fatty acid oxidation, PPARγ 
(expressed predominantly in adipose tissue) activates genes involved in lipogenesis and 
209 
 
adipocyte differentiation (62-65). A substantial body of evidence has suggested that 
PPAR α and γ agonists increase the expression of adiponectin (52, 66-73). While the 
mechanism by which PPARγ agonists induce the expression of adiponectin mainly 
includes adipogenesis and transactivation of adiponectin gene (67, 74), the role of 
PPARα and its underlying mechanisms in regulating adiponectin is unclear. 
A direct role of PPARγ in adipogenesis was suggested based in two main forms of 
evidences: 1) the expression of PPARγ was very low in preadipocytes cell lines (such as 
3T3-L1) but its expression surges when these cell lines undergo differentiation (even 
before other differentiation markers such as activating protein 2; aP2) (75) and 2) PPARγ 
agonists such as thiazolidinidiones were able to promote the differentiation of 
preadipocytes to adipocytes (76). The secretion of adipocytokines from the adipose tissue 
is a function of the adipocyte state/size (74). While smaller adipocytes secrete insulin 
sensitizing and anti-inflammatory molecules such as adiponectin, larger hypertrophied 
adipocytes secrete inflammatory molecules such as TNFα (74). As potent inducers of 
adipogenesis, PPARγ agonists are capable of promoting the secretion of adiponectin. In 
addition, Iwaki et al. demonstrated that PPARγ may also transactivate the adiponectin 
gene and thereby induce the expression of this protein (67).  
There is very little information regarding the role and involvement of PPARα in 
the expression of adiponectin. Clinical and preclinical studies have demonstrated that 
administration of PPARα specific agonists (fibrates) results in pleotropic increases in the 
expression of adiponectin (69-71, 73, 77). Such an effect was not observed in PPARα 
deficient adipocytes or PPARα knockout mice (PPARα-/-) (73). In fact, even the basal 
expression of adiponectin in PPAR-/- mice and diet-induced obese mice was significantly 
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lower when compared to age matched wild-type littermates (52, 57, 78). Administration 
of PPARα agonists promotes revascularization in response to ischemia in an 
AMPK/endothelial nitric oxide synthase (eNOS) dependent manner (downstream 
effectors of adiponectin) – an effect that was abrogated in adiponectin knockout mice 
(71). Further, Hiuge et al. demonstrated that the fibrates (PPARα agonists) induce the 
expression of adiponectin in white adipose tissue of mice and that this effect was 
abolished in PPARα -/- mice (73). All these findings suggest that PPARα plays a direct 
role in the regulation of adiponectin expression, particularly in pathological states such as 
diabetes, obesity and dyslipidemia.  
While the adipose tissue serves as a primary source of adiponectin, Maddineni et. 
al. demonstrated that in chickens, the pituitary gland, liver, skeletal muscle, kidney, ovary 
and spleen can also secrete adiponectin (79). Similar to these observations, in humans 
and rodents its expression was also found in tissues other than the adipocytes. These 
include the bone marrow (80), osteoblasts (81), fetal tissue (82), skeletal muscle (83), 
cardiomyocytes (84-87), salivary glands (88) and the liver (89, 90).  These findings 
suggest an autocrine or paracrine role of adiponectin in these tissues. In fact, cardiac 
adiponectin is demonstrated to act in an autocrine/paracrine manner (independent of 
serum levels) to regulate cardiac metabolism and functionality, and that deregulation of 
this could be a determinant in the development of various cardiac pathologies (84, 87, 
91). For example, cardiac adiponectin has been shown to protect against myocardial 
ischemia-reperfusion injury and hypertrophy (87, 91). In addition, Skurk et. al.  have 
further demonstrated that cardiac adiponectin is downregulated independent of its serum 
levels in diabetic cardiomyopathy (84). There is compelling evidence which supports the 
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role of PPARα and adiponectin as regulators of energy homeostasis. However, the 
regulation of a local adiponectin system at the level of the liver has not been explored yet. 
Kaser et al. reported no correlation between circulating adiponectin levels and liver 
adiponectin expression in patients with steatohepatitis (89). Considering the predominant 
expression of PPARα in the liver and its important role in lipid homeostasis (62-65), it 
may play a significant role in the possible regulation of adiponectin at the level of the 
liver.   
Elevated long chain fatty acids (LCFA) are associated with metabolic and 
cardiovascular complications that also foresee decreased expression of adiponectin. The 
fact that LCFA have been suggested to be ligands for PPARα (92, 93), implicates an 
important role of ligand-activated PPARα in the regulation of adiponectin. We thus 
hypothesize that LCFA that serve as ligands for hPPARα regulate the expression of 
adiponectin in HepG2 cells (human hepatoma cells). Therefore, the main goal of this part 
of the dissertation was to determine whether ligand-activated hPPARα directly regulates 
the expression of adiponectin in HepG2 cells. It is likely that endogenous ligands found 
in Chapter I of this dissertation could have a profound effect on the expression of 
adiponectin. The outcome of this research could help explain the importance of dietary 
nutrients and their correlation to differential transcription, expression or activity of 
proteins involved in the pathophysiology of the metabolic syndrome.  
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Materials and Methods 
Chemicals: While fatty acid ligands and clofibrate were purchased from Sigma-
Aldrich (St. Louis, MO), bovine serum albumin (lipid-free) was obtained from Gemini 
Bioproducts (Sacramento, CA). Rosiglitazone (LKT labs) was a kind gift from Dr 
Khalid Elased.  
Electrophoretic mobility shift assays (EMSAs): Promoter analysis for adiponectin 
revealed two putative PPRE at -2345/-2358 (PPRE1) and -335/-368 (PPRE2) base pairs 
upstream of the transcription start site. Gel-shift assays were performed to measure the 
DNA-binding ability of hPPARα-hRXRα heterodimers in the presence and absence of 
ligands using in vitro reactions. Purified recombinant hPPARα was purified as described 
in chapter I of this dissertation. The bacterial expression plasmid for full-length hRXRα 
(6xhis-GST-hRXRα) was produced by Dr. S. Dean Rider, Jr. (Wright State University) 
and the recombinant hRXRα protein purification was conducted by Ms. Frances Soman 
(Hostetler Lab). Double-stranded oligonucleotides spanning from -2337/-2366 and -327/-
376 were obtained from the adiponectin promoter. Additional mutant oligonucleotides 
were also be generated to confirm the binding of the heterodimeric complex to the 
putative PPRE tested. Double-stranded oligonucleotides of the following sequences were 
used: wild-type adiponectin PPRE 1, 5’ –
CAGACTCCTGACCTCAAGTGATCTGCCCG-3 and wild-type adiponectin PPRE 2, 
5’ -TGTGGTTTTGACTTTTGCCCCATCTTCTG-3; mutant adiponectin PPRE 1, 5’ – 
CAGACTCCCTTAATGGTCTGATCTGCCCG – 3 and mutant adiponectin PPRE 2, 5’ 
– TGTGGTTTCATATATGTCGACATCTTCTG – 3’.  In vitro reactions containing 39 
nM of each recombinant protein (hPPARα and hRXRα) along with 2.1 pmol  of double 
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stranded oligonucleotides (wild-type or mutant) in 13 mM Tris pH 8.0, 40mM KCl, 35 
mM NaCl, 1 mM dithiothreitol, 0.1 mM EDTA, 0.05 % nonidet P-40 and 8 % glycerol 
were incubated at room temperature for 20 minutes, cross-linked and loaded onto 7% 
nondenaturing polyacrylamide gels. The gels containing separated DNA, protein or both 
were stained using an EMSA kit (Molecular Probes, Eugene OR) containing two 
fluorescent dyes for detection, SYBR Green EMSA stain (DNA) and SYPRO Ruby 
EMSA stain (Protein). The bands were visualized on the Fujifilm LAS 4000 and 
quantified densitometrically using Image J.  
Cell culture and treatments: HepG2 cells (ATCC, Manassas, VA) cultured in 
Eagle’s minimum essential medium (EMEM) with 10% fetal bovine serum (FBS) at 
37°C with 5% CO2 in a humidified chamber were used in this study. Cell were seeded 
onto 6-well culture plates and upon reaching 70-80% confluency, media was replaced 
with serum-free media followed by incubation for 2 hours. Next, confirmed hPPARα 
ligands (stearic acid, C18:0; oleic acid, C18:1; docosahexanoic acid, C22:6; from chapter 
I) were added to the media and the cells were allowed to grow for 22-24 hours. Fatty 
acids were added to the cells as a complex with BSA (as described in chapter I of this 
dissertation) and clofibrate and rosiglitazone (controls; solubilized in DMSO) were added 
directly to the media. Although each ligand was examined at 10 µM, a dose of 100 µM 
was also tested initially. This was followed by determination of adiponectin mRNA and 
protein levels by qRT-PCR and Western blotting.  
RNA isolation and qRT-PCR: Total RNA was extracted using the Taqman
®
 Cells-
to-CT kit (Ambion, Grand Island, NY) and reverse transcribed at 37°C for 60 minutes 
followed by 95°C for 5 minutes on a Multigene thermocycler (Labnet International Inc., 
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Edison NJ). The expression of adiponectin, PPARα (control) and 18S rRNA (internal 
control) was determined using the Taqman
®
 Gene Expression Assays On Demand
™
 
designed for these specific genes (human adiponectin, Hs00605917_m1 FAM ;hPPARα, 
Hs00947536_m1 FAM; 18S, Hs99999901_s1 FAM). Briefly, 4 µl of each reverse 
transcribed product served as a template in a 20 µl PCR containing 16 µl of a gene 
specific mastermix (10 µl Taqman® Master Mix, 1 µl of respective Taqman
®
 Gene 
Expression Assays On Demand
™
 and 5 µl of nuclease-free water). The PCR was carried 
out on a MicroAmp 96-well plate (Applied Biosystems, Grand Island, NY) and the 
amplification was a carried using a StepOnePlus thermocycler (Applied BioSystems, 
Grand Island, NY). The amplification conditions included 50°C for 4 minutes, 95°C for 
10 minutes, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Cycle 
threshold (Ct values) thus obtained, were used to calculate the ΔΔCt and the fold change 
for each gene and treatment condition as described previously (94). 
Western Blotting Analysis: HepG2 cells treated with ligands as indicated above 
were lysed by sonication in a buffer containing 5 mM HEPES, 0.4% triton X, 100 mM 
Na3VO4, (sodium orthovanadate) 2 U of apritinin/ml, 5 U of Leupeptin/ml and 2 U of 
pepstatin/ml. Whole-cell lysates were denatured by boiling in sodium dodecyl sulfate 
(SDS) sample buffer and dithiothreitol and resolved on a 12% SDS-PAGE gel followed 
by electrophoretic transfer to a nitrocellulose membrane. Proteins were detected using 
specific antibodies against adiponectin (Abcam, ab22554), PPARα (Santacruz, sc-9000) 
and β-actin (Sigma, A5316) followed by incubation in respective secondary antibody 
(Sigma, St. Louis, MO) prior to visualization by enhanced chemiluminescence on the 
Fujifilm LAS 4000 (Fujifilm Medical Systems USA Inc., Stamford, CT). The relative 
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amount of a given protein for each condition was examined by densitometry (ImageJ) 
and compared to controls.  
Plasmids: Mammalian expression plasmids for the overexpression of hPPARα 
(pSG5-hPPAR and hRXRα (pSG5-hRXRα) have already been described in chapter I 
of this dissertation. In order to generate luciferase constructs with the adiponectin 
promoter, a 2.4 kb fragment of the adiponectin promoter containing both putative PPRE 
and the minimal transcriptional machinery was amplified from cDNA derived from 
HepG2 cells with the following primers: 5'- cggtaccTTCACCATCTTCGTCAGGCT-3' 
and 5'- cgagctcAGACTGCAGTCAGAATGGAA -3'. In these and subsequent primers, 
lowercase represents nucleotides outside of the open reading frame with restriction sites 
underlined. This PCR product was cloned into the pGEM
®
-T easy vector (Promega 
Corp., Madison, WI), sequenced to confirm amplification and subsequently cloned into 
the Kpn I and Sac I sites of the pGL4.17 luciferase construct (Promega Corp., Madison, 
WI) to produce pHH 83 
In order to test selective PPARα activation by one or the other response element 
(PPRE1 or PPRE2), mutant luciferase constructs for adiponectin promoters were also 
generated with either one or both PPRE abolished. In order to mutate PPRE1, pHH 83 
was amplified using 5’–
cggtaccTCAGACTCCTTTAAAGGTCTGATCTGCCCGCCTCAG–3’ and 5'- 
cgagctcAGACTGCAGTCAGAATGGAA such that the PCR product had the 
mutated/scrambled nucleotides in place of the PPRE (marked in the primer). This PCR 
product was cloned into the pGEM
®
-T easy vector (Promega Corp., Madison, WI), 
sequenced to confirm amplification and subsequently cloned into the Kpn I and Sac I 
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sites of the pGL4.17 luciferase construct (Promega Corp., Madison, WI) to produce 
pHH 145. In order to mutate PPRE 2, pHH 83 was used to amplify 2 PCR products 
using the following primers: 5'- cggtaccTTCACCATCTTCGTCAGGCT-3' and 5’ – 
TGTCGACATATATGAAACCACAGCAGGAAAACAAGA – 3’ (giving a ~2.0 kb 
fragment with mutated/scrambled PPRE 2) and 5’ –
GGTCGACATCTTCTGTTGCTGTTGTAGGAG – 3’ and 5’ – 
CgagctcAGACTGCAGTCAGAATGGAA – 3’ (giving a ~300 bp fragment with a 
mutated/scrambled half of the PPRE 2). Both these fragments were individually cloned 
into the pGEM
®
-T easy vector (Promega Corp., Madison, WI) followed by sequencing 
to confirm amplification. These two fragments - Kpn I/Sal I fragment (~2.0 kb) and Sal 
I/Sac I fragment (~300 bp), were subsequently directionally cloned into the Kpn I and 
Sac I sites of the pGL4.17 luciferase construct (Promega Corp., Madison, WI) to 
produce pHH 142. To mutate both PPRE 1 and PPRE 2, pHH 142 was used to amplify 
a PCR product using the following primers: 5’–
cggtaccTCAGACTCCTTTAAAGGTCTGATCTGCCCGCCTCAG–3’ (containing 
mutated/scrambled PPRE 1) and 5'- cgagctcAGACTGCAGTCAGAATGGAA. The 
PCR product with both PPRE’s mutated/scrambled and was cloned into the pGEM
®
-T 
easy vector (Promega Corp., Madison, WI), sequenced to confirm amplification and 
sub-cloned into the Kpn I and Sac I sites of the pGL4.17 luciferase construct (Promega 
Corp., Madison, WI) to produce pHH 146. 
Transactivation assays: COS-7 cells are derived from CV-1 cells (African 
green monkey kidney cells) and have classically been used in transactivation 
experiments for nuclear receptors such as the PPARs (95). In addition to having the 
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basal transcriptional machinery, they have low basal expression of PPARs and have 
relatively high transfection efficiencies (96). COS-7 cells (ATCC, Manassas, VA) were 
grown in DMEM supplemented with 10 % fetal bovine serum (Invitrogen, Grand 
Island, NY) at 37°C with 5% CO2 in a humidified chamber.  Cells were seeded onto 
24-well culture plates and transfected with Lipofectamine™ 2000 (Invitrogen, Grand 
Island, NY) and 0.4 µg of each full-length mammalian expression vector (pSG5-
hPPARα, pSG5-hRXRα or both) or empty plasmid (pSG5), 0.4 µg of each luciferase 
reporter construct (pHH 83, pHH 142, pHH 143, pHH 146) and 0.04 µg of the internal 
transfection control plasmid pRL-CMV (Promega Corp., Madison, WI) as previously 
described (92, 97).  Following transfection incubation, medium was replaced with 
serum-free medium for 2 h, ligands (1µM) were added, and the cells were grown for an 
additional 20-24 h.  Fatty acids were added as a complex with bovine serum albumin 
(BSA) as described (98). Clofibrate and rosiglitazone (solubilized in DMSO) were 
added directly to the media.  Firefly luciferase activity, normalized to Renilla luciferase 
(for transfection efficiency), was determined with the dual luciferase reporter assays 
system (Promega, Madison, WI) and measured with a SAFIRE
2
 microtiter plate reader 
(Tecan Systems, Inc. San Jose, CA).  No treatment samples overexpressing both 
PPARα and RXRα were arbitrarily set to 1. 
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Results and Discussion 
Since the discovery of PPARα, it has been postulated that one of its main 
functions is to sense LCFA and/or their metabolic intermediates as ligands and induce 
downstream genes that are either directly or indirectly involved in fatty acid metabolism 
(62-65). Adiponectin also functions to regulate energy homeostasis by promoting fatty 
acid oxidation, glucose uptake and decreasing gluconeogenesis (26, 33). Studies also 
suggest that PPARα agonists (69-71, 73, 77) and polyunsaturated fatty acids (PUFA) (66, 
72, 99) could induce the expression of adiponectin. Given all the background on the lipid-
sensing role of PPARα, we anticipated that hPPARα plays an important role in ligand 
dependent regulation of adiponectin.  
Electrophoretic mobility shift assays (EMSAs): PPARα-RXRα heterodimers bind 
to human adiponectin PPREs. Since adiponectin promoter analysis revealed two putative 
PPRE (PPRE 1, -2345/-2358 and PPRE 2, -335/-368), EMSA were performed to confirm 
the binding of PPARα-RXRα heterodimers to each of the identified PPRE. While 
hPPARα alone or hRXRα alone did not bind to either adiponectin PPRE, hPPARα-
hRXRα incubated together with either PPRE 1 or PPRE 2 resulted in retarded movement 
of the DNA – suggesting binding of hPPARα-hRXRα to these PPRE (Fig. 33A). The 
signal of such band was diminished by 40-50 % when hPPARα-hRXRα were incubated 
with mutant forms of these PPRE (Figure 33B and 33C). According to the classical mode 
of action for nuclear receptors, ligand binding induces specific conformational changes 
that promote heterodimerization and DNA binding (62-65, 100, 101). Previous mobility 
shift assays have not only demonstrated the binding hPPARα-hRXRα heterodimers to 
DNA in absence of ligand, but have also shown that such binding was enhanced in the 
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presence of synthetic agonists such as Wy-14,643 (100, 101). Thus we anticipated 
differences in DNA binding in the presence of hPPARα ligands. However, the addition of 
hPPARα ligands such as stearic acid (C18:0), oleic acid (C18:1), eicosapentanoic acid 
(EPA) or clofibrate did not cause any significant differences in DNA binding or 
hPPARα-hRXRα-DNA band intensities (Figure 33B and 33C). Based on the outcome of 
these experiments, three points specifically need to be addressed here. These include 1) 
binding of unliganded hPPARα-hRXRα to PPRE, 2) no significant changes in ligand 
induced DNA binding and 3) only 25-45% reduction in DNA binding with the use of 
mutated or disrupted PPRE.  
Firstly, in vitro binding of hPPARα-hRXRα to PPRE sequences even in the 
absence of a ligand has been demonstrated by a large number of studies (almost 2 
decades ago) (100, 101). While such binding of unliganded receptors to specific DNA 
sequences has been attributed to the independent function of the DNA binding domain 
(DBD) in the nuclear receptors, Brazda et. al. recently demonstrated that nuclear 
receptors are in continuous motion, such that they rapidly bind and unbind DNA. The 
addition of a ligand by and large only increases their residual time on the DNA (102). 
These findings help explain the binding of nuclear receptors (hPPARα-hRXRα) to DNA 
sequences (PPRE sequences) even in absence of a ligand. Secondly, addition of ligands 
to the in vitro reactions did not alter DNA binding. Balanarasimha et al. also demonstrate 
similar findings where the binding of hPPARα-hRXRα heterodimers to the ACOX PPRE 
(classical PPARα responsive gene) is not affected by ligand binding (103). It is likely that 
hPPARα-hRXRα heterodimers by themselves bind very well to the PPRE (in vitro) such 
that no difference in DNA binding is seen in the presence of hPPARα ligands. Van der 
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Meer et. al. utilized chromatin immunoprecipitation with genomic sequencing (ChIP-seq) 
and transcriptomics to demonstrate that, of all the genomic binding sites for PPARα 
(corresponding to about 2875 genes) about 82% of the genes are bound by PPARα 
equally well in the presence or absence of ligand (104). Since 
transactivation/transrepression is also a function of promoter occupancy and cofactor 
binding to the nuclear receptor dimeric complex, DNA binding may not be representative 
of the amount of ligand induced activation/repression seen in vivo (62-65, 102). 
Lastly, we have demonstrated specific binding of hPPARα-hRXRα to both 
PPRE1 and PPRE2 (Fig. 33A). However, we were able to achieve only 25-45% reduction 
in DNA/PPRE binding with the use of mutant PPREs (as opposed to complete ablation of 
such binding). Such binding of hPPARα-hRXRα to mutated PPRE1 and PPRE2 could be 
a result of some non-specific binding to the DNA. Such non-specific interactions on a 
gel-shift assay have also been observed with other transcription factors and could be 
attributed to the conditions used in such assays or even the degeneracy of the 
oligonucleotides (67, 105). The PPRE motif belongs to the direct repeat 1 category (DR-
1) and consists of two repeats of a hexameric core motif, separated by one nucleotide (62-
65). Since DR-1 motifs (constituting the PPRE) are quite degenerate in nature (62-65), 
other factors may determine nuclear receptor specificity to the DR-1 such as the 5’ 
flanking extension (to DR1), spacing nucleotide or assisted binding to the response 
elements (via other proteins or DNA sequences) (106-108). Competition based mobility 
shift assays have shown that mutated unlabelled PPRE sequences also reduce the signal 
of PPAR-RXR binding to wild-type labeled PPRE sequences (although not as 
dramatically as wild-type unlabelled PPRE) (67). Similarly, Van der Meer et al. reported 
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the binding of nuclear receptors to DNA even the absence of a consensus DR-1 motif (in 
ChIP-chip studies) (104). These occurrences may be a result of the degeneracy of the 
core motif, indirect protein-protein interactions and DNA looping (in case of ChIP-chip 
studies), assisted binding to the DR-1 core motif as a result of the other nuclear receptor 
partner (in our case either PPARα or RXRα) or due to aberrant binding due to structural 
and electrostatic end-effects  (105). However, having tested only one mutant per PPRE, it 
is difficult to rule out the possibility of some non-specific binding of hPPARα-hRXRα to 
the PPRE.  
Albeit the many drawbacks, our data suggests that hPPARα-hRXRα heterodimers 
may be capable of binding the two putative PPREs in the human adiponectin promoter. 
One of these PPREs (PPRE 2, -335/-368) has also been previously reported to bind 
PPARγ-RXRα heterodimers (67). It is possible that based on the cell-type/organ system 
and the concentrations of PPARα versus PPARγ, adiponectin may be regulated by both 
these nuclear receptors. Nonetheless, the effects of hPPARα ligands on adiponectin 
transactivation/transrepression still remain elusive. It will be interesting to 1) see the 
outcome of competitive inhibition of hPPARα-hRXRα heterodimer binding to these 
PPREs and 2) to obtain PPARα promoter occupancy data from human heptoma cells 
(HepG2 cells; from van der Meer et al. (104)) particularly to determine PPARα binding 
sites in the adiponectin promoter.   
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Fig. 33. Electrophoretic mobility shift assays (EMSAs): Oligonucleotides containing 
putative PPRE from the human adiponectin promoter (PPRE 1 or PPRE 2) were 
incubated with recombinant hPPARα and hRXRα in the presence or absence of ligands. 
The position shifted hPPARα/hRXRα-oligonucleotide complex was labeled with SYBR 
Green EMSA stain (DNA) and SYPRO Ruby EMSA stain (Protein). A) SYBR green 
staining of the two PPREs incubated in the presence of hPPARα alone, hRXRα alone or 
both hPPARα/hRXRα (absence of any ligands). B) SYBR green staining of the position 
shifted hPPARα/hRXRα-oligonucleotide complex in the presence or absence of hPPARα 
ligands. Ligands tested include stearic acid (C18:0), oleic acid (C18:1), eicosapentanoic 
acid (C20:5) and clofibrate. C) SYBR green band intensities resulting from the 
hPPARα/hRXRα-oligonucleotide complex in the presence or absence of hPPARα ligands 
measured using ImageJ software, and plotted as relative mean bound DNA ± SEM, n ≥ 7.    
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Adiponectin expression in HepG2 cells and its regulation by hPPARα ligands: 
Fewer studies have demonstrated hepatic expression of adiponectin in humans as well as 
mice (89, 90, 109-111). Therefore cultured human heptoma cells (HepG2) which 
represent the most widely used cellular model for human liver cells (104), were used to 
study the effect of hPPARα ligands on the mRNA and protein expression of adiponectin. 
While we were not able to detect adiponectin mRNA using Taqman
®
 Gene Expression 
Assays specific for human adiponectin (qPCR), western blotting using a specific antibody 
for adiponectin demonstrated the presence of adiponectin protein in the cell lysates from 
all treatments (Fig. 34A). Adiponectin mRNA remained undetectable under different 
conditions such as overexpression of PPARα-RXRα and/or treatment with various 
hPPARα ligands.  
Although we did not test any positive controls validating the Taqman
®
 Gene 
Expression Assays used to detect human adiponectin, these probes have been commonly 
used for detection of adiponectin mRNA in other tissues (112-114). The lack of detection 
of adiponectin mRNA in HepG2 cells was unexpected, especially because we were able 
to detect adiponectin protein using specific antibodies in western blotting (Fig. 34A). It 
was later determined that adiponectin was present in the fetal-bovine serum (FBS) 
present in the EMEM media used to grow HepG2 cells. Thus, detection of adiponectin in 
the western blots from cell lysates could be an artifact resulting from contamination of 
media with bovine adiponectin (from FBS; Fig. 34B).  
The lack of detection of adiponectin in cultured liver cells (HepG2) in our hands 
was surprising and contrary to some studies in the literature (89, 90, 109-111). However, 
upon careful review of the literature, we found that our results were also in agreement 
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with some other reports (115, 116). Immunohistochemistry based studies done in human 
and mouse livers revealed that adiponectin expression in the liver tissue was primarily 
localized to the endothelial cells of portal vessels and/or liver sinusoids and hepatic 
stellate cells (115, 116). It was also suggested that this staining could be a result of some 
“contamination” from circulating plasma adiponectin (115, 116). Similarly, Knotts et al. 
(using the same Taqman
®
 Gene Expression Assay as our study) were also not able to 
detect the expression of adiponectin mRNA in HepG2 cells (114).  
One major cause of such differences in results for hepatic expression of 
adiponectin could be due to the physiological/pathophysiological state of the 
patient/mice/HepG2 cells. For example, morbidly obese patients with steatosis (90) or 
mice treated with carbon tetrachloride (model for hepatic fibrosis) (117) or infected with 
hepatitis B virus express adiponectin in the liver (110).  Similarly, adiponectin was also 
detected in HepG2 cells infected with hepatitis B virus (111) or stimulated with an 
inflammatory cytokine such as interleukin-6 (IL-6) (117). In these experiments, the levels 
of adiponectin in wild-type or control HepG2 cells were either very low (111) or not 
detectable (117). Based on these observations, it is possible that adiponectin secretion 
from HepG2 cells occurs only under situations that are far from normal homeostatic 
conditions. Yoda-Murakami et al. demonstrated that treatment of mice with carbon 
tetrachloride (to induce liver injury/fibrosis) resulted in a gradual increase in the 
adiponectin mRNA with time (117). It is speculated that as the liver damage progresses, 
there is increased production of inflammatory cytokines such as IL-6 which in turn 
trigger the production of anti-inflammatory adiponectin locally in the liver. Thus under 
conditions that were used in our experiments, we were not able to gather convincing data 
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on the detection of adiponectin. Therefore it is difficult to predict the effect of PPARα 
ligands on the expression of adiponectin in these cell lines/culture conditions/treatments.  
The other possibility that needs to be considered is that the HepG2 cells do not 
express adiponectin. Assuming that all the data showing adiponectin protein expression 
in human or mouse livers and HepG2 cells was biased due to “contamination” from the 
circulating forms of adiponectin or “contamination” from cell media, the question that 
still remains unexplained is the detection of adiponectin mRNA in liver samples 
(humans/mice). The human liver is composed of primarily hepatocytes (more than 60%) 
(118). However, it also consists of other cell types such as the kupffer cells (20%) and 
liver sinusoidal endothelial cells (15%) (118). Since immunohistochemistry based 
staining of adiponectin was localized to these cells in certain studies (115, 116), it is 
possible that adiponectin mRNA in the liver tissue arises from these cells (and not 
hepatycytes).       
To answer all these questions/concerns, it is important to test our hypothesis in 
HepG2 cells under stimulation/stress (proinflammatory cytokines) or in a different cell 
line that constitutively expresses adiponectin such as adipose tissue. PPARγ is 
predominantly found in the adipose tissue where it plays a major role in adipogenesis. 
Considering the PPARγ involvement in the regulation of adiponectin, it will be 
challenging to test PPARα-mediated regulation of adiponectin in these cells. Several 
groups have reported expression of PPARα in the adipose tissue (73, 119), where it plays 
major role in lipolysis and fatty acid oxidation (119). Hiuge et al. also demonstrated that 
PPARα agonists directly regulate the expression of adiponectin in white adipose tissue in 
mice as well as mouse primary adipocytes and 3T3-L1 cultured adipocytes (73). This 
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effect was not seen in PPARα knockout mice or cells where PPARα expression was 
knocked down (73). It will be interesting to study the effects of PPARα ligands in PPARγ 
knockdown adipocytes. 
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Fig. 34. Adiponectin expression in HepG2 cells and its regulation by hPPARα ligands. 
A) HepG2 cells treated with 10 µM of the indicated ligand and incubated for 18-20 hours 
following which whole cell extracts were analyzed by SDS PAGE and probed with 
indicated antibodies. B) Serially diluted fetal bovine serum (FBS) and EMEM media 
(containing 10% FBS) were by SDS PAGE and probed for adiponectin. 
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Transactivation assays: To examine whether PPARα is directly involved in 
transactivation/transrepression of the adiponectin promoter, COS-7 cells were transfected 
with mutant or wild-type adiponectin luciferase reporter constructs along with 
mammalian expression plasmids for hPPARα alone, hRXRα alone, both hPPARα and 
hRXRα and/or empty vector (pSG5). Transactivation was measured as percent firefly 
luciferase activity normalized to Renilla luciferase (internal transfection control) is 
depicted in figure 35. When compared to cells overexpressing empty vector (pSG5; Fig 
35.D), PPARα alone (Fig. 35B) or RXRα alone (Fig. 35C), the basal transactivation for 
the wild-type adiponectin promoter was significantly increased in cells overexpressing 
both PPARα and RXRα (Fig. 35A). These findings are consistent with findings from 
transactivation assays using PPRE×3 TK LUC reporter construct (Chapter I), suggesting 
that both PPARα and RXRα work as heterodimeric partners to regulate gene expression. 
Compared to the transactivation seen for the wild-type adiponectin promoter in cells 
overexpressing both PPARα and RXRα, about 60 ± 9 % transactivation was even 
observed in cells overexpressing RXRα alone (Fig. 35C) – suggesting that in addition to 
the PPARα-RXRα heterodimers, other factors (possibly RXRα dependent/driven) may 
also play a role in the regulation of the adiponectin promoter.  
In cells overexpressing both PPARα and RXRα, mutating PPRE 1 versus PPRE 2 
makes a considerable difference in the basal promoter activity (Fig. 35A). Mutating both 
PPRE 1 and PPRE 2 in the adiponectin promoter caused a considerable decrease in 
transactivation when compared to the wild-type promoter construct (50 ± 1%; Fig. 33A). 
While such decrease in transactivation was also observed when only PPRE 2 was 
mutated, no decrease in transactivation was seen when PPRE 1 was mutated 
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(transactivation similar to wild-type). These findings, although in contrast with our data 
from mobility shift assays, suggest that only one PPRE (PPRE 2) may be responsive to 
PPARα activation (Fig. 35A). There were no differences in the DNA binding ability of 
hPPARα-RXRα (to PPRE1 vs. PPRE2) in mobility shift assays. However, 
transactivation/transrepression is also a function of cofactor binding to the hPPARα-
hRXRα complex (62-65, 102), and DNA binding reflected in our mobility shift assays 
does not take this factor into consideration. Thus DNA binding in our mobility shift 
assays may not be representative of the amount of ligand induced activation/repression 
seen in reporter assays. 
PPRE 2 is the same response element that has also been shown to be regulated by 
PPARγ (67). Over the years, scientists have suggested sharing of response elements 
between nuclear receptors. In fact genomic profiling of transcription factor binding sites 
has revealed a lot of degeneracy and overlaps of binding sites (104, 105, 120). Boergenes 
et al. have further demonstrated that there is substantial overlap between liver X receptor 
(LXR) and PPARα binding sites. They further suggest that PPARα may bind to the 
particular site in one cell type, whereas LXR may predominate such binding in another 
cell type (120). Similarly, since PPARα and PPARγ share the same degenerate PPRE 
motif in the adiponectin promoter (PPRE 2), it is likely based on the cell-type/tissue-type 
each PPAR subtype plays a differential role in the regulation of adiponectin. This can be 
extended to the physiological role of the tissue (example, liver vs. adipose tissue) and the 
specific function of adiponectin desired (example, fatty acid oxidation, gluconeogenesis, 
glucose uptake or anti-inflammatory function).    
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Fig. 35.  The transactivation of the adiponectin promoter-luciferase construct or 
mutants where one or both of the putative PPRE were disrupted was measured in  
COS-7 cells transfected with A) both PPARα and RXRα, B) PPARα alone, C) RXRα 
alone or D) pSG5 empty vector. The y-axis represents values for firefly luciferase 
activity that have been normalized to Renilla luciferase (internal control) The PPARα 
and RXRα overexpressing cells with wild-type adiponectin promoter-luciferase 
construct was arbitrarily set to 1  a n d  the bar graph represents the mean values (n 
≥ 3) ± standard error. * P < 0.001. 
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Compared to the basal transactivation of the adiponectin promoter (Fig. 35), it is 
not clear whether hPPARα ligands have any effect on the adiponectin promoter activity 
(Fig. 36). While PPARα ligands such as stearic acid and clofibrate did cause any 
significant changes in transactivation of the wild-type adiponectin promoter, the addition 
docosahexanoic acid resulted in a significant decrease in such transactivation (Fig. 36A). 
Since PPARγ has previously been shown to transactivate adiponectin (67), cells were 
also treated with a synthetic PPARγ agonist (rosiglitazone) to account for the possible 
PPARγ involvement in such regulation. Similar to docosahexanoic acid, the addition of 
rosiglitazone also resulted in a significant decrease in transactivation of the adiponectin 
promoter (Fig. 36A). Such decrease in transactivation (with C22:6 or rosiglitazone) was 
seen consistently in all transfections, including mutant adiponectin promoter constructs or 
cells overexpressing both PPARα and RXRα (Fig. 36A), PPARα alone (Fig. 36B), RXRα 
alone (Fig. 36C) or pSG5 vector (Fig. 36D). This suggests that the resultant decrease in 
transactivation could be resulting from indirect effects or effects that are independent of 
the peroxisome proliferator-activated receptor response elements.  
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Fig. 36.  Effect of PPARα ligands on the transactivation of adiponectin promoter.  
COS-7 cells transfected with A) both PPARα and RXRα, B) PPARα alone, C) RXRα 
alone or D) pSG5 empty vector were analyzed for transactivation of the adiponectin 
promoter-luciferase construct in the presence of bovine serum albumin (BSA) 
based vehicle (controls for fatty acid ligands; open bars), d imethyl  su lfoxide 
(DMSO) based vehicle (cont rols  for  drugs;  diagonally upward bars), 10 µM 
BSA linked-stearic  acid  (C18:0; diagonally downward bars), 10 µM  BSA-
docosahexanoic acid (cross-hatched  bars), 10 µM  clofibrate (PPARα agonist 
solubilized in DMSO; horizontal  lined  bars), and 10  µM rosiglitazone (PPARγ 
agonist solubilized in DMSO; vertically lined bars). The y-axis represents values for 
firefly luciferase activity that have been normalized to Renilla luciferase (internal 
control), where PPARα and RXRα overexpressing cells in the presence of BSA 
vehicle controls were arbitrarily set to 1.   The bar graph represents the mean 
values (n ≥ 3) ± standard error. * P < 0.05 in comparison to BSA controls and # P < 
0.05 in comparison to DMSO controls. 
 
 
 
 
 
 
 
 
235 
 
Apart from PPARγ and the possible involvement of PPARα, the adiponectin gene 
has been shown to be regulated by multiple transcription factors. Some of these 
transcription factors include transcriptional activators such as CCAAT/enhancer binding 
protein (C/EBP) (121, 122), nuclear factor Y (NF-Y) (121), adipocyte determination and 
differentiation-dependent factor 1/Sterol regulatory element-binding protein 1c 
(ADD/SREBP1-c) (60), and transcriptional repressors like activating transcription factor 
(ATF3) (123), cAMP response element binding protein (61), nuclear factor of activated T 
cells (NFAT) (123). Although these transcription factors are reported to regulate the 
expression of adiponectin, the significance of some of these results are not clear. For 
example, subjects with insulin resistance, obesity or metabolic syndrome (with low levels 
of adiponectin) do not have any changes in their levels or activity of C/EBP (a positive 
regulator of adiponectin (124). Nonetheless, the regulation by multiple transcription 
factors suggests the transcription of adiponectin is under intricate regulation by various 
upstream signals.  
Upon manually analyzing the adiponectin promoter constructs in our experiments, 
it was found that the putative binding sites for all of these transcription factors are located 
in the region of the adiponectin promoter that was cloned upstream of the luciferase gene. 
Thus, the possible involvement of these transcription factors could not be ruled out. 
Alternatively, since increased transactivation is only seen when both PPARα and RXRα 
are overexpressed (and not when PPARα ligands are added or PPARα alone or RXRα 
alone are overexpressed), it is also possible that these effects are mediated indirectly by 
PPARα-RXRα heterodimers – via regulation/cross-talk of other transcription factors. For 
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example, human SREPB-1c (positive regulator of adiponectin) is also under regulation of 
PPARα through a PPRE in its promoter (125).  
Genomic profiling of transcription factor binding sites has revealed a lot of 
degeneracy and overlaps of binding sites (105, 120, 126). Thus it has been suggested that 
there might be clustering of transcription factors and/or other accessory proteins to the 
regulatory regions of genes resulting in stabilization of protein-protein interactions such 
that, they function as a complex (105, 120, 126). Profiling of PPAR binding sites has 
revealed that genes that are activated by the PPARs are enriched in specific transcription 
factor binding sites other than the PPARs (104, 127). For example, genes containing a 
PPRE-like motif are likely to have a C/EBP binding element, TATA binding protein 
binding motif and signal transducer of transcription (STAT) binding motifs in their 
vicinity (104, 127). Such clustering has also been demonstrated for estrogen receptor with 
C/EBP and octamer transcription factor 1 (Oct1) binding elements in its vicinity (128). It 
is possible that PPARα-RXRα heterodimers are a part of a cluster of transcription factors 
that aid in transactivation of the adiponectin gene such that, activation is not achieved by 
PPARα ligands but rather by just the presence of the PPAR-RXR heterodimer. 
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Future Directions 
  Owing to the drawbacks of our study, it is not clear whether PPARα has any role 
in the regulation of adiponectin. Clinical and preclinical evidences strongly suggest that 
PPARα agonists induce the expression of adiponectin. However, it is not clear whether its 
involvement in such regulation is a direct or an indirect effect of PPARα activation. In 
addition, adiponectin is speculated to be under complex regulation by a number of 
transcription factors and upstream signals (59). Thus it is challenging to tease apart the 
involvement of PPARα in such regulation. Some of the drawbacks of this study include 
lack of competition based gel-shift assays, lack of a cell line that constitutively expresses 
adiponectin and lack of consideration of other transcription factor involvement in the 
regulation of adiponectin. Future studies should address some of these concerns and lay 
emphasis on the kind techniques used (example, avoid use of media/FBS containing 
adiponectin) and cell lines used. Considering the involvement of PPARγ and the presence 
of a common PPRE in the adiponectin promoter it is essential to tease apart the effects of 
PPARγ versus PPARα. One way of doing this it to make use of a cell line that lacks 
either PPARα or PPARγ.  
Another aspect of adiponectin regulation that has not been approached in this 
study is the involvement of adiponectin receptors (AdipoR1 and AdipoR2). The 
expression of these receptors is speculated to be under complex regulation by adiponectin 
itself, insulin/feeding/fasting conditions as well as nuclear receptors such as PPARα and 
PPARγ (27-31). While the expression of AdipoR’s was downregulated in obese patients 
with coronary artery disease (129), livers of obese mice (51, 52) and in hyperglycemia 
(130), their levels were upregulated upon fasting (51) and upon treatment with a PPARα 
238 
 
agonist (52). These observations warrant further study mainly because the cause/effect 
relationship of such regulation is largely unknown. For example, decreases in levels of 
AdipoRs could be a result of low circulating levels of adiponectin (auto-regulation) and 
increases in levels of adiponectin receptors due to a PPARα or PPARγ agonists could be 
the result of increased expression of adiponectin or vice versa (31). Since strategies that 
would either increase the expression of adiponectin or its signaling (via its AdipoR) could 
improve a number of parameters associated with the metabolic syndrome, it is crucial to 
understand the molecular mechanism of the adiponectin system.  
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LIST OF ABREVIATIONS 
 
ABCA1  ATP-cassette transporter A1  
ACBP   Acyl-CoA binding protein 
ACC     Acetyl CoA carboxylase 
ACOX   Acyl-CoA oxidase 
ACOX-/-   Acyl-CoA oxidase knockout mice 
ACS     Acyl-CoA synthetase 
ACSL   Long chain acyl-CoA synthase 
ADD/SREBP1-c Adipocyte determination and differentiation-dependent factor 
1/Sterol regulatory element-binding protein 1c  
AdipoR  Adiponectin receptors 
AdipoR1    Adiponectin receptor 1 
AdipoR2    Adiponectin receptor 2 
AF-1   Ligand-independent transactivation function 
AF-2   Ligand-dependent transactivation function 
AMPK   Adenosine monophosphate (AMP)-activated protein kinase 
(AMPK) 
Apo   Apolipoprotein  
APPL1  Adaptor protein containing a pleckstrin homology domain, a 
phosphotyrosine domain and a leucine zipper motif  
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ATF-3   Activating transcription factor 
BSA     Bovine serum albumin 
C/EBP   CCAAT/enhancer binding protein 
CARLA  Coactivator-dependent receptor ligand binding assays 
CD     Circular dichroism 
ChIP-seq  Chromatin immunoprecipitation and sequencing  
COX-2  Cyclooxygenase-2  
CPTI     Carnitine palmitoyl transferase I 
CTE   COOH-terminal extension 
CVD   Cardiovascular disease 
CYP7A  Cholesterol 7α-hydroxylase  
DBD   DNA binding domain 
DEHA   Di-(2-ethylhexyl)-adipate 
DEHP   Di-(2-ethylhexyl)-phthalate 
DMEM  Dubelco’s modified Eagle’s media 
DMSO   Dimethyl sulfoxide 
DR1     Direct repeat 1 
EMEM Eagle’s minimum essential medium 
EMSA   Electrophoretic mobility shift assays 
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eNOS   Indothelial nitric acid synthase 
FABP    Fatty acid binding protein 
FA-CoA    Fatty acyl-coenzyme A 
FAS     Fatty acid synthase 
FAT/CD36  Fatty acid translocase  
FATP    Fatty acid transport protein 
FBS   Fetal-bovine serum 
FCS   Fluorescence correlation spectroscopy 
FRAP   Fluorescence recovery after photobleaching 
HAT   Histone acetyltransferase activity  
HDAC   Histone deacetylase activity  
HDL   High density lipoprotein 
HepG2 cells    Human hepatoma cells 
HETE   Hydroxyeicosatetraenoic acid 
HMW   High molecular weight 
hPPARα    human peroxisome proliferator activated receptor α 
HSP-90  Heat-shock protein-90 
IL-1   Interleukin-1 
IL-6   Interleukin-6 
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iNOS   Inducible nitric acid synthase  
KCL   2-ethylphenylpropanoic acid derivative 
LBD     Ligand binding domain 
LCFA   Long chain fatty acid 
LCFA-CoA  Long chain fatty acyl-CoA 
LDL    Low density lipoprotein 
LIC   Ligand induced assays 
LMW   Low molecular weight 
LPL   Lipoprotein lipase 
LSD   Least significant difference 
LTB4   Leukotriene B4 
LXRE   LXR response element 
LXRα   Liver X receptor alpha 
MCAD   Medium chain acyl CoA dehydrogenase 
MMW   Medium molecular weight 
mPPARα   murine peroxisome proliferator activated receptor α 
NCoR   Nuclear receptor corepressor 
NFAT   Nuclear factor of activated T cells 
NF-Y   Nuclear factor-Y 
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NfκB    Nuclear factor κ B  
NURR1  Nuclear receptor related protein 1 
P450     Cytochrome P450 fatty acid ω-hydroxylase 
PC     Photon counting spectrofluorometry 
PGC-1   PPARγ coactivator-1 
PPAR    Peroxisome proliferator activated receptor 
PPARα (-/-) mice   Peroxisome proliferator activated receptor α knockout/null mice 
PPARα  Peroxisome proliferator activated receptor alpha 
PPARβ/δ  Peroxisome proliferator activated receptor beta/delta 
PPARγ  Peroxisome proliferator activated receptor gamma 
PPbP   Peroxisome proliferator-binding protein 
PPRE    Peroxisome proliferator response element 
PUFA    Polyunsaturated fatty acids 
qRT-PCR    Quantitative real-time polymerase chain reaction 
RAR   Retinoic acid receptor 
RXR    Retinoid X receptor 
SDS PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SMRT   Silencing mediator of retinoid and thyroid hormone receptors  
SNP   Single nucleotide polymorphisms 
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SRC-1   Steroid receptor coactivator 
SREBP  Sterol regulatory element-binding protein 
STAT   Signal transducer of transcription 
TBP   TATA binding protein 
TG   Triglycerides 
TIF-2   Transcriptional mediators/intermediary factor 2  
TK   Thymidine kinase 
TNFα   Tumor necrosis factor α 
TR   Thyroid receptor 
UCP-1   Uncoupling protein-1 
VDR   Vitamin D receptor 
VLDL   Very low density lipoproteins 
WHO   World health organization 
 
 
 
 
 
 
 
